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ABSTRACT 
 
Each year, NHS clinical laboratories carry out more than 700 million laboratory 
tests, of which 50 million are microbiology investigations. Several studies have 
shown that between 25% and 40% of all tests sent to the laboratory are 
unnecessary, and up to 46% of ordered microbiology tests are inappropriate. In 
light of these accounts, the present study was undertaken to evaluate the process 
of microbiology specimen management in order to assess microbiology test 
utilisation and the appropriateness of the test ordering processes. The study 
focussed on respiratory tract specimens using sputum microbiology as a model for 
the microbiology service inappropriate test utilisation. 
 
The overall main aim of this study was to determine the appropriateness of clinical 
microbiology test utilisation, its clinical relevance and cost-effectiveness, hence 
recommend better utilisation strategies.  
 
A total of 15,941 respiratory tract samples from Barts and The London NHS Trust 
were randomly selected from the years 2004/05 and analysed retrospectively. 
Seven hundred microbiology laboratory request forms from patients for whom 
respiratory tract cultures were requested over a three month period were examined 
in detail. These requests were derived from 511 sputum specimens, 100 throat 
swabs, 63 ear swabs and 76 samples from other respiratory tract sites. 641 (91%) 
of microbiology test requisition forms were completed, provided all requested 
details by the service users and were therefore considered as appropriate 
microbiology test requisitions. 660 (94%) of those examined stated the patient’s 
clinical diagnosis and only in 65 (13%) of these patients was the stated diagnosis 
as respiratory tract infection.  
 
Sixty percent of sputum specimens examined were considered as poor quality.  
Forty percent of respiratory specimens were reported as culture positive, based on 
the local hospital criteria of microbiology test reporting. In sputum culture, 39% was 
reported as culture positive; however, less than 18% were positive with recognised 
respiratory pathogens, whilst 27% of throat swabs were reported as culture 
positive, of which 67% had throat pathogens. From the beginning of this study and 
before, there were no microbiology test comments and interpretation of test results 
provided with the test result reporting.  
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The test turnaround time of respiratory microbiology results reported within three 
days in 2004/2005 was only 20%. The total inappropriate respiratory specimens 
processed locally were 9,575. Extrapolating from our results, this suggests that 
2,153,977 nationally were inappropriate in NHS hospitals in 2004/2005. The total 
cost of inappropriate respiratory microbiology test use was approximately £152,000 
in local NHS hospitals. Extrapolating from our results, this suggests that £23,900, 
000 nationally was the total cost of inappropriate tests in the NHS hospitals.  
 
Following implementation of this study, follow up studies in 2006 and onwards 
indicated that there has been an improvement in the quality of the microbiology 
service. The number of good quality sputum specimens was 69% compared to 40% 
in 2004/2005. While the total microbiology test turnaround time that was reported 
within three days in 2009/2010 was more than 94%. From mid 2006 onwards, test 
interpretation comments have been used in all microbiology test result reporting. 
The total workload of respiratory tract microbiology activity decreased from 
18,915/year to 16,651/year over the years 2004/2005 to 2007/2008, which is down 
nearly 8%.  
 
Analysis of the findings showed that the usefulness of culture results was limited by 
the collection of inappropriate specimens, and lack of clinical information on the 
microbiology request form. The crucial importance of the role of clinical and nursing 
staff is stressed if the clinical relevance of sputum culture is to be maximised. The 
increasing introduction of electronic pathology test requests gives new opportunities 
to restrict the collection of inappropriate specimens and make substantial savings in 
resources, both in the ward and the laboratory. This type of study and audit can 
give invaluable information about the rationale behind testing, and the 
appropriateness of sampling and transport time. Appropriate measures for 
corrective actions can be identified.  
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Chapter 1       Introduction  
  
The pathology service is a largely hidden science that saves numerous lives. 
Clinical Laboratory testing plays an essential role in the delivery of quality 
healthcare. Laboratory tests provide physicians, nurses, and other healthcare 
providers with objective information that is needed to prevent, diagnose, treat, and 
manage disease. It is estimated that more than 70% of clinical decisions involve 
pathology laboratory test results (Forsman 2002, Regan and Forsman 2006), and 
yet pathology accounts for less than 5% of the NHS budget (Lord Carter of Coles 
2006). 
 
Recognition of this central role that pathology provides in the delivery of medical 
care to patients has led to a previous Government initiated programme of 
modernisation of the pathology service (Department of Health 2005). One of the 
principal aims of this programme was to identify novel ways of delivering pathology 
services that are more responsive to patient needs. This may well include an 
expansion of point of care testing, that is the delivery of pathology services by non-
laboratory staff at sites outside the laboratory (e.g. pharmacies, GP surgeries, 
outpatient departments and wards) with nurses and other non-laboratory healthcare 
professionals becoming more involved in patient testing. 
 
NHS clinical laboratories carry out more than 700 million pathology investigations 
every year, including 50 million microbiology tests (Lord Carter of Coles 2006). A 
report by the Audit Commission in 1993 revealed that around 85 million pathology 
test requests were being processed annually by around 400 NHS clinical pathology 
departments in England and Wales (Audit Commission 1993). Over the intervening 
years, the workload has continued to rise by up to 10% per annum (Beastall 2004). 
There is currently an estimated year on year increase of 6% in the number of tests 
performed (Anon 2012). 
 
In addition to the modernisation of pathology services, the last Government ordered 
Lord Carter to review NHS pathology services in England (Lord Carter of Coles 
2006). Before this review had begun, the author of this thesis started the following 
study project to investigate the appropriateness of clinical microbiology laboratory 
investigations and carried out a retrospective study of the cost and clinical 
relevance of specimen management and processing. The concept of the project 
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was to provide valuable research information to establish an optimal clinical 
microbiology service based on sound principles that is to provide a clinically 
relevant microbiology (appropriate utilisation). 
 
Healthcare reform and economics are driving dramatic changes in healthcare 
delivery and numerous strategic reviews have begun since this project started. 
Drivers for change in pathology services include: 
 
1. Implementations of Carter recommendations: - commissioners, payment by 
results (PbR), pathology tariff, plurality of providers, consolidation networked 
laboratories, quality, end to end service and efficiency savings required of 
20% (Lord Carter of Coles 2008). 
2. Healthcare Commission’s report 2007. Getting results: Pathology services in 
acute and specialist trusts (Healthcare Commission 2007). 
3. Implementations of Lord Darzi recommendations: - high quality care for all, 
and healthcare for London (Lord Darzi 2008). 
4. Modernising Scientific Careers (MSC):- which is an ambitious work 
programme which seeks to ensure that the healthcare science workforce is 
well equipped to meet the challenges and opportunities of the future delivery 
of care. Modernising Scientific Careers: The UK Way Forward (Department 
of Health 2010). 
5. Changing Technology and Microbiology Total Automation; - Nowadays, 
MALDI TOF technology has been implemented as a valuable tool for the 
identification of micro-organisms (Giuseppe Cornaglia and René J. Courcol 
2012). Chemistry and haematology services have long had the advantage 
of total laboratory automation. Automation will eventually become the norm 
in the microbiology laboratory and opening a new era (Matthews and 
Deutekom 2011). 
6. The introduction of a National Laboratory Medicine Catalogue: - will bring 
greater standardisation and more appropriate use of tests and pathology 
knowledge. This catalogue is the first comprehensive standard for pathology 
test requests and result reporting, and will be available from July 2012. 
 
In the following parts of this introductory chapter, it will briefly discuss the discipline 
of clinical microbiology, microbial infectious diseases, and microbiological 
investigation strategies, how they are applied and the role of clinical microbiology 
laboratories. The following part of the introduction will describe the background to 
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this study, illustrating the problems of inappropriate use of clinical microbiology 
tests and the importance of this current study using sputum specimen as a study 
model for appropriate or inappropriate utilisation of the microbiology laboratory 
service. 
 
The second part of the introduction reviews the literature; the issues related to this 
study that are reviewed here include the common examples of pitfalls in routine 
microbiology laboratory investigations, the appropriate utilisation of clinical 
microbiology, such as the clinical relevance and cost-effectiveness, and turn around 
times in clinical microbiology tests. In addition to these, the impact of specimen 
management in clinical microbiology tests and total testing process will be 
described briefly. 
 
The final part of this review will illustrate the reasons for the selection of respiratory 
tract specimens for this study, the role of microbiology in the diagnosis of lower 
respiratory infections, and the latest guidelines that are available to clinical 
microbiology laboratories for the evaluation of respiratory tract microbiology 
specimens, potential limitations and clinical indications for their use will be taken 
into account. Finally, the importance of sputum specimen ‘quality’ and methods of 
its assessment will be reviewed, and at the end aims and objectives of the project 
will be stated. 
 
1.1 Clinical microbiology 
 
Clinical microbiology is a clinical service which supports the investigation and 
management of patients suspected of having infections and infectious diseases 
through all stages of their care, from diagnosis, to therapy, to prognosis. The 
clinical microbiology laboratory uses methods for detection, isolation, identification, 
characterisation, sero-diagnostic investigation, laboratory surveillance, and 
antimicrobial susceptibility testing of clinically significant microbial pathogens or 
their products of diagnostic significance, e.g., toxins, antigens and nucleic acids.  
 
An infectious disease is a clinically evident disease resulting from the presence of 
pathogenic microbial agents. Therefore, clinical microbiology studies their biology, 
diagnosis, treatment, control and prevention. To clinicians caring for patients with 
infectious diseases, the clinical microbiology laboratory provides a wide range of 
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facilities to assist in the diagnosis and treatment of infectious diseases and other 
related health conditions susceptible with microbial infections. Samples from a wide 
range of body sites are analysed to determine whether pathogenic micro-organisms 
are present in clinical specimens collected from patients with suspected infections. 
If micro-organisms are found, these are identified and their susceptibility profiles, 
when indicated, are determined.  
 
Approximately 25% of all deaths worldwide are due to infectious diseases, and in 
some countries this number approaches 50% (World Health Organisation 1997). 
New infectious diseases, such as HIV, SARS, Avian Flu and Swine Flu, are 
continually emerging, and old diseases, such as tuberculosis are re-emerging. 
Across the globe, infectious diseases account for greater than 60% of the deaths of 
children less than four years of age. Governments are spending billions to combat 
the threat of bioterrorism. Thus, all of the above areas represent topics of major 
concern in the field of clinical microbiology. Common topics of interest to clinical 
microbiology include the nature of the etiologic agents, their interactions with the 
immune system, and the diagnosis and epidemiology of the infectious disease.  
 
For microbiological investigations, the collection of patient specimens is driven by 
symptomatology and clinical examination of the patient. The first step taken is the 
collection of specimens before antibiotic therapy has been started and quickly sent 
to the microbiology laboratory. Sampling may be performed for epidemiologic 
purposes; here the goal is to detect patient colonisation by potentially hazardous 
and multi-drug resistant bacteria. The major goal of microbiological investigation is 
to diagnose microbiological infection and treat the patient with appropriate 
antibiotics. The bacteria may be detected in one or more of the following ways: (1) 
analysis of bacteriological samples by microscopy (2) culture and identification of 
bacteria from samples (3) serological tests and nucleic acid tests. 
 
Diagnosis and effective treatment of an infection depends not just on isolating an 
organism, but in establishing a plausible link between the patient’s clinical 
conditions, results from non-microbiological tests, microbiological findings, and the 
recognised syndromes. One of the major problems encountered in a clinical 
microbiology laboratory is the separation and identification of infectious micro-
organisms (pathogen) from those that are normal or normal flora (non-pathogen). 
The normal microbial flora of the human body is mainly located in the superficial 
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layers and gastrointestinal tract. Certain areas of the body, such as skin, upper 
respiratory tract, intestinal tract, female genital area and open wounds, develop an 
environment of normal microbial flora, or micro-organisms. These sites are called 
non-sterile body sites. These sites are open to the external environment and 
normally contain bacteria.  
 
Lower respiratory and upper urogenital tracts are normally sterile, but they are 
susceptible to microbial invasion from adjacent sites. Sterile body sites are areas 
that normally do not contain any bacteria, so any bacteria found there are 
significant. Blood and cerebrospinal fluid (CSF) are good examples. However, 
microbial contamination during specimen collection, processing and culturing in the 
laboratory, plus the patient’s microbial colonisation as a result of long term 
antimicrobial treatments and in hospital environments could also cause significant 
difficulties for the interpretation of microbiological results. 
 
The validity of clinical microbiology laboratory results and reports is dependent 
upon the following factors:  
 
1. Appropriateness of specimen  
2. Proper collection and adequacy of specimen  
3. Appropriate transport to the laboratory  
4. Use of culture media of known quality  
5. Culture and isolation by knowledgeable personnel using equipment known to be       
     correctly functioning  
6. Confirmation by tests of known quality 
7. Results interpreted and reported by professional staff  
8. No transcription or computer errors. 
 
The clinical microbiology laboratory test results can have a positive impact on 
patient’s healthcare and have positive outcomes, such as: 
  
1. The reduced length of hospital stay 
2. The reduced cost of hospital stay 
3. The reduced turnaround time for diagnosis of infection 
4. The change to appropriate antimicrobial therapy 
5. The customer (physician/clinician or patients) satisfaction. 
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Thus, the clinical microbiology laboratory service is a cornerstone for infectious 
diseases diagnosis, and the philosophy behind the clinical microbiology laboratory 
is to place maximum emphasis on speed of processing number of tests on 
specimens often obtained from complicated infections and associated disease.  
 
1.1.1 The role of clinical microbiology laboratories 
 
The role of clinical microbiology laboratories evolves in response to clinical needs 
and flow of information between patients, clinical microbiologists and physicians 
and could change in the future, with some tests being carried out by patients and 
doctors, and redistribution of clinical microbiology services to large, centralised 
laboratories (Bartlett et al. 1994, Barenfanger 2001, Reller et al. 2001, Baron 2011). 
The role of the microbiology laboratory and microbiologist are especially important 
to the clinician caring for a patient with compromised host defences. The 
microbiologist can assist in establishing a differential diagnosis and selection of 
laboratory tests to make an infectious diagnosis. Complete understanding of 
microbiology test results not only improves patient management, but also reduces 
the cost of medical care. Therefore, one of the main goals of the clinical 
microbiology laboratory is to improve the usefulness of microbiological results and 
data to clinicians, and the multiple roles of the clinical microbiology laboratory can 
be summarised as following: 
 
1. Diagnosis of a microbiological infection 
2. Antibiotic therapy advice 
3. Epidemiological surveillance: multi-drug resistant bacteria (MDR) 
4. Introduction of new diagnostic tests 
5. Identification of new bacterial species 
6. Identification of new resistance mechanisms.   
 
The delivery of microbiology services is an integrated service that requires a range 
of trained professionals (clinical microbiologists, clinical scientists, biomedical 
scientists, nurses, pharmacists and information technology specialists) working in 
an organisational framework for the delivery of clinical care (primary, secondary 
and tertiary care) and health protection, and also draws in expertise from academia 
and industry.  As part of the pathology services, the clinical and health protection 
requirements of a microbiology service must also be balanced within the overall 
pathology modernisation programme that was announced by the Department of 
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Health (DOH) in 2004, and which aims to provide a networked responsive and 
quality assured pathology service (Department of Health 2004). 
 
The science of clinical microbiology has, and is, undergoing radical transformation 
and modernisation to cope with an ever-increasing problem of new, emergent, and 
re-emergent infectious diseases, as stated earlier. Recently, the diagnostic 
microbiology laboratories at some UK hospitals has introduced a new method of 
rapid microbial identifications, MALDI-TOF (matrix-assisted laser desorption 
ionization-time of flight) which is a  modified mass spectrometry method (Seng et al. 
2009, Seng et al. 2010, Cherkaoui et al. 2010, Van Veen, Claas and Kuijper 2010).  
This makes diagnostic microbiology tests more clinically relevant in a shorter time 
frame, which is very important in modern healthcare, with its emphasis on shorter 
lengths of stay, ambulatory style care, and also in public health. MALDI-TOF 
technology has improved the test turnaround time (TAT) and the accuracy of 
organism identification, speed, minimal reagent and labour costs of the technology 
(Van Veen et al. 2010, Cherkaoui et al. 2010, Wolk and Dunne Jr 2011). 
 
In addition to MALDI-TOF technology, the diagnostic clinical microbiology 
laboratory has seen rapid developments in the area of laboratory automation over 
the last few years, some as a result of new and affordable technology allowing 
automation of routine processes. Meanwhile, laboratories have also faced 
increasing workload demands, and an increasing need for cost-effectiveness. In the 
bacteriology laboratory, two thirds of a medical laboratory scientist’s time may be 
spent on non-core activities, with one-quarter being spent on inoculation of plates 
and broths. The development of systems combining biology, informatics, imaging 
and engineering can allow automation of repetitive tasks, enabling the medical 
laboratory scientist’s and microbiologists to focus on ‘high value added’ activities. In 
microbiology, successful automation means ‘fast microbiology’. Fast microbiology is 
based on the premise of faster results; reducing the time needed for results, to 
allow earlier and optimised patient management (Dumitrescu, Dauwalder and Lina 
2011, Matthews and Deutekom 2011, Greub and Prod’hom 2011, Mulatero, 
Bonnardel and Micolaud 2011). 
 
In the past four years, several automated specimen processing instruments have 
been placed on the European market and in the United States (Paxton 2011). The 
WASP (Walk Away Specimen Processor), manufactured by Copan in Italy, was 
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introduced in 2008 as a new system for automated plating and streaking of all 
microbiology samples, and in 2010 the next-generation of WASP was introduced. 
The second preanalytical device is the PREVI Isola, made by the French firm 
BioMérieux. The PREVI Isola employs advanced robotics to inoculate, streak, and 
label specimens, managing 90% of the steps required to process liquid 
microbiology specimen samples. Another instrument, the Innova Preanalytical 
Automated Microbiology Specimen Processor, formerly made by Canadian 
company Dynacon, is now owned by Becton Dickinson and marketed in Europe. 
One other similar instrumentation in Europe is Kiestra Laboratory Automation, 
which is now owned by Becton Dickinson and specialises in total laboratory 
automation for the bacteriology laboratory. Kiestra is a laboratory automation 
system from end to end for specimen processing and culture reading using image 
analysis of bacterial growth.  Kiestra stresses the modular, open architecture of its 
system components, which can be adjusted to fit the space available. The goal of 
microbiology laboratory automation is to benefit healthcare systems by speeding up 
laboratory test turnaround times, while also eliminating the cost of laboratory 
services. 
 
Clinical microbiology may direct decisions regarding hospitalisation, isolation and 
anti-infective therapy, but it is not effective at the time of initial presentation for 
example at A&E (Cohen-Bacrie et al. 2011). To resolve the time lag between test 
results and patient care, effective microbiology test is needed in the form of point of 
care testing (POCT). These tests address the need to hospitalise patients, to 
isolate contagious individuals and to initiate and focus anti-infective therapy. For 
example, the rapid testing of Group B Streptococcus colonisation in pregnant 
women at delivery enables timely, focused prophylaxis of materno-fetal infections 
(El Helali et al. 2009, Cohen-Bacrie et al. 2011). This strategy might represent a 
major evolution of decision-making regarding the management of infectious 
diseases and patient care. We assume that clinical microbiology in the 21st century 
will focus on concerns regarding the real-time management of patients by delivering 
results at the time of care.  
 
Clinical microbiology staff are at the forefront of responses to high profile healthcare 
problems (e.g., MRSA, antibiotic resistance, Clostridium difficile infection, HIV, 
syphilis, chlamydia, and respiratory diseases such as influenza). Thus, the clinical 
microbiology laboratory is organised to provide rapid, relevant and clinically useful 
services. Good two-way communication between clinicians and medical 
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microbiology laboratory staff is of utmost importance. Clinicians should identify and 
mention factors and conditions which will direct the management of microbiological 
investigations, while the medical microbiology laboratory should inform clinicians 
about changes in nomenclature, interpretation criteria, and the introduction of new 
or modified tests, and assist in the interpretation of the results they generate.  
 
As far as the clinicians are concerned, the aim of laboratory medicine is generating 
information from clinical specimens. As “information brokers”, clinical 
microbiologists play an important role in how that information is generated and 
used. This role starts with the specimen and accompanying information received in 
the laboratory (in the form of test orders from the physician) and is completed when 
the final product is presented and distributed (in the form of test reports to the 
physician).   
 
The design and utilisation of both test order forms and reports, whether written or 
electronic, provide an opportunity for clinical microbiologists to educate those 
involved in these processes and improve the quality of patient care. As the test 
report is directly viewed by the clinician managing the patients, presentation of 
additional information in the form of textual comments provides an important direct 
and continuing opportunity to educate about appropriate test utilisation and 
interpretation.  
 
The importance and demand for microbiological tests is increasing due to 
healthcare drivers, including the aging population, increasing infections in the 
modern society, such as those related to immunocompromised patients 
(splenectomised patients, renal haemodialysis patients, chronic ambulatory 
peritoneal dialysis (CAPD) patients, solid organ transplant patients, AIDS patients, 
haematology and oncology patients), intravenous drug users, and intensive care 
patients. There is an unknown threat from biological warfare or bio-terrorism and 
pandemic flu. As a result of these increases, it has been estimated that workloads 
in microbiology are likely to increase in the future, particularly as a result of: 
 
1. The growing burden of microbial disease, for example new and emerging 
microbial infections and the development of antimicrobial resistance e.g. MRSA. 
2. Initiatives requiring microbiological support, for example cancer networks, HIV 
and the sexual health strategy, tuberculosis. 
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3. Initiatives on healthcare associated infections. 
4. Initiatives on the use of antimicrobial drugs, including antiviral drugs, and effort 
to control the emergence of drug-resistant infections. 
5. Increased requirements for clinical microbiology advice as a result of patients 
with more complex conditions, with a delegated service delivery to 
multidisciplinary teams and increasing specialised care in the community. 
 
From this introductory account it is clear that, as stated in the beginning, 
approximately 70% or more of medical decisions made by clinicians are based 
upon laboratory tests, and microbiology laboratory results have an impact on 
patient care. It also shows that all laboratory results need to be accurate, precise, 
timely, and relevant, and must reflect true patient state. In addition to this, the goal 
of a microbiology testing is to detect and identify the causative infectious agent(s), 
guide effective treatment and eliminate infection as a cause of clinical presentation. 
On the other hand, there are risks of poor microbiology test results, such as not 
detecting the infectious agent causing disease and attributing infection to non-
causing micro-organisms. Either case is an injustice to the patient, and the 
healthcare system. These will cause inappropriate therapy e.g. no treatment when 
needed, over treatment when not necessary and poorly directed therapy. Similarly, 
it will cause additional work up and testing of patients, as well as confounding 
information and unnecessary cost. The present study will investigate the 
inappropriate utilisation of microbiology tests.  
 
1.1.2  Background and rationale for the study 
 
To be appropriate, a test should have the potential to affect a patient management 
decision. In clinical microbiology, this primarily occurs through demonstration and 
identification of micro-organisms and determination of their antibiotic 
susceptibilities. This generates several test results, each of which may influence 
clinical decision making and reduce the length of patient stay in the hospital.  
 
Appropriate use of clinical microbiology tests depends largely on one’s perspective. 
For the clinician or physician, appropriate laboratory use is defined by what is 
believed to be necessary to care for a specific patient at a specific point in time. For 
a laboratory providing services to that clinician or physician, appropriate use might 
be defined by test performance parameters, test cost, or the availability of 
alternative test methods.  
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For third-party payers (e.g., financial departments and insurance companies), 
appropriate use is likely to be defined as that which limits testing to minimise 
healthcare costs. For public health officials, appropriate use may be defined as that 
required to screen patient populations for diseases or infections of public health 
interest. For regulatory bodies, appropriate laboratory use is defined by the 
principle of medical necessity.  
 
Above all other considerations, defining appropriate test use must be based on the 
clinical relevance of tests. The term ‘clinical relevance’ is roughly synonymous with 
‘clinical significance’ and ‘clinical importance’, as described in the review of 
literature in section 1.2.3. Tests that are not clinically relevant have no appropriate 
use. It is unlikely that tests that are not cost effective, have poor performance 
parameters, or have an unacceptable TAT can be used appropriately.  
 
Most of the published literature regarding inappropriate test use deals with the 
issues of overuse and strategies to decrease it. Relatively few controlled studies 
have been conducted on the issue of under use. Yet, as Van Walraven and Naylor 
(1998) and Lundberg (1998) have pointed out, inappropriate use has yet to be 
defined. Nonetheless, it is easy to recognise that the use of some tests is 
inappropriate. These include tests that: 
 
1. Are requested or performed on specimens that were collected improperly or from 
an inappropriate site. 
2. Are performed on specimens for which the performance parameters are 
unknown, or for which the test has not been approved or cleared for testing by the 
regulatory bodies. 
3. Result in increased healthcare costs without benefit to the patient or to the 
healthcare system, one example being duplicate tests, particularly when the same 
test is ordered by different clinicians or physicians caring for the same patient 
(Valenstein, Leiken and Lehmann 1988, Branger et al. 1995). 
4. Result in harm to the patient (e.g., unnecessary procedures, tests, or therapies, 
wrong therapy, or prolonged hospitalization).   
 
The challenge for tests in this category is not in recognising them, but rather to 
decrease or eliminate their use by physicians/clinicians. In the same way, it is easy 
to recognise that the use of some tests is appropriate. A test that is: 
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1. Performed on a properly collected and appropriate specimen. 
2. Performed using a method with known performance parameters. 
3. Done in an accredited laboratory. 
4. Completed in a clinically relevant time frame. 
5. Easily interpreted by physicians or clinicians. 
6. Is used to initiate, modify, or stop therapy that is less likely to be used 
inappropriately.  
 
Little has been written about the significance and impact of the inappropriate 
ordering of laboratory tests for infectious diseases (Baron and Peterson 2001, 
Wilson 2002). Inappropriate and redundant laboratory testing is not only wasteful, 
but more importantly it may lead to unwarranted and potentially toxic drug treatment 
(Wilson 1997). Inappropriate laboratory utilisation harms the patients, is expensive, 
unnecessary and may be clinically misleading. The utilisation of the laboratory 
service, and the running cost, has increased recently. It may be due to 
inappropriate test orders, staff salaries, and/or costs of supplies and services.  
 
Conversely, we should consider not only factors responsible for inappropriate or 
excessive use, but also those that foster under use. The latter includes failure to 
review test results and an inability to interpret them. Optimising clinical microbiology 
laboratory utilisation requires explicit criteria regarding when laboratory tests should 
be used, and development of methods to insure that the resulting data are utilised 
properly. In the review of literature section, some examples of the common 
problems of inappropriate use of clinical microbiology services in the field of 
infectious disease that clinicians should be aware of while ordering clinical 
microbiology tests will be illustrated.  
 
A report on a systematic review of laboratory audits performed by Naylor and Carl 
van Walraven in 1998 demonstrated that inappropriate testing is very common, and 
they pointed out that this is not only causing unnecessary patient discomfort, but it 
also increases the likelihood of increasing the number of false positive results, 
causing unnecessary worry and the need for further investigations (van Walraven 
and Naylor 1998).  
 
This systematic review report of laboratory test use showed up to 46% of ordered 
microbiology tests were inappropriate and unnecessary, as shown in Table 1.1 (van 
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Walraven and Naylor 1998). The question left unanswered was that of how to 
change behaviour to prevent inappropriate requesting and perhaps save 
considerable sums of money, improve value for money, and reduce the huge 
workloads placed on our laboratories. 
 
Table 1.1 Summary of inappropriate test use  
 
Study  Number 
of reports 
Number 
of tests 
Percentage 
inappropriate 
Range 
(%) 
Studies with implicit criteria 
 
General biochemistry & haematology 
 
Microbiology  
 
Cardiac enzymes 
 
Thyroid function 
 
Drug monitoring  
11 
 
5 
 
7 
 
2 
 
4 
 
16 
5360 
 
63030 
 
4979 
 
843 
 
2490 
 
2787 
56 
 
15 
 
46 
 
39 
 
30 
 
46 
11-95 
 
11-70 
 
5-95 
 
38-96 
 
17-55 
 
5-83 
The data in this table is compiled from reference (van Walraven and Naylor 1998). 
 
The studies of the common pitfalls of routine microbiology laboratory investigations 
have been described in the review of literature in section 1.2.1, these clearly 
demonstrate how such testing may lead to inappropriate use of tests and 
unnecessary antimicrobial treatment, which can be expensive and associated with 
potential adverse effects. In this era of increasing antibiotic resistance, it is crucial 
to educate medical students, clinicians, and staff physicians about the deleterious 
consequences of misusing both antimicrobial agents and laboratory tests (Hayden 
and Frenkel 2000). The use of computerised reminders for test requesting 
physicians is an educational tool that holds promise for decreasing unnecessary 
laboratory testing (Bates, Boyle and Rittenberg 1998). Furthermore, microbiology 
laboratories should develop and implement specific guidelines that allow them to 
reject inappropriate specimens.  
 
In addition to unnecessary laboratory tests, specimens submitted for 
microbiological testing require proper handling, from the time of collection through 
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all stages of transport, storage and processing. Issues common to all clinical 
specimens submitted for microbiological testing include, not only proper 
identification, but also collection techniques that maximise recovery of 
microbiological pathogens and minimise contamination. For specimens like sputum 
and urine, the relative proportions of micro-organisms present in vivo, must be 
preserved, or culture results can be misleading. If specimens are handled properly, 
culture results are easier to interpret, patient care is improved and costs are 
potentially decreased.  
 
As the above stated reviews of inappropriate use of clinical microbiology tests and 
associated problems indicate, there is a need to address this issue both locally and 
nationally. Hence, this study was carried out to investigate and provide information 
about the appropriate use of clinical microbiology tests with reference to specimen 
management, particularly respiratory tract specimens.  
 
1.1.3 Purpose of the study 
  
Given the crucial role that microbiology laboratory results play in healthcare 
decision making, it is important that they are accurate and specific. Compared to 
other types of laboratory results, such as chemistry or haematology, microbiology 
results have greater potential for misunderstanding and misinterpretation, because 
there are no normal values in microbiology test results. It is therefore the 
responsibility of the microbiologist to provide clinicians with reports with clear-cut 
conclusions that include only clinically relevant results. The microbiologist should 
not assume that the physician is aware of current laboratory best practices or 
organism names, and should provide interpretive information whenever necessary, 
as in the case of organisms that represent contamination.  
 
Further to this, clinical microbiology is distinct from other disciplines in laboratory 
medicine. The diversity of specimens and analyses in microbiology is much greater 
than in other disciplines, and materials are often highly variable in nature. 
Microbiology laboratories work with live pathogenic micro-organisms that need to 
be propagated for detection, and there may be the presence of contaminating 
indigenous or environmental flora. Organisms can be pathogenic at one time but 
play a commensal role at another. Microbiology results are, therefore, often 
interpretative with no “normal levels” as previously stated. The majority of 
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specimens submitted to the clinical microbiology laboratory do not yield a clinically 
relevant pathogen. 
 
The outcome of microbiology tests is directly influenced by the quality of the initial 
specimen; an improperly collected specimen means uninterpretable results. Proper 
specimen management, therefore, has a significant impact on the final outcomes, 
measured in post-analytical benefits to the patient. Simply put, time spent 
developing results for which there is no clinical benefit, on specimens that were 
poorly collected, is wrong. Specimens are the key to accurate microbiological 
diagnosis, in particular, they: 
 
1. Directly affect patient care and patient outcomes.  
2. Influence therapeutic decision-making. 
3. Impact on hospital infection control. 
4. Impact on patient length of stay, hospital costs and laboratory costs. 
5. Influence laboratory efficiency. 
 
However, with the growing pressure for laboratories to decrease costs and increase 
efficiency, it is important to critically evaluate the clinical utility of diagnostic tests. 
One of the ways we can improve patient care while lowering costs is to establish 
rules “up front” on when to culture and when not to culture. The service users and 
microbiologists must work together and develop laboratory guidelines. 
 
The current research project investigates the ways in which existing microbiology 
laboratory services could be used appropriately, investigates the use and 
misuse/abuse of routine microbiology investigations and examines the efficiency 
with which services users use routine microbiology tests. 
 
The focus of this study is on respiratory tract specimens using sputum samples as 
quality indicators for the examination of the total testing process in the microbiology 
service, as there are some common denominators for specimen quality. 
Respiratory specimens represent the most perplexing problem for clinical 
laboratories. Specimens which are representative of infection in the lower 
respiratory tract alveoli (lungs) cannot be easily obtained without contamination by 
upper respiratory tract secretions.  The normal flora of the respiratory tract contains 
many organisms which can, under certain circumstances, act as pathogens. 
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Recovering organisms is not the main challenge; rather, it is determining their 
significance. 
 
In addressing the appropriateness of specimens and interpretation of test results, it 
is important to evaluate the quality of specimens submitted to the laboratory.  A 
model for the assessment of the quality of sputum specimens for routine 
microbiology is described. Using similar methods, the other clinical specimen types 
from respiratory tract systems were examined briefly for their appropriateness, 
including the following: throat swab, ear swab, nose swab, mouth swab, bronchial 
washing (BAL), nasopharyngeal aspirate (NPA), tongue swab and tracheal 
secretion. 
 
The cost implication of inappropriate test utilisation (cost-effectiveness) was 
assessed during the study. The data from this project was used for the introduction 
of cost effective and clinically relevant strategies for the work up of microbiology 
services and other similar pathology sub-specialities in the modern NHS. 
 
1.2 Review of literature 
            
For the literature search strategy, databases were searched by crossing several 
subject headings (laboratories, diagnostic services, and diagnostic service-routine, 
quality assurance-healthcare) with several topic headings (guidelines, utilisation 
review) or text words (unnecessary, duplication, efficiency, inappropriate, over 
utilisation, underutilisation, quality control, quality assurance, guidelines, utilisation, 
utilisation review).  Databases were also searched for the following terms: clinical 
microbiology service, pathology services, NHS, medical laboratory service, service 
utilisation, cost effective. 
 
The data bases used included: PubMed, PubMed and Medline, Embase and 
PubMed and Cochrane Library. The relevant health circulars and publications were 
searched for the Department of Health internet site (www.doh.gov.uk). Additional 
resources and other databases used included the National electronic Library for 
Health (www.nelh.uk) and the British Library (www.bl.uk). Endnote was used for 
bibliographies formatting and simplifying reference.  
 
Online search for information and articles, the following Key words were used 
separately on different occasions: sputum, poor quality, lower respiratory tract 
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infections, community acquired pneumonia, pneumonia, Gram stain, sputum 
culture, test utilisation, clinical relevance, cost effective, specimen management, 
sputum macroscopic examination, sputum quality, microbiology laboratory test 
utilisation service, pathology service, NHS pathology, cost of pathology services. 
                    
Pathology tests, including clinical microbiology, are not optimally used. Referring 
back to an editorial he had written in the Journal of the American Medical 
Association (JAMA) in 1984, Professor George Lundberg asked the question in a 
further 1998 JAMA editorial: have we had advances in the field of best practice (in 
Pathology)? “Sadly, the answer in 1998 is that we still do not know, not even in a 
research mode. We not only haven’t gotten to first base, we haven’t even picked up 
our bat” (Lundberg 1998). 
 
Laboratory medicine testing is increasing at around 6-10% annually (Smellie 2003). 
In the UK, changes in National Health Service contracting will mean that increased 
pathology expenditure must ultimately be paid for by reducing clinical activity. 
Regardless of country, unnecessary testing carries a large financial burden. Large 
inequalities exist in testing activity between different general practices and hospital 
laboratories. These are not explained by patient or practice factors (number of 
practitioners, age, sex distribution of patient list, deprivation index etc.) (Smellie et 
al. 2002).  
 
Inappropriate use of tests leads to unnecessary expenditure, avoidable further 
investigation and referrals, and conversely, under use of certain tests leaves 
patients with sub-optimal management and potentially missed diagnoses (Barth 
and Jones 2003). Failure to act appropriately on the result of a test also has serious 
potential repercussions on patient management. The need for a better evidence 
base and for improvement in the use of pathology tests was recognised twenty 
eight years ago (Rinsler 1984), although little progress has been made. This has 
been the subject of several recent reviews. There is good evidence that practice 
behaviour can be changed by a combination of educational and facilitating 
mechanisms (Solomon et al. 1998), although these must begin with knowledge of 
what is best practice, followed by interventions to introduce this knowledge into 
practice. There is good evidence, for example, that outreach visits can help in this 
area. 
 
 -   34 
There has to date been no concerted attempt to collate all of the available evidence 
and guidance for pathology tests in a form supported by all of the relevant 
professional associations. The mismatch between resources used to develop and 
study new tests, and everyday guidance for users, has left many users uncertain as 
to the best use of tests. Although there is abundant scientific literature dealing with 
increased laboratory quality (mainly analytical), the literature on appropriate use of 
clinical microbiology tests is scarce. The task facing us now is how to introduce the 
knowledge we have into clinical care to reduce the adverse effects of inappropriate 
testing and the actions following on, and optimise the care that good use of tests 
can bring. 
 
This review section will focus on this issue in the field of the clinical microbiology 
laboratory reviewing inappropriate utilisation of the service and comparing it, where 
possible, with appropriate use.  
 
1.2.1  Common pitfalls of microbiology laboratory investigations  
 
The following common routine microbiological specimen examples illustrate some 
of the common pitfalls of the microbiology laboratory in the investigation of 
infectious diseases and infections that need to be investigated.  
 
Daily sputum cultures and poor quality of sputum specimens: One example of 
inappropriate use of clinical microbiology tests is daily requests for sputum cultures. 
In order to reduce this unnecessary practice, the laboratory must work with 
clinicians to help them collect the correct specimen for the test desired, organism 
suspected, or clinical condition of the patient (Sharp et al. 2004). For example, 
multiple specimens within 48 hours should not be processed. Also, a test of cure is 
not necessary if the patient has responded to therapy. 
 
Sputum quality screening is important, since sputum is among the least clinically 
relevant specimens, with no agent isolated in 40 to 60% of cases (Forbes, Sahm 
and Weissfeld 1998, Isenberg 2004). Respiratory specimens are frequently 
contaminated with resident flora; therefore, it is difficult to determine what is a 
respiratory tract pathogen. Direct Gram stain results should be used to aid in the 
selection of organisms to work up in the culture (Heineman, Chawla and Lopton 
1977, Skerrett 1997). Most of the literature supports the usefulness of the Gram 
stain in screening sputum specimens (Geckler et al. 1977, Heineman et al. 1977, 
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Kalin, Lindberg and Tunevall 1983, Joyce 1986, Skerrett 1997). However, the Gram 
stain has varying sensitivity and specificity, depending on the specimen and the 
reader’s level of skill (Isenberg 2004). 
 
However, for the diagnosis of lower respiratory tract bacterial infections, sputum is 
the gold standard specimen, but the quality of the specimen is the key, because 
oral and gastrointestinal secretions may contaminate it. Ideally, there should be 
“good quality” sputum for microbiological processing, and samples must be properly 
collected in order to be clinically relevant and provide a quality culture and 
susceptibility result for the patients. As stated by Bartlett, a culture of lower 
respiratory secretions may result in more unnecessary microbiologic effort than any 
other type of specimen (Bartlett 1974). More details of what is meant by good 
quality sputum specimens will be described in the review section of microbiological 
investigations of respiratory specimens (sections 1.2.8 and 1.2.9).  
 
Routine stool culture of patients more than three days in hospital: Several 
studies have shown that microbiology laboratories need to perform only a very 
limited range of tests on in-patients with hospital acquired diarrhoea (Hobbs et al. 
1997, Ozerek and Rao 1999, Gopal Rao, Ozerek and Jeanes 2001, Bauer et al. 
2001, Guerrant et al. 2001). If the diarrhoea is community acquired or acquired 
from travelling, the minimal testing recommended is: (a) perform cultures (which 
detect Salmonella, Shigella, and Campylobacter spp.) and suspected patients with 
bloody diarrhoea are tested for Escherichia coli 0157. (b) if the patient has taken 
antibiotics or chemotherapy in recent weeks, then additional testing for Clostridium 
difficile toxin is recommended. 
 
If the diarrhoea is nosocomial (hospital acquired, has onset after >3 days of 
hospitalization), then only C difficile toxin should be requested. C difficile is the most 
common enteric pathogen causing diarrhoea in hospitalised patients, and 
pseudomembranous colitis can occur in patients who have not been recently 
exposed to antibiotics (McFarland, Surawicz and Stamm 1990). The detection rate 
for bacterial pathogens such as Salmonella, Shigella, Campylobacter, and Yersinia, 
and for enteric parasites is less than 0.5% for persons who have been in hospital for 
greater than 72 hours (Siegel, Edelstein and Nachamkin 1990, Chitkara, 
McCasland and Kenefic 1996). Therefore, there should not be routine stool culture 
from hospitalised patients and the "three day rule" should be applied when ordering 
stool investigation in a hospitalised patient who develops loose stools. 
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The "three day rule" advises clinicians to avoid ordering tests for enteric bacteria 
and stool parasites for patients who have been hospitalised for more than three 
days, unless there is an ongoing nosocomial outbreak of food poisoning, or unless 
investigation determines that patients have access to food which may have been 
prepared under unhygienic conditions. Patients seropositive for HIV, neutropenic 
patients, and patients more than 65 years of age with immunosuppressive co-
morbid illnesses can be considered exceptions to the "three day rule" (Bauer et al. 
2001). Indiscriminate requests for routine bacteriology and for the examination of 
faeces for ova, cysts and parasites are a great nuisance to microbiology 
laboratories; the microbiological examination of faeces specimens is highly labour 
intensive. 
 
Repetitive daily cultures from a suspected site of infection (catheter tips): 
One of the repetitive daily cultures from a suspected site of infection is the catheter 
tip. It has been shown that qualitative intravenous catheter cultures have minimal 
value as predictors of catheter related bacteraemia and such culturing of catheter 
tips should be discouraged (Nahass and Weinstein 1990, Widmer et al. 1992). 
Some laboratories will not process a catheter tip sent for culture if a concurrent 
blood culture has not been submitted within a 24 hour period, either before or after 
the catheter removal, or if a recent (≤24 hour) blood culture is negative 
(Schreckenberger 2001).  Bacterial growth from catheter tips generally represents 
clinically insignificant catheter colonisation or contamination (Maki, Weise and 
Sarafin 1977). Patients collected from such repetitive qualitative catheter tips could 
lead to an incorrect conclusion that the patients were infected and treated with 
antibiotic therapy and unnecessary exposure to potentially toxic drugs. 
 
Swab sampling of superficial patient material (surface of an open ulcer): 
While swab culture from the surface of an open ulcer can identify wound 
colonisation that may help determine appropriate isolation precautions (for 
example, as in the case of MRSA, vancomycin resistant enterococcus, or other 
multi-drug resistant bacteria), it frequently leads to an uninterpretable result that 
does not accurately reflect the true underlying pathogen (Mackowiak, Jones and 
Smith 1978, Cierny and Mader 1984, Wheat et al. 1986, Perry, Pearson and Miller 
1991). Micro-organisms recovered from the surface of a wound do not reliably 
predict the causative pathogens to be found deep within underlying soft tissue or 
bone. Cultures of material obtained from curettage of the ulcer, or from deep tissue 
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biopsy, will be less contaminated and provide cultural information more useful in 
guiding antimicrobial therapy. 
 
Daily culture of urine specimens: Urinary tract infection is one of the most 
commonly encountered acute infectious diseases and accounts for the majority of 
the workload in clinical microbiology laboratories. Due to the large workload, 
identification of what are often insignificant organisms can waste laboratory 
resources, confuse the physician, and ultimately result in unnecessary antimicrobial 
therapy, which leads to resistance. It is now widely accepted that currently available 
urine “dip sticks”, which detect nitrites and leukocyte esterase, have high negative 
predictive values (90-95%) and can be used to exclude urinary tract infection in 
most patients (Hobbs et al. 1997). Similarly, catheter specimens of urine (CSU) 
should be tested only in the presence of symptoms. Routine testing of CSUs is 
wasteful and may lead to unnecessary antibiotic treatment. 
 
Other microbiological specimens that have similar pitfalls include the daily collection 
of CSF (lumbar puncture) for cultures from patients without suspected meningitis 
infection performed routinely (Campos 1994) and excessive numbers of 
contaminated blood cultures collected from patients in A&E departments (Kelly 
1998). 
 
In addition to these examples of common microbiological pitfalls, these studies also 
highlight the lack of communication between the microbiology laboratory, clinical 
and medical staff. Communication between the laboratory and clinical staff is 
perhaps the most important ingredient of a quality service from a microbiology 
laboratory. Good advice on specimen collection can be priceless, while the 
relevance of microbiological results often only become clear in a discussion 
between a clinical microbiologist and a treating physician. Antimicrobial sensitivity 
testing may guide therapy, but optimal therapy cannot be advised without 
considering certain patient-related factors, such as the site of infection, which may 
have a profound effect on the ability of a specific agent to act effectively. 
 
The conclusions from the above examples and studies illustrate the frequency and 
importance of minimising unnecessary laboratory tests, or tests that have no clinical 
relevance. In this context, the current study will investigate the factors affecting the 
quality of sputum specimens.  
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1.2.2 Appropriate utilisation of clinical microbiology tests 
 
As stated previously, clinical microbiology laboratories perform tests to aid in the 
diagnosis of infectious diseases, to help guide therapy for those diseases, to help 
control and prevent infection in healthcare settings, and to educate and train 
healthcare professionals. This is a broad and challenging mission. To accomplish 
this mission, a clinical microbiology laboratory must provide a wide variety of tests 
that span a number of different disciplines, from bacteriology to virology to 
parasitology to antimicrobial susceptibility testing. This mission has become even 
more challenging in recent years because of the emphasis on cost control in 
healthcare, the introduction of new (and often more expensive) diagnostic 
technologies, and increasing regulations. Thus, to meet their mission, laboratories 
must maintain or expand their services with fewer resources. One of many 
approaches to this dilemma is for laboratories to focus and limit testing to those 
tests that are both clinically relevant and cost-effective.  
 
The issues of utilisation and appropriateness are related. While utilisation is 
primarily concerned with the frequency of testing, appropriateness is concerned 
with the use in the right patient in the correct setting for the proper diagnostic, 
monitoring, or therapeutic reasons. Improving utilisation has the ability to reduce 
laboratory costs, while precluding several less pleasant alternatives, such as 
rationing laboratory tests or eliminating some altogether.  
 
It has long been evident that laboratory tests are over requested. Until recently, 
however, efforts to curb unnecessary laboratory testing were undermined by lack of 
incentives for change, and because of inability to predictably modify physician test 
ordering patterns. As with any type of laboratory testing, the cost-effectiveness and 
clinical relevance of microbiology tests are affected by pre-analytical, analytical and 
post-analytical variables, as discussed in the following section.  
 
The published data regarding appropriate laboratory utilisation has, until recently, 
focused on the issues of the relative accuracy of diagnostic methods, clinical 
relevance of tests, or the cost-effectiveness of different diagnostic methods. These 
issues first received emphasis in the early 1970s, when controlled clinical 
comparisons of diagnostic laboratory methods became more common, 
investigators began looking at the clinical relevance of diagnostic tests, and the 
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issue of cost control became increasingly important. As noted by van Walraven and 
Naylor (1998) and commented on by Lundberg (1999), much of the published 
literature about clinical relevance and cost-effectiveness lacks the scientific rigor 
that characterises evaluations of other diagnostic modalities and therapies. 
 
These criticisms are almost certainly valid, but holding laboratory tests to the same 
standards as other diagnostic procedures or methods may be unrealistic. There are 
two reasons for this. First, laboratory methods are usually used to confirm clinical 
impressions or to supplement clinical, radiographic, or other laboratory data. This is 
different from, for example, histological examination of a biopsy that, by itself, may 
provide definitive diagnostic information. In other words, many microbiology 
laboratory tests do not stand alone for the purposes of making diagnoses, whereas 
many other types of diagnostic methods or therapies do.  
 
Second, the clinical impression of the provider has an important effect on the 
interpretation of the test result. This is because the pre-test probability of a disease 
affects the post-test probability of a laboratory test result (Irwig et al. 2002). Thus, 
while it is often possible to design controlled clinical trails of novel diagnostic 
methods or therapies, evaluating laboratory methods is not as straightforward 
because other factors affect the interpretation of the laboratory test. This is not true 
of many other types of clinical evaluations, in which the process of blinding the 
study can remove clinical impressions as a factor in test interpretation. 
 
Despite these limitations, some issues regarding laboratory tests can be studied 
adequately via controlled clinical trails, including product comparisons, comparison 
of new diagnostic tests with older methods, evaluations of the relative cost 
effectiveness of different tests, and even some evaluations of clinical relevance. 
Some aspects of the clinical effects of laboratory testing can also be studied 
adequately, such as the impact of the timeliness of result reporting.  
 
One can approach the issue of laboratory appropriate utilisation from a number of 
perspectives, including those that are based on financial models, staffing ratios, 
productivity or other benchmarks, treatment and evaluation guidelines, and so on. 
Regardless of the approach that is taken, the one principle that must play a role in 
any assessment of laboratory utilisation, is that of clinical relevancy; no test can be 
cost-effective, no laboratory can be efficient and productive, and no organisation 
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can provide good patient care unless laboratory testing is clinically relevant. The 
other approaches that affect the patients care, include the cost-effectiveness of the 
tests and TAT of the test results. 
 
1.2.3 Clinical relevance in clinical microbiology tests 
 
An important criterion of quality for a microbiological test is how much it contributes 
to the prevention or cure of infectious diseases; this is called its clinical relevance. 
The term ‘clinical relevance’ is roughly synonymous with ‘clinical significance’ and 
‘clinical importance’. The term is not used consistently, however, because there is 
no standard definition, nor is there yet a quantifiable way to measure clinical 
relevance. This lack of objectivity should not impede assessments of clinical 
relevance, or lead to inaction. Clinically relevant tests share certain characteristics 
that can be used in assessment and, to be clinically relevant and cost-effective, 
diagnostic laboratory tests must have certain characteristics, as shown in Table 1.2. 
 
Table 1.2 Characteristics of clinically relevant microbiology tests 
 
1. Therapy can be altered based on test results. 
2. Test results can be used to alter therapy. 
3. Test results are available in a clinically relevant time frame. 
4. Tests are sufficiently sensitive and specific to provide false-positive and 
false-negative results with a frequency and consequences acceptable to 
users. 
5. Test positive and negative predictive values are appropriate for the type of 
test and clinical setting. 
6. Users can easily interpret test results. 
 
Therefore, the guiding principle for all microbiologic testing should be that of clinical 
relevance (Wilson 1997). No microbiology test should be ordered or performed 
unless it is of immediate relevance to a physician caring for a patient, or it is 
needed by public health authorities or hospital epidemiology and infection control 
personnel. For the physician, clinically useful tests yield results that allow the 
physician to initiate, stop or modify therapy based on the test result. For public 
health authorities, clinically useful tests allow for treatment of patients, follow up of 
case contacts, and collection of epidemiologic information. For hospital 
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epidemiology and infection control personnel, clinically useful tests allow patients to 
be placed in or removed from isolation, case contact follow up to occur, patients to 
be cohorted, and epidemiologic information to be collected and collated. 
 
Determining the clinical relevance of tests is challenging, however, because (1) 
physicians order laboratory tests for many reasons, and a given test has varying 
clinical relevance when used in different settings or for different reasons (Kassirer 
1989, Pannall et al. 1996); (2) laboratory tests are interpreted in the light of complex 
clinical scenarios, not as isolated or independent results; (3) clinical diagnoses are 
based on both objective and subjective information and (4) physicians presented 
with the same information may have differing interpretations of the importance or 
relevance of a test result. Both clinicians and laboratory scientists recognise that 
clinical medicine is not a simple matter of matching signs and symptoms with the 
results of laboratory or radiologic tests to generate a diagnosis and treatment plan. 
Most tests may be of more or less relevance to the physician depending on the 
clinical history, review of systems, family history, signs and symptoms, physical 
examination, and the results of other tests or studies. As a result, the pre-test 
probability of a disease (infectious disease) or condition substantially influences the 
physician’s interpretation and the clinical relevance of the test result (Aronson and 
Bor 1987). Moreover, the results of many laboratory tests cannot be interpreted 
accurately outside the context of clinical information. 
 
Use of algorithms is also a potential mechanism for limiting a physician’s pursuit of 
diagnostic certainty. Clinical relevance should inform laboratory practice at every 
stage in the process. The father of the drive for clinical relevance in diagnostic 
microbiology laboratories is Raymond Bartlett, a distinguished microbiologist from 
the United States (Bartlett 1974). Clinical relevance can only be ensured when 
there is good communication between the clinician and the laboratory. 
 
1.2.4  Cost effectiveness in clinical microbiology tests 
 
The term cost effective is poorly defined. It is often used as a euphemism for 
inexpensive, least expensive, or expensive but still worth doing (Wilson 2000). It 
was considered anti-academic, impure, or even dangerous by traditional 
microbiologists. Another way to view the issue, however, is the application of 
clinical relevance to diagnostic microbiology. The point is not to identify every 
organism that might be recovered, or to perform susceptibility tests on every 
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organism that will grow in the laboratory. The point is to provide clinicians with 
information that will allow them to provide the best care for their patients. In the 
process, the work can usually be done more economically than if everything 
possible is done. Thus, clinical relevance usually equals cost-effectiveness. Cost-
effectiveness does not mean cheap: it means the best value for money, as 
indicated in Table 1.3. 
 
Table 1.3: Characteristics of cost-effectiveness in microbiology tests 
_________________________________________________________ 
1. Test methodology is technically feasible, reproducible, reliable and economical. 
2. Test volume is sufficient to maintain performer competence. 
3. Test results are readily interpretable by laboratory staff. 
4. Test results are easily communicated. 
5. Tests are sufficiently sensitive and specific to provide false-positive and false-
negative results with frequencies and consequences acceptable to users. 
___________________________________________________________ 
 
Therefore, appropriate test use depends on the use of the most cost-effective test 
for a given purpose. Unfortunately, for obvious reasons, these definitions are 
inadequate. Using expensive microbiology tests when cheaper but acceptable 
alternatives are available, or using inexpensive tests that do not provide accurate 
test results, both increase costs without benefiting either the physician or the 
patent. A better, albeit descriptive, definition is “the least expensive method that 
yields clinically relevant test results in a timely manner and that does not increase 
costs elsewhere in the healthcare system” (Wilson 2000). What is needed beyond a 
descriptive definition, are definitions, particularly mathematical descriptions that can 
be used in controlled clinical evaluations to quantify and compare the cost 
effectiveness of alternative tests or methods. 
 
When alternative test methods are well characterised and have similar performance 
parameters and test TAT, then the most cost-effective method may be defined 
simply by its cost. In this case, the least expensive method is likely to be the most 
cost-effective method. On the other hand, for many clinical microbiology tests, 
alternative methods differ not only by cost, but also by their performance 
parameters and test TAT. In this case, the least expensive test may still be the 
most cost effective, but if a more expensive test has better performance parameters 
or test TAT then it may be the most cost effective method. This is one of the 
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problems with defining cost effectiveness: the cost of performing a test may or may 
not be the most important factor (or even a relevant factor) in determining whether 
the method is cost effective or not. A related issue is determining the point at which 
the costs required to achieve incremental gains in test performance parameters or 
test TAT make the method no longer cost effective. 
 
For example, nucleic acid amplification (NAA) tests are the most analytical sensitive 
tests for detecting and identifying pathogenic microorganisms, but increased 
analytic sensitivity may or may not result in increased diagnostic sensitivity. If a test 
method does not increase diagnostic sensitivity, or increases it only marginally, 
then the higher cost of using the method makes it less cost effective compared with 
one that has lower analytic but higher diagnostic sensitivity. Defining cost 
effectiveness is perhaps even more challenging than defining clinical relevance, 
partly because the cost effectiveness of a test depends on its clinical relevance, but 
also because many other variables must be considered. As another example, use 
of rapid automated methods for bacterial identification and antimicrobial 
susceptibility testing may result in improved clinical outcomes, decreased use of 
other laboratory tests, shorter hospitalisation, and decreased hospital costs 
(Granato 1993, Doern et al. 1994). 
 
Even in the absence of rigorous definitions and analytic methods, there is much 
that clinical microbiology laboratories can do to increase the cost effectiveness of 
microbiology tests. One of the ways to increase cost effectiveness of the tests is to 
follow the principles of cost effectiveness and clinical relevant microbiology testing, 
as previously described and stated in Table 1.4. 
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Table 1.4: Principles of cost effective and clinically relevant microbiology testing
a 
_________________________________________________________ 
 
1. Test only properly collected, transported, and labelled specimens. 
2. Test only appropriate specimens; reject inappropriate specimens. 
3. Perform and interpret tests according to their Food and Drug Administration 
approval or clearance. 
4. Perform and interpret tests according to manufacturer’s recommendations. 
5. Perform and interpret tests using standard microbiologic methods. 
6. Use adequately trained and competent staff to perform tests. 
7. Perform tests only if there is sufficient test volume to ensure competency 
and  proficiency. 
8. Refer esoteric tests to the most appropriate reference laboratories. 
9. Minimise test result turnaround time. 
10. Report test results using the most appropriate mechanism for the 
importance of the test. 
11. Develop and implement effective laboratory consultation and education 
programmes. 
 
a)  
adapted from: Clinically relevant, cost-effective clinical microbiology: strategies for 
decreasing unnecessary testing. Am J Clin Path 1997; 107:154-67 (Wilson 1997). 
 
1.2.5  Test turn around times in clinical microbiology 
 
TAT is the interval between the beginnings of one event to the end of another in the 
total testing process. Typically measured as the collection to reporting time, or as 
the receipt of specimen in clinical laboratory to reporting time. Inadequate clinical 
laboratory test TAT is one of the most common complaints that come to the 
laboratory manager. Since clinical evaluations typically require support from 
laboratory testing, until results are available, diagnoses are less certain and 
management decisions are delayed. From an outcome perspective, slow test TAT 
leads to longer waiting times for the patient, or incomplete information at the time of 
a clinical encounter. As a general rule, faster service is associated with higher costs 
and sometimes lower quality of test results. Therefore, it is the laboratory manager’s 
responsibility to determine the most effective overall testing processing and 
schedules that will provide the most cost effective and reliable results within a time 
frame that is clinically appropriate.  
 -   45 
Microbiology test results that are not available within a reasonable period of time 
are unlikely to be clinically relevant or to be used appropriately. The first challenge 
is to define a reasonable test TAT for each method, for each type of healthcare 
professional who uses the results, and for different healthcare organisations 
(Howanitz et al. 1993). A second challenge is to determine which measure of test 
TAT should be used (Valenstein and Emancipator 1989), and to develop a system 
to monitor and improve test TAT.  A third challenge is to determine what can be 
done to decrease test TAT to acceptable levels, and how much it will cost to 
achieve the shorter TAT. The final challenge is the question of whether one can 
satisfy clinician’s demands for shorter TAT, or if the laboratory should even try to do 
so (Valenstein 1989, Valenstein 1996). Satisfying physician’s expectations for 
improved test TAT is a complex process for which there is no single solution 
(Steindel and Howanitz 2001). 
 
No one argues that the results of some microbiology tests must be available 
quickly. At the same time, no one argues that physicians do not need the results of 
some laboratory tests for days or weeks (or it is not possible to obtain the results 
more quickly than that). It is easy to manage the TAT for those tests that fall into 
these two categories, which lie at either end of a continuum. It is much more difficult 
to manage the test TAT for those tests that fall between these categories; for most 
laboratory tests the acceptable test TAT is defined by the clinical status of the 
patient. For many tests, the acceptable test TAT may be minutes for one patient or 
days for another. 
 
The issue of test TAT is especially problematic in a clinical microbiology laboratory. 
Most clinical microbiology testing still relies on a culture-based isolation of 
microorganisms, biochemical identification, and traditional methods for antimicrobial 
susceptibility testing. Test TAT has been decreased significantly in some areas of 
clinical microbiology, such as mycobacteriology (if used rapid techniques e.g. PCR 
and microscopy examination), but for much routine microbiologic testing there has 
been little or no change in TAT. Some manufacturers have introduced more rapid 
methods, but there are only limited data to indicate whether the shortened test TAT 
improves the outcome of patient care (Granato 1993, Doern et al. 1994, Schifman, 
Pindur and Bryan 1997). In addition, where such data do exist, it should be 
emphasised that improvement in the outcome demonstrated for shortened test TAT 
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for a given test may not occur with other but similar tests, in different healthcare 
settings, or for patients with different clinical scenarios.  
 
The turnaround times for tests in microbiology are quite varied. Ranging from 24 
hours to a few weeks and an average microbiology tests TAT is as following: 
bacteriology culture and sensitivity – 2 to 4 days, serology tests – 1 to 24 hours 
onwards, TB culture – up to 6 weeks, mycology tests – up to 4 weeks, 
parasitological microscopic examination- few minutes to hours and tests sent to 
reference laboratories – 2 to 3 weeks.  
Electronic reporting of culture results instead of reporting on paper may shorten the 
turnaround time and may ensure correct communication of results (Bruins et al. 
2011).  Clinician’s value electronic reporting of clinical microbiology results, 
because it increases the efficiency in their medical practice and saves valuable 
time. Final culture results may be available sooner compared to the former practice 
of reports by paper, but, in contrast to current opinions, this shorter turnaround time 
does not automatically influence medical decision making. Where the fast reporting 
of first results is of importance, telephone reporting is still the communication 
method of choice.  
 
1.2.6 Total testing process and test ordering 
 
The total testing process (TTP) is a multistep process that begins and ends with the 
needs of the patient. The total testing process consists of three key components or 
phases as shown in Figure 1.1 and is presented here in briefly with reference to 
appropriate utilisation of clinical microbiology tests. These phases are pre-
analytical, analytical and post-analytical phase. 
 
Identifying the many steps in the TTP and planning and using an interdisciplinary 
team to begin a coordinated effort will improve the process and offer optimal patient 
care. The TTP is one of the systems used in applying quality management 
approaches to the clinical laboratory (Barr and Silver 1994, Schumacher and Barr 
1998). The TTP refers to the sequence of eleven steps of laboratory testing, 
outlined in Figure 1.1, beginning with a clinical question prompted by the patient-
clinical encounter and concluding with the impact of the test result on patient care.  
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Clinical microbiology testing, like other clinical laboratory testing, is a highly 
complex process. Therefore, TTP describes the full sequence of laboratory testing 
activities, which, when applied to the analysis and interpretation of clinical 
microbiology specimens, leads to decision that influence patient outcome resulting 
from test results. 
 
The testing cycle, commonly called the TTP was well described several years ago 
by George D. Lundberg, who pictured it as a “brain-to-brain” (Lundberg 1999). The 
starting point for a microbiology test, a question made by the physician to the 
laboratory, can concern diagnostic, prognostic and monitoring processes, and/or 
health maintenance and promotion. The end result of the testing cycle is patient 
outcome and the effectiveness of laboratory information in improving medical and 
economical outcomes. In this cyclical process, the laboratory test is ordered, the 
patient identified, and the specimen collected, transported and prepared for 
analysis and process. After the specimen has been analysed, the results are 
interpreted and reported to the physician or whoever ordered the tests. The action 
finally taken is based on the interpretation of the test results.  
 
Traditionally, microbiology laboratories have focused their attention on quality 
control methods and quality assessment programmes dealing with analytical 
aspects. However, a growing body of evidence accumulated in recent decades 
demonstrates that quality in clinical laboratories cannot be assured by simply 
focussing on purely analytical aspects (Plebani and Carraro 1997). A study review 
of errors in laboratory medicine concluded that in the delivery of laboratory testing, 
mistakes occur more frequently (pre-analytical phase) and after, the test has been 
performed (Bonini et al. 2002).  
 
Many of the mistakes in TTP are referred to as “laboratory errors”, but are actually 
due to poor communication, actions taken by others involved  in the testing process 
(physicians/clinicians, nurses and phlebotomists) or poorly designed processes 
which are outside the laboratory’s control (Plebani and Bonini 2002). Likewise, 
there is evidence that laboratory information is only partially utilised: a recent report 
demonstrates that 45% of the results for urgent laboratory tests requested by A & E 
department of one hospital were never accessed, or were accessed far too late 
(Kilpatrick and Holding 2001). In the modern approach to total quality management 
in clinical laboratory, which is centred on patient’s needs and satisfaction, the risk of 
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errors and mistakes in pre-and post-examination steps must be minimised in order 
to guarantee total quality of laboratory services.  
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Figure 1.1: The total testing processa   
 
a) adapted From: The total testing process applied to therapeutic drug monitoring. 
Therapeutic Drug Monitoring, 47-82 (Barr and Schumacher 1995).   
 
Today, many clinical laboratories still operate according to the traditional laboratory 
model, the old laboratory model (Figure 1.2), which is a linear, unidirectional flow 
process of one activity preceding the next activity. The traditional (current) clinical 
microbiology laboratory is isolated from what tests are ordered (input) and how their 
results are interpreted (output). The traditional laboratory cycle operates in one 
direction. The major concern in this model is the quality of test performance and the 
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production features and internal organisation of the laboratory (analytical phase). In 
the traditional model, the focus is on the science and technology and quality of test 
performance, and communication is almost non existent prior to the test request, or 
after the result is released. In this model, the clinical laboratory is not concerned 
with clinical appropriateness or interpretation of test results (Barr 1999). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  The traditional laboratory cycle 
 
The new laboratory model (Figure 1.3) is an interactive process, and the scope of 
laboratory services is broader. In the interactive clinical microbiology laboratory 
cycle, laboratory scientists and clinicians interact to improve how tests are ordered, 
how tests are performed, and how results are interpreted. The interactive laboratory 
cycle operates both directions. In this model, the focus is not only on the quality of 
test data generated (process/analytical), but also on the clinical appropriateness of 
test requests (input/preanlytical) and the correct interpretation of and response to 
laboratory information (output/postanalytical). The laboratory’s involvement in the 
entire total testing process will have a positive impact on patient outcomes, improve 
the clinical relevance and value of the laboratory’s service, and greatly enhance the 
cost-effectiveness of the laboratory operation (Barr 1999).  
 
To demonstrate how appropriate test utilisation will promote a better integration of 
laboratory services into the patient care process. This was described by Barr, and 
is known as Barr’s model of laboratory utilisation (Barr 1999). This model identifies 
the factors that affect the clinician’s decisions or actions at each step of the 
laboratory utilisation process. 
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Figure 1.3: The New Interactive Laboratory Cycle 
 
According to Barr’s model, in the input phase (pre-analytical), one must question if 
the test is appropriate for the stage of the clinical condition and if the time of 
specimen collection is correct. During the process phase (analytical), one must 
determine if, within clinically relevant guidelines, the test result is accurate and 
precise and timely with respect to the TAT needs of physicians. Finally, in the 
output phase (post-analytical), one must evaluate if the results are properly 
interpreted and integrated into patient care or if data overload is confusing or 
misleading physicians (Barr 1999).  
 
Barr’s model also demonstrated any appropriate roles for the laboratory scientist at 
each step of this process. Starting with the clinician’s assessment of the patient’s 
condition, the laboratory utilisation process moves to laboratory testing phases, 
which result in the application and integration of the test results into patient care. All 
three phases are critical. If a test is clinically indicated, or the laboratory’s precision 
is beyond that needed for clinical judgements, or if the result is misinterpreted, then 
an accurate and precise laboratory result is of no value.  
 
1.2.7 Impact of specimen management in microbiology tests 
 
Recent years have seen significant advances in the technology available within the 
clinical microbiology laboratory. Traditional methods have been improved with the 
availability of chromogenic media and spiral platers, while automated systems are 
used for blood culture, urine handling and analysis, immunoassay, bacterial 
identification and antibiotic susceptibility testing. Difficult cases will yield their 
answers to advanced molecular techniques, such as ELISA and PCR. These 
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methods, combined with the technical expertise of dedicated clinical 
microbiologists, enable laboratories to provide accurate results quickly, often on-
line, so that patients can be treated appropriately and effectively. 
 
The one area that is often overlooked is that of specimen management particularly 
specimen collection and transport. Centralised laboratory services often mean 
microbiology specimens being sent to laboratories many miles away. Although 
some laboratories may provide 24 hour service, this is not universal and specimens 
often have to wait until the next day for processing. 
 
In addition to this, specimen’s method of collection,  time of sampling, the source of 
the specimen and sample transport are often outside the direct control of the 
microbiology laboratory, but have a direct bearing on the ability of the laboratory to 
achieve reliable results. The other factors that the laboratory can control and that 
affect quality are the specimen quality assessment, identification, storage, and 
preparation (processing) of specimens. The laboratory therefore has a role in 
educating those taking and transporting specimens. Written instructions should be 
made available and regularly reviewed with the clinical and nursing staff. 
 
The clinical utility of clinical microbiology culture results is directly related to the 
types of specimens submitted for culture and their quality. If this initial requirement 
for specimen quality fails to be met, subsequent processing and culture work-up 
becomes irrelevant for meaningful patient management. The adage “garbage in 
results in garbage out” can be used to descriptively refer to the issue of specimen 
quality in the clinical microbiology laboratory. 
 
Specimen management in microbiology includes all the steps involving the 
specimen submitted for analysis of meaning selection, collection, transport, 
storage, analysis, and reporting. When errors occur at any point in this specimen 
management process, regardless of who might be responsible for error, the 
outcome of laboratory analysis can be affected and could lead to a negative 
outcome, such as misdiagnosis, extended length of stay, or inappropriate therapy. 
 
Specimens submitted for microbiological testing require proper handling from the 
time of collection through all stages of transport, storage, and processing. Issues 
common to all clinical specimens submitted for microbiological testing include not 
only proper identification but also collection techniques that maximise recovery of 
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microbial pathogens and minimise contamination. For specimens such as sputum, 
and urine, the relative proportions of different micro-organisms present in vivo must 
be preserved, or culture results may be misleading. If specimens are handled 
properly, culture results are easier to interpret, patient care is improved, and costs 
are potentially decreased. Although most guidelines for specimen handling remain 
unchanged, recent emphasis has been placed on modifying traditional practices to 
decrease or eliminate unnecessary work, increase laboratory efficiency, and make 
microbiological testing more cost effective (Miller 1999).  
 
Proper collection of microbiology specimens requires complex procedures that 
frequently have to be done by personnel outside the microbiology laboratory. 
Physicians, clinicians, nurses, and other healthcare personnel, as well as the 
patients or a parent, must perform the collection(s) of different types of 
microbiological samples from various sites. Although the microbiology laboratory 
provides collection instructions for different specimen types in the guide to 
microbiology services, specimen collection problems are the most common sources 
of laboratory error in microbiology operation.  
 
The basic principle of microbiological specimen collection states that the material 
must be from the actual site of infection, collected with a minimum of contamination 
from adjacent tissues, organs, or secretions. For example, throat swabs for 
streptococcal screening should be taken from the peritonsillar fossae and posterior 
pharyngeal wall, avoiding contact of the swab with other areas in the mouth. 
Contamination of sputum or lower respiratory specimens with oropharyngeal 
secretions must also be minimised. Respiratory culture the source of contamination 
is from improper mouth care prior to collection of specimen and lack of deep cough 
to obtain lower respiratory material. 
 
Microbiology specimens should be transported to the microbiology laboratory as 
quickly as possible. For instance, in a hospital setting, a maximum two hour time 
limit between collection and delivery of specimens to the laboratory is 
recommended (Wilson 1996, Wilson 1997, Miller 1999, Sharp et al. 2004). This 
time limit poses a problem for specimens collected in general practices and 
healthcare centres.  Delays in transportation of microbiology specimens to the 
microbiology laboratory may result in a falsely negative result because the over 
growth of the normal flora over the pathogen(s) or pathogens may not survive in the 
delayed specimen transport.  
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Specimen acceptability should be based on various factors that apply to a particular 
source/site of sampling. The quality and/or volume of the specimen as well as its 
condition upon arrival at the microbiology laboratory are all important 
considerations. Microbiology specimen acceptance criteria for testing and the lists 
of microbiology specimens suitable for culture provided the specimens have met 
with the appropriate collection and transportation guidelines is in Appendix 1.1. and 
Table 1.5. 
 
Similarly, the criteria for rejection of unsuitable specimens for culture must be 
established in microbiology laboratories (Wilson 1997). Although general guidelines 
exist and accrediting agencies have established standards, each microbiology 
laboratory must decide which parameters to utilise, depending on local conditions. 
Microbiology request forms and specimen labels must be checked to see that all 
essential information is included and is internally consistent. Should there be a 
problem; collection of a fresh sample is the best course of action. If the specimen 
cannot be re-collected, a responsible person should be contacted to make 
corrections. A comment should be entered on the final report that the specimen 
was received with a (specified) problem, and the name of the person who corrected 
the problem should be appended. Criteria for rejection must be readily available 
and microbiology laboratory specific. A list of specimen types or culture requests 
that should not be processed and rejected is shown in Table 1.5.  
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Table 1.5: Microbiology specimen rejection criteria  
_________________________________________________________________ 
1. Unlabelled or improperly labelled specimens (should not be processed from 
non-invasive sites and those from invasive procedures discuss with sender).  
2. Specimens received in leaking, cracked, or broken containers or improper 
container or use of improper transport medium. 
3. Improper temperature during transport or storage. 
4. Excessive transport time. 
5. Specimen received in fixatives. 
6. Oropharyngeal contaminated sputum. 
7. Duplicate specimen’s stools, sputum within a 24 hour period for the same 
test. (There may be exceptions in some patient cleared by the microbiology 
laboratory). 
8. Specimens not appropriate for a particular test (specimens unsuitable for 
request e.g. anaerobic request from aerobic transport or tests of little or no 
diagnostic value) or improper collection site for test request. 
9. Dry swab. 
10. Unpreserved specimens received more than agreed time after collection 
(should not be processed specimens with prolonged transportation). 
11. Twenty-four hour collection of urine or sputum for AFB or fungal culture. 
12. Other criteria specific to the microbiology laboratory. 
__________________________________________________________ 
    
The most common causes of specimen rejection by clinical microbiology 
laboratories include the following: 
 
1. Unacceptable specimens due to inappropriate collection. 
2. Specimens with labelling errors. 
3.  Specimens received without date of collection. 
4. No specimen received, only request form received. 
5. Specimens with insufficient quantity. 
6. Specimens received with no form or no name on the form. 
 
As reported in the previous sections, the TTP begins with the patient–physician 
interaction. At some point, the physician should formulate a potential diagnosis to 
be ruled in or ruled out by microbiology data. Microbiology tests are ordered and 
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the necessary specimens are selected, collected, and transported to the 
microbiology laboratory, often by someone other than the physician or the 
microbiologists. In fact, the early steps that occur before the specimen arrives in the 
microbiology laboratory are perhaps the most critical in the entire testing process, 
yet they are often conducted by those who may know the least about what the 
physician or microbiologists needs. 
 
Obtaining accurate and cost-effective microbiological test results is possible only 
when specimens are collected, transported, and stored properly. When proper 
procedures are followed, cultures of specimens are less likely to be contaminated 
and more likely to yield pathogens. Not only does this make interpretation of tests 
results easier, but it also reduces unnecessary work and, as documented for some 
specimens, reduces healthcare costs. Proper collection include submitting the 
appropriate number of specimens, submission of more that the recommended 
number of specimens does not improve the physician’s ability to interpret test 
results. The result of any laboratory result is only as good as the sample received in 
the laboratory. “Most laboratory work and the greatest cost will be associated with 
specimens of the least clinical value” according to  Bartlett (Bartlett 1974).  
 
From these accounts describing the impact of specimen management in 
microbiology investigation, it is clear that microbiological confirmation of clinical 
diagnosis of infection depends upon the collection of high quality specimens and 
their rapid despatch to the microbiology laboratory with all the necessary supporting 
information, as stated previously.  Laboratory tests detect micro organism or their 
products, or evidence of a patient’s immune response to infection. While coming 
from different perspectives, culture and serologic methods are important, 
cooperative, approaches to the identification of clinically important pathogens. 
Interpretation of culture results depends upon the source of the specimen. From 
sites that are normally sterile, any isolated organism is significant. From sites 
colonised by commensal flora, isolating and identifying the pathogen can be more 
difficult. Good communication between the clinician and the microbiologists is 
extremely important.      
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1.2.8 Microbiological investigations of respiratory tract specimens  
 
Lower respiratory tract infections (LRTI) are a very common cause of illness, 
representing a high proportion of consultations with GPs and also hospital 
admissions (NICE 2008). The following illnesses are different types of LRTI: 
pneumonia, including community acquired pneumonia (CAP), hospital acquired 
pneumonia (HAP), bronchitis and exacerbation of chronic obstructive pulmonary 
disease (ECOPD).   
 
Pneumonia remains a major cause of death worldwide and the sixth most common 
in the United Stated of America. The one year mortality rates may be as high as 
40% in patients who have been admitted to the hospital with CAP (Niederman 
2009, Johansson et al. 2010). The median overall mortality is approximately 14%. 
In hospitalised patients mortality is as high as 30% (Fine et al. 1996). The 
population of patients above 65 years of age is increasing in the developed 
countries and CAP in this population, requiring hospitalisation, has an incidence of 
1012 cases per 100,000 persons (Marston et al. 1997). 
 
The facts about the burden of respiratory diseases, including respiratory tract 
infections in the UK are stark. A report from the British Thoracic Society in 2006 
stated that the respiratory disease now kills one in five people in the UK as 
indicated in Figure 1.4 (British Thoracic Society 2006). CAP is a common cause of 
morbidity and mortality in the United Kingdom (British Thoracic Society 2006). 
Admissions relating to CAP accounted for 1.2 million bed days in 2004-2005 and 
CAP was identified as the cause of death in 34,000 people in 2004 (29% of all 
respiratory deaths) (British Thoracic Society 2006). 
 
The report also shows that the treatment and investigations of  respiratory disease 
costs the NHS £6.6 billion in 2004: 49% (£3.0 billion) inpatient care costs, 33% 
(£1.9 billion) in medication costs, 17% (£1.7 billion) in primary care costs and 1% in 
day cases costs. The cost of respiratory diseases is more than the running cost of 
the whole NHS pathology services, including clinical microbiology, which was £5.2 
billion as reported by Lord Carter in 2006 (Lord Carter of Coles 2006.).    
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Figure 1.4: Deaths by cause in the United Kingdom  
 
Both in primary care and in hospitals, doctors frequently use antibiotics to treat 
LRTI. Antibiotics are the appropriate therapy when the cause of LRTI is pathogenic 
bacteria, but are unhelpful when the LRTI has a viral or fungal origin  (Bartlett 
2010).  It is estimated that most LRTIs do not have a bacterial origin and that 
antibiotics are over used (Bartlett 2010). Antibiotics frequently cause side effects 
including nausea, vomiting, diarrhoea and skin rashes. Also, the over use of 
antibiotics has been linked to the emergence of bacterial strains that are resistant to 
standard antibiotic therapy, and which cause infections that are difficulty to treat.  
 
Patients admitted to hospitals with suspected LRTI undergo clinical examination 
and a series of investigations which may include: 
 
 Sputum culture – to detect bacteria. 
 Blood culture – to detect bacteria. 
 Chest X-Ray. 
 Standard blood tests, including arterial blood gases. 
 Blood tests for biomarkers of inflammation or infection e.g. C-reactive 
protein. 
 Urine test for legionella antigen. 
 Nose/throat swabs to detect viral infection. 
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The aims of the medical investigations are to differentiate LRTI from other chest 
illness (e.g. pulmonary embolism), identify the LRTI subtype (bronchitis, ECOPD or 
pneumonia), to guide the correct therapy and possible pathogens (Table 1.6).  
 
Table 1.6: Most common pathogens implicated in LRTI a 
______________________________________________________________ 
Disease and pathogen    Percentage of cases (%) _____ 
Acute bronchitis 
Respiratory virusesb         90 
Bordetella pertussis & Bordetella parapertussis    5–10c 
Mycoplasma pneumoniae       5–10c 
Chlamydia pneumoniae        5–10c 
Community-acquired pneumonia 
Streptococcus pneumoniae       66 
Haemophilus influenzae       1–12 
Legionella species        2–15 
Mycoplasma pneumoniae       2–14 
Klebsiella species        3–14 
Enteric gram-negative bacilli       6–9 
Staphylococcus aureus       3–14 
Chlamydia species        5–15 
Influenza virus         5–12 
Hantaviruses        1–2 
Other viruses         1–12 
Mycobacterium tuberculosis       1–10 
Moraxella catarrhalis        1–2 
Unknown        23–49 
Hospital-acquired pneumonia 
Gram-negative bacilli 
Pseudomonas aeruginosa        16 
Enterobacter species       11 
Klebsiella pneumoniae       7 
Other enteric gram-negative bacilli     9 
Acinetobacter        3 
Legionella species        0–2 
Haemophilus influenzae       0–2 
Other         0–10 
Gram-positive cocci 
Staphylococcus aureus       17 
Streptococcus pneumoniae       2–20 
Other         2–5 
Anaerobes         10–20 
Fungi           0–10 
Mixed         13–54 
__________________________________________________________ 
 
a The information in this table is compiled from reference (Carroll 2002). 
b Influenza A virus, Influenza B virus, parainfluenza virus type 3, respiratory syncytial virus, 
coronavirus, adenovirus, and rhinovirus. 
c The values represent the collective contribution of all four pathogens listed. 
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For the above stated reasons, early diagnosis of the organism causing CAP should 
ensure that appropriate and specific antibiotic treatment is instituted, potentially 
reducing cost and antibiotic related events such as Clostridium difficile enteritis, and 
for Legionella infection, allowing relevant public health measures to be taken.  
 
Diagnosis of LRTIs is frequently complicated by the contamination of specimens 
with upper respiratory secretions during specimen collection. As the upper 
respiratory tract may be colonised with potential pathogens (potential respiratory 
pathogens) not involved in the infection of the lower tract, and may yeild organisms 
capable of inhibiting the bacteria involved in lower tract pathology, this is the main 
challenge for the microbiology laboratory to ensure that an appropriate specimen is 
processed.  
 
Sputum is the most common lower respiratory tract specimen received by the 
microbiology laboratory. It is also often the most problematic to assess due to 
contamination by oropharyngeal flora (Sharp et al. 2004, Loens et al. 2009). Other 
problems include difficulty in interpretation due to contamination of the sample by 
upper respiratory tract flora, which may include potential pathogens such as 
Streptococcus pneumoniae and coliforms (especially in patients already given 
antibiotics). 
 
From the above stated short accounts and figures, it is clear that infections of the 
respiratory tract represent a significant proportion of all healthcare associated 
infections and a firm diagnosis of pneumonia and other LRTIs is not easy to make 
and it is even more difficult to establish its microbial aetiology. This is the reason it 
has been selected as a respiratory tract specimen for this study. 
 
The role of diagnostic microbiology tests is based on the level of evidence and 
degree of the grading guideline recommendations based on the strength of the 
evidence gathered, using a three-tier scale (Table 1.7). The grading used in this 
review is from the updated guidelines of the Infectious Diseases Society of 
America/American Thoracic Society (IDSA/ATS) consensus guidelines on the 
management of CAP in adults released in 2007 (Mandell et al. 2007). The British 
Thoracic Society (BTS) guidelines in 2001(Macfarlane et al. 2001)and BTS updated 
version in 2004 (Macfarlane and Boldy 2004) also used a similar grading system in 
the last BTS update in 2009 (Lim et al. 2009). 
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These guidelines suggest that patients with LRTI should be investigated for specific 
pathogens that would significantly alter standard (empirical) management 
decisions, when the presence of such pathogens is suspected based on clinical 
and epidemiologic clues (strong recommendation; level II evidence). 
 
Table 1.7: Levels of evidence ª 
________________________________________________________________ 
Evidence level    Definition 
_______________________________________________________________ 
Level I (high)   Evidence from well-conducted, randomized controlled trials. 
 
Level II (moderate)  Evidence from well-designed, controlled trials without 
randomization (including cohort, patient series, and case-
control studies). Level II studies also include any large case 
series in which systematic analysis of disease patterns 
and/or microbial aetiology was conducted, as well as reports 
of data on new therapies that were not collected in a 
randomized fashion. 
 
Level III (low)  Evidence from case studies and expert opinion. In some 
instances, therapy recommendations come from antibiotic 
susceptibility data without clinical observations. 
_________________________________________________________________ 
ª Level of evidence simplified from IDSA/ATS guidelines in 2007 (Mandell et al. 2007) 
 
The British Thoracic Society (BTS) Guidelines for the Management of Community 
Acquired Pneumonia in adults-2004 update and new guidelines in 2009 specifies a 
rationale for microbiological investigation in CAP as well as more specific guidance 
about particular investigations (Macfarlane and Boldy 2004, Lim et al. 2009), based 
on published evidence since the previous guidelines in 2001 (Macfarlane et al. 
2001). The microbiological investigations that are recommended for patients with 
CAP are summarised in Table 1.8. 
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Table 1.8: Recommendations for microbiological investigation of CAP ª  
 
 
Pneumonia severity Treatment site Preferred microbiological tests 
Low severity Home  None routinely 
Low severity Hospital  None routinely 
Moderate severity Hospital   Blood cultures 
 
 Sputum for routine culture and 
sensitivity tests for those who have not 
received prior antibiotics (± Gram stain) 
 
 Pneumococcal urine antigen test 
 
 Pleural fluid, if present, for MC & S 
and PAT 
 
 PCR or serological investigations 
     For mycoplasma and respiratory virus  
 
 Where legionella is suspected: 
(a) Urine for legionella antigen 
(b) Sputum or other respiratory sample 
 for legionella culture and direct 
immunofluorescence (if available). 
High severity Hospital   Blood cultures (minimum 20 ml) 
 Sputum or other respiratory sample 
for routine culture and sensitivity 
tests (± Gram stain) 
 
 Pleural fluid, if present, for MC & S 
and PAT 
 
 Pneumococcal urine antigen test 
 
 Investigations for legionella 
pneumonia:  
(a) Urine for legionella antigen 
(b) Sputum or other respiratory sample 
 for legionella culture and direct 
 immunofluorescence (if available) 
 
 Investigations for atypical and viral 
pathogens: 
 
 
ª This table simplified from BTS guidelines update in 2009 (Lim et al. 2009) 
 
In summary, it suggests that for patients with non-severe CAP routine 
microbiological tests may not always be needed, particularly for patients with no co-
morbid illness. It suggests collection of a sputum sample in patients with moderate 
severity CAP who are freely expectorating and in patients with severe or high 
 -   62 
severity CAP, it suggests that a “full range of microbiological investigations should 
be performed”, including sputum Gram stain, culture and blood culture as explained 
in Table 1.8. 
 
However, the microbiological diagnosis of pneumonia is hampered by sputum 
cultures, which may yield unreliable microbial aetiologies of pneumonia (Broughton 
et al. 1991, Reed et al. 1996). In addition culture results are available after 48 hours 
and techniques of rapid diagnosis, such as PCR, are not sufficiently accurate and 
not available in every place (Ieven and Goossens 1997). Furthermore, reliable 
methods as bronchoscopic protected specimen brush and bronchoalveolar lavage 
cannot be used in everyday practice, and are not available in every hospital 
(Broughton et al. 1991). 
 
For the microbiological investigation of lower respiratory tract infections there are a 
number of specimen types, corresponding to the various inflamed areas of the 
lower respiratory tract that may be submitted for microbiological analysis. These 
samples may be obtained non-invasively or by an invasive bronchoscopic or 
transthoracic procedure. The most common respiratory specimen received in the 
microbiology laboratory is sputum, expectorated or induced and blood culture 
samples from mainly hospitalised patients. Other types of specimens included in 
this category are tracheal aspirates, transtracheal aspirates, bronchial washes, 
bronchial brushings, and bronchoalveolar lavage fluids. 
In addition, for specific bronchial pathogens, it may be appropriate to submit upper 
respiratory samples (e.g., throat or nasopharyngeal) for detection of the suspect 
agent. For a select group of infectious agents, urine may be submitted for the 
diagnosis of Legionella pneumophila infections and pneumococcal antigen testing, 
and in a few situations, serum may be collected to establish a retrospective 
diagnosis using serologic testing. 
 
Sputum microbiological investigation is requested to establish the microbial cause 
of lower respiratory tract infections, particularly pneumonia and, as mentioned 
before, therefore is useful for several reasons: 
 
(1) Identification of respiratory pathogens and antibiotic sensitivity patterns to select 
of optimal antibiotic regiments to treat patients with pneumonia. 
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(2) Targeted and narrow spectrum antibiotic therapy limits drug costs and the 
threat of antibiotic resistance and adverse drug reactions such as C difficile 
associated diarrhoea.  
(3) Isolation of specific pathogens has public health or infection control 
significance, including legionella and penicillin resistant Streptococcus 
pneumoniae etc. 
(4) Microbiological investigations allow monitoring of the spectrum of pathogens 
causing community acquired pneumonia and other lower respiratory tract 
infections over time. This allows trends regarding aetiology and antibiotic 
sensitivity to be tracked for public health needs. 
 
However, the yield of sputum bacterial cultures is variable and strongly influenced 
by the quality of the entire process, including specimen collection, transport, rapid 
processing, satisfactory use of cytological criteria, absence of prior antibiotic 
therapy, and skill in interpretation. The yield of S. pneumoniae, for example, was 
only 40%–50% from sputum cultures from patients with bacteraemic pneumococcal 
pneumonia in studies performed a few decades ago (Barrett-Connor 1971, Lentino 
and Lucks 1987). A study of 100 cases of bacteraemic pneumococcal pneumonia 
found that sputum specimens were not submitted in 31% of cases and were judged 
as inadequate in another 16% of cases (Musher, Montoya and Wanahita 2004). 
When patients receiving antibiotics for > 24 hours were excluded, the Gram stain 
showed pneumococci in 63% of sputum specimens, and culture results were 
positive in 86%. For patients who had received no antibiotics, the Gram stain was 
read as being consistent with pneumococci in 80% of cases, and sputum culture 
results were positive in 93%. 
 
Collecting good quality sputum samples is always a challenge. Given the number of 
variables involved, samples often arrive inadequately labelled, leaking or overgrown 
with contaminating bacteria. 
 
1.2.9 Assessment of sputum quality as diagnostic tool 
 
Sputum quality is important for the microbiological diagnosis and treatment of the 
LRTI and the reliability of sputum culture results depend on the quality of the 
specimens (Sharp et al. 2004, Loens et al. 2009, Campbell and Forbes 2011). 
Sputum examination is a simple and rapid diagnostic tool for the presumptive 
identification of pathogens and may be the oldest and most entrenched techniques 
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still in use in the microbiology laboratory. However, the usefulness of sputum 
examination such as Gram stain and culture in the initial approach to a patient with 
CAP is still controversial. While several authors have outlined important limitations 
of this tool in terms sensitivity, reliability, and impact on treatment decisions 
(Woodhead et al. 1991, Bates et al. 1992, Theerthakarai et al. 2001, Ewig et al. 
2002, García-Vázquez et al. 2004), others consider sputum examination useful in 
the initial evaluation of patients with CAP (Boerner and Zwadyk 1982, Gleckman et 
al. 1988, Rosón et al. 2000, Kuijper et al. 2003, Musher et al. 2004).  
 
Recent trends that favour a diminishing role for diagnostic testing in management 
algorithms and all the attendant controversies are well reflected in two major 
consensus guidelines. The infectious Disease Society of America (IDSA)/American 
Thoracic Society (ATS) consensus guidelines encourage that an expectorated 
sputum sample for Gram stain and culture should be obtained from hospitalised 
patients with clinical indications such as intensive care unit admissions, failure of 
outpatient antibiotic therapy, cavitary infiltrates, etc, but are optional for patients 
without these conditions (Mandell et al. 2007). 
 
Sputum culture may identify the causative agent in CAP including unexpected or 
antibiotic resistant pathogens such as Staphylococcus aureus or antimicrobial 
resistant Streptococcus pneumococci. Routine sputum cultures are, however, 
neither very sensitive nor specific (Bartlett et al. 2000) and often do not contribute 
to initial patient management (Taylor et al. 1999). Problems include: 
 
 The inability of patients to produce good specimens. 
 Prior exposure to antibiotics. 
 Delays in transport and processing. 
 Difficulty in interpretation due to contamination of the sample by upper 
respiratory tract flora, which may include potential pathogens such as S. 
pneumoniae and “coliforms” (especially in patients already given antibiotics) 
as stated previously. 
 
Traditionally, a Gram stain done on a valid expectorated sputum specimen has 
served as a guide for initial selection of antimicrobial therapy for patients with 
bacterial pneumonia (Boerner and Zwadyk 1982). There are a number of reasons 
why Gram stain testing is widely accepted, such as: 
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 Readily available, inexpensive and entails no risk to the patient. 
 Does not require sophisticated equipment. 
 Evaluation is completed within a few minutes. 
 Provides valuable diagnostic and prognostic information (Ieven and 
Goossens 1997). 
 
Controversy exists in the medical literature regarding the reliability of sputum Gram 
stain to guide initial antimicrobial treatment of CAP (Hahn and Beaty 1970, Ries, 
Levison and Kaye 1974, Flatauer, Chabalko and Wolinsky 1980, Boerner and 
Zwadyk 1982, Kalin et al. 1983). These studies however, have used sputum culture 
as reference standard. In two studies as reference standard was used blood 
culture, but only for S. pneumoniae (Gleckman et al. 1988, Musher et al. 2004). 
There are many factors which need to be borne in mind when considering the 
reliability and usefulness of Gram stain results. These are summarised below: 
 
 Strict criteria for interpretation require appropriate operator training 
 Validity of results is directly related to the experience of the interpreter (Fine 
et al. 1991) 
 Sputum Gram stains correlate poorly with culture results in conditions other 
than CAP (Croce et al. 1998). This poses practical difficulties for 
laboratories that frequently have to interpret results with little or no clinical 
information 
 Lack of availability: a survey of diagnostic microbiology laboratories in 
England and Wales (Roberts et al. 2008) revealed that, of 138 respondents, 
53 laboratories (38%) do not provide a sputum Gram stain service at all 
and, of the remainder, 52 laboratories (38%) do so only on special request. 
Thus, ready availability of sputum Gram stain cannot be assumed. This lack 
of availability reflects the opinion of many microbiologists that sputum 
examination is rarely helpful in the diagnosis of CAP. 
 
These studies support that performance of routine and reporting of sputum Gram 
stain on all patients is unnecessary, but can aid the laboratory interpretations of 
culture results. However, microscopic examinations using Gram stain may be 
useful for the assessment of quality of sputum samples (cytological content) with 
rejection of poor quality samples and it can also aid the interpretation of culture 
results and occasionally give an early indication of possible aetiology as shown in 
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Figure 1.5 The Gram stain (x1000) in this figure is an example of inadequate 
sputum specimen. It shows squamous epithelial cells, absence of inflammatory 
cells, and mixed bacterial flora, primarily consisting of Gram-positive organisms of 
multiple morphologies (including cocci in pairs, chains, and clusters) as well as 
Gram-negative rods and cocci. 
 
 
 
 
 
Figure 1.5: Sputum Gram staining from poor quality specimen 
 
Determining the quality of the specimen is based on the numbers of 
polymorphonuclear leucocytes and squamous epithelial cells (SECs) present: 
purulent specimens may be selected for culture and non-purulent specimens or 
specimens contaminated with squamous epithelial cells may be rejected. A number 
of authors based rejection of sputum on an absolute number of SECs and/or 
leucocytes per field (Isenberg 2004, Sharp et al. 2004). Others based their rejection 
criteria on leucocyte/SEC ratio (Sharp et al. 2004). The advantage of using a ratio 
is that it compensates for the possibility of uneven distribution of cells in the smear. 
The microbiology laboratory automatically rejects sputum specimens such as this 
one shown in Figure 1.6. This Gram staining indicates poor quality sputum 
specimen full of squamous epithelial cells. 
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Figure 1.6: Gram staining of sputum with squamous epithelial cells 
 
However, a useful guide to the quality of a sputum specimen can be obtained by its 
macroscopic appearance. Few studies have examined the relationship between 
macroscopic cues and specimen quality. Since 1974 no empiric studies related 
sputum specimen quality to macroscopic appearance. A quality of most 
expectorated sputum can be predicted from their appearance, this fact has not 
been emphasised in the literature.  
 
For the macroscopic examination of an expectorated sputum sample is often 
sufficient to indicate whether it is primarily sputum or entirely or predominantly 
saliva. Sputum is customarily described macroscopically as mucoid (mostly 
mucus), mucopurulent (green looking with pus and mucus) or purulent (green 
looking, mostly pus), mucosalivary (mucus with a small amount of saliva) whilst the 
presence of frank or altered blood provides additional valuable information as 
described in Appendix 1.2. 
 
The close macroscopic examination of sputum physical or gross appearance shows 
the presence of saliva, mucoid, blood and pus as detected with the naked eye. The 
other sputum macroscopic appearance includes the fleck, blood, and amount of 
froth or bubbles.  The sputum consistency is described according to its physical 
factors of watery, mucoid, mucopurulent and purulent. 
 
Salivary samples are watery expectorated sputum specimen with heavy froth and 
bubbles. On microscopic examination they show predominance of epithelial cells 
and on Gram stain a variety of micro-organisms typical of the normal oropharngeal 
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bacterial flora. This contrasts with the appearance of good quality sputum samples 
from a patient with pneumococcal pneumonia where the Gram stain provides 
valuable information on the presence of pus cells, and typical staining appearance 
of pneumococci as shown in Figure 1.7. The Gram stain in this figure shows 
abundant inflammatory cells and Gram-positive diplococci which are Streptococcus 
pneumoniae and this is an example of good quality sputum specimen. 
 
 
 
 
Figure 1.7: Gram staining of sputum from good quality specimen 
 
Some microbiology laboratories will discard sputum specimens which are mucoid 
on naked eye examination, but this may be unreliable and those for examination for 
mycobacteria should be processed. Most laboratories discard specimen which 
appear to be only saliva and request a further sample. There is great variation in 
the method of processing sputum and, because there is no clear consensus. Based 
on the macroscopic and microscopic evaluation of sputum specimen, there is no 
reason to culture spit. The sender should be notified to recollect an appropriate 
specimen and this needs timely communication. The culture plate in Figure 1.8 is 
an example of culture of expectorated sputum showing different colonial 
morphologies on blood agar, which represents mixed flora; this result is common, 
even in the absence of a bacterial lower tract respiratory infection. 
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Figure 1.8: Sputum culture showing growth of mixed flora on blood agar 
 
In addition to sputum quality assessment, sputum culture and sensitivity, many 
clinical microbiology laboratories do not pass judgment on the significance of 
isolates from patients specimens and instead report to clinicians all of their 
microbiologic findings. This policy leaves the responsibility for interpretation in the 
hands of the physicians. One of the important functions that a microbiologist 
performs is to decide what is clinically relevant regarding specimen work up, what 
organisms to look for and report, what organisms are pathogenic, what constitutes 
normal flora. Inadequate reporting may lead to unnecessary action, reporting 
without a comment may lead to inappropriate antimicrobial therapy. Therefore, 
sputum culture results should be interpreted based upon the quality of the 
specimen, quantisation of growth (light, moderate, or heavy), clinical correlation and 
if possible correlation with the Gram stain. 
 
The sputum normal results from a healthy person would have no growth on culture. 
A mixture of microorganisms, however, normally found in a person's mouth and 
saliva, often contaminates the culture. If these micro-organisms grow in the culture, 
they may be reported as normal flora contamination. The normal respiratory tract 
flora includes Coagulase-negative staphylococci, Micrococcus species, a 
Diptheroids, Non-pathogenic Neisseria species, Alpha-haemolytic Streptococcus 
species, Non-haemolytic Streptococcus species. 
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From these accounts and reviews, the proper management of respiratory tract 
specimens is important for microbiological testing to inform the diagnosis as 
bacterial and indicate the key pathogen in the respiratory tract infections so that 
therapy can be pathogen directed, when possible, because of the public health 
benefit of making a specific diagnosis that allows recognition of epidemiologically 
important pathogens, contact tracing, and more rational use of antibiotics, and to 
promote further development of knowledge base producing guidelines and 
improving diagnosis of respiratory tract infections. In light of these accounts, this 
study was aimed to assess the appropriateness of microbiological test utilisation 
based on sputum culture. 
 
 
1.3 Aims and objectives of the study 
 
The overall main aim of this study was to determine the appropriateness of clinical 
microbiology test utilisation, evaluate the clinical relevance, cost-effectiveness, and 
hence recommend better utilisation strategies. The following steps were used: 
 
1. To assess the appropriateness of microbiology test requests and determine 
the proportion of tests that are appropriate and identify ways to eliminate 
unnecessary and inappropriate test requisitions in routine microbiology. 
 
2. To evaluate the quality of sputum specimens and processing practices to 
identify those unsuitable for microbiological testing by assessing the sample 
acceptance/rejection/processing criteria. 
 
3. Review the actual test results (negative and positive) and organisms 
detected and compare with the clinical profile of the patient’s and available 
evidence base for the actual process. 
 
4. To assess the reporting of microbiology results by evaluating the final report 
with reference to clinical relevance, appropriateness and service user’s to 
interpret the results. 
 
5. Determine the total cost of microbiology investigations and determine the 
cost of unnecessary tests to develop improved guidelines for working up of 
clinical specimens for microbiology testing. 
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Chapter 2 Methodology  
   
2.1 Introduction 
 
The present study was undertaken to evaluate the process of microbiology 
specimen management in order to assess microbiology test utilisation and the 
appropriateness of test ordering. From this work it was hoped to estimate the 
prevalence of inappropriate laboratory utilisation and identify the proportion of 
inappropriate tests. A systematic review of laboratory tests used showed up to 46% 
of ordered microbiology tests were inappropriate and unnecessary, as shown in the 
previous Table 1.1 (van Walraven and Naylor 1998). The current study investigated 
in more detail the inappropriateness of microbiology tests, particularly respiratory 
tract specimens using sputum microbiology as model for the microbiology service 
utilisation. 
 
The aim of the sputum study was to investigate the quality of sputum specimens, 
appropriateness of test requisition, adherence to specimen collection principles and 
laboratory compliance with the standard operative procedures (SOP). 
 
2.2 Ethical issues 
 
Ethical approval was obtained from the Bart’s and The London NHS Trust (BLT) 
Ethical Committee for the data collection phase of the study, which involved the 
retrospective collection of data from patients microbiology laboratory request forms 
and computer records during the study periods. The letter from the Ethical 
Committee is attached in the appendix section of the thesis (Appendix 2.1). 
 
2.3 Hospital setting and study design 
 
This study was conducted at the Microbiology Department of the Barts and The 
London NHS Trust, which comprises the three hospitals of St. Bartholomew’s, The 
Royal London and London Chest Hospital. BLT hospitals are tertiary care and 
teaching hospitals as well as referral centres with a total number of 1,172 beds (at 
the time this study was started) offering all modern medical specialties. This Trust 
provides a service to a catchment area population of over 2.5 million people from 
the City of London, East London and further afield. The total number of patients 
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attending every year is more than 766,844. This consists of 97,329 inpatients, 
507,599 outpatients, and 161,916 accident and emergency patients. The Trust data 
updates were obtained from BLT annual review 2005/06 at hospital web site 
(www.bartsandthelondon.nhs.uk). 
 
Similarly, the BLT Microbiology Department provides comprehensive diagnostic 
services to the hospitals within the Trust described above, as well as General 
Practice, Community and Newham Healthcare NHS Trust hospitals and community 
practice. Laboratory services are extensive and the microbiology laboratory 
processes over 436,000 microbiological specimens per year. The annual workload 
of respiratory tract specimens is more than 20,000, approximately 5% of the total, 
of which the number of sputum specimens is 9,566 (60%) and make up the largest 
fraction.  
 
The study retrospectively reviewed the microbiology laboratory request forms and 
computer records from the microbiology laboratory using standardised data 
collection forms. The research plan of the study proceeded in different phases and 
was conducted in three phases as described below. 
 
During the first phase (Phase 1), the study initially screened and evaluated the total 
number of respiratory tract specimens that have been requested for microbiological 
examination. Respiratory specimens were drawn anonymously from all patients in 
which respiratory bacteriology culture were requested in one calendar year (2004) 
that were sent to the microbiology laboratory for microbiological examination. The 
aim of this phase was to evaluate the usefulness of routine microbiological 
investigations for respiratory tract specimens and to assess it according to 
relevance of organisms reported during the actual test results. 
 
During the second phase (Phase 2), the study conducted in-depth analysis and 
detailed microbiological evaluation of representative respiratory tract specimens. 
Respiratory specimens were drawn from samples processed and cultured from 
March 12, to May 31, 2004 (three months). There were two aims in phase: 1. To 
review specimen-processing practices and criteria of specimen acceptability based 
on local standards (as described in the microbiology procedure manual of BLT 
microbiology department), national and internationally established guidelines and 
other available evidence-based practice. 2. To assess and evaluate clinicians/users 
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adherence to hospital microbiology laboratory guidelines and British Thoracic 
Society recommendations for microbiological investigation. 
 
During the third phase (Phase 3), the study conducted post evaluation and follow 
up of representative respiratory tract specimens. Respiratory specimens were 
drawn from samples processed and cultured from July 9, to July 18, 2006 (two 
weeks). The aim of this phase was to evaluate and follow up the impact of 
departmental policy changes due to rationalisation of the microbiology service and 
the outcome of this study based on the results obtained during Phase 1 and Phase 
2. 
 
2.4  Inclusion and exclusion criteria 
 
All the respiratory tract specimens requested for routine microbiological 
examination were included and assessed for their microbiological test 
appropriateness. These specimens were BAL, ear swab, ETT, mouth swab, nose 
swab, NPA, sputum, throat swab, tongue swab and tracheal aspirate. These 
specimens were selected to assure that the inclusion of specimens with the most 
commonly encountered in the diagnostic microbiology laboratory. Fifteen thousand 
and nine hundred and forty one respiratory tract specimens were studied during the 
period of this study. The respiratory tract specimens requested for AFB tests and 
samples for cystic fibrosis microbiological investigations were excluded and were 
not included in the present study. 
 
 
2.5 Data sources and specimen types 
 
The respiratory tract specimens were collected from various patients attending or 
treated BLT hospitals and Newham NHS Trust. The total respiratory tract workload 
activity in 2004-2005 was 18,915 (Barts and The London NHS Trust 2005, National 
Pathology Benchmarking Review 2005). 15,941 (84.3%) of the total workload was 
randomly selected for this study due to time consumed of the data accessibility. 
Table 2.1 provides a breakdown of the sources and the type of the respiratory tract 
specimens. The majority of the requests originated from BLT inpatients, followed by 
GP patients and were mainly sputum specimens followed by throat swab 
specimens. 
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Table 2.1: Sources and types of respiratory specimens in Phase 1 
______________________________________________________________ 
Specimen /Sources AE CL GP IP OP UNK Total (%) 
______________________________________________________________ 
BAL   1 59 0 43 4 0 107 0.7 
Ear swab  85 319 746 152 88 3 1,393 8.7 
ETT   0 0 0 425 6 0 431 2.7 
Mouth swab  8 36 70 39 9 1 163 1.0 
Nose swab  2 51 74 242 41 0 410 2.6 
NPA   4 0 3 204 0 0 211 1.3 
Sputum  198 538 655 7349 817 12 9566 60.0 
Throat swab  640 194 1260 854 585 16 3549 22.3 
Tongue swab  2 11 31 14 2 0 30 0.4 
Tracheal aspirate 2 1 1 44 3 0 51 0.3 
 
Total   942 1206 2840 9366 1555 32 15941 100.0 
 
Percentage  5.9 7.5 17.8 58.7 9.7 0.20 15941 100.0 
______________________________________________________________ 
 
 AE: accident & emergency, CL: chest/specialist clinics, GP: general practice, IP: 
inpatients, OP: outpatients and UNK: unknown. 
 
 
 During Phase 2 of the study period, of the 700 representative respiratory cultures 
that were studied in detail, 460 (65.7%) were obtained from inpatients, 113 (16.1%) 
outpatients, 89 (12.7%) GP patients, 21 (3.0%) accident & emergency department 
and 17 (2.4%) specialists’ clinics as shown in Table 2.2.  
 
Over the three month study period, out of 700 specimens, 511 (73.0%) were 
sputum specimens, 100 (14.3%) throat swabs, 63 (9.0%) ear swabs, 12 (1.7%) 
bronchial washings and there were smaller number of mouth swabs (6), nose swab 
(5) and few other respiratory specimens as shown in Table 2.2.  
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Table 2.2: Sources and types of respiratory specimens in Phase 2 
 
______________________________________________________________ 
Specimen /Sources AE CL GP IP OP UNK Total (%) 
______________________________________________________________ 
BAL   0 8 0 4 0 0 12 1.71 
Ear swab  0 0 23 6 34 0 63 9.0 
Mouth swab  0 0 1 2 3 0 6 0.86 
Nose swab  0 0 1 2 2 0 5 0.71 
NPA   0 0 0 1 0 0 1 0.14 
Sputum  2 7 9 427 66 0 511 73.00 
Throat swab  19 2 55 16 8 0 100 14.29 
Tongue swab  0 0 0 1 0 0 1 0.14 
Tracheal aspirate 0 0 0 1 0 0 1 0.14 
 
Total   21 17 89 460 113 0 700 100.00 
 
Percentage  3.00 2.43 12.71 65.71 16.14 0 700 100.00 
________________________________________________________________ 
    
During Phase 3 of the study period, 133 respiratory cultures followed up over a two 
week period, 119 (89.5) were sputum samples, 11 (8.3%) throat swabs and there 
were smaller number of mouth swab (2) and ETT (1) specimens as shown in Table 
2.3. 76.7% of the total specimens were from inpatients, 9.0% were from GP’s and 
followed by 7.5% from specialist clinics. 
 
 
 
 
 
 
 
 
 
 
 
 
 -   76 
  Table 2.3: Sources and types of respiratory specimens in Phase 3 
 
_______________________________________________________________ 
Specimen /Sources AE CL GP IP OP UNK Total    (%) 
_______________________________________________________________ 
Sputum  2 8 6 99 3 1 119 89.47 
Throat swab  3 2 5 1 0 0 11 8.27 
Mouth swab  0 0 1 1 0 0 2 1.5 
ETT   0 0 0 1 0 0 1 0.75 
 
Total   5 10 12 102 3 1 133 100.00 
 
Percentage  3.76 7.52 9.02 76.69 2.26 0.75 133 100.00 
_______________________________________________________________ 
 
2.6 Data collection 
 
In order to assess the microbiology test utilisation and appropriateness of the test 
ordering, suitable data collection kits were developed and structured in an 
appropriate format to review and evaluate the test utilisation practices and total 
testing processing as shown in Appendix 2.2. As stated before, data was collected 
from the laboratory request forms and computer reports using developed data 
collection tool designed to capture all relevant information. 
 
The major data elements collected included patient’s demographic details, 
microbiological test requisition of respiratory samples for M, C & S, patient’s clinical 
diagnosis, site of infection, quality of processed specimens based on macroscopic 
inspection, age of the specimens when received in the laboratory, whether patients 
were on antibiotic treatment, culture results (negative or positive), whether 
organisms isolated were pathogens or non-pathogens, TAT, final report issued and 
the interpretation of results. 
 
2.7 Data evaluation  
 
At arrival in the microbiology laboratory a biomedical scientist examines the quality 
of sputum specimen and decides if it is acceptable or unacceptable to process. 
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Combining the data from request forms and the data from the microbiology result 
report review allowed the data evaluation and assessment for the appropriateness 
of microbiology test utilisations. Microbiology test ordering was evaluated and 
judged to be justified (appropriate) if its request was in accordance with the clinical 
episode and widely accepted disease management guidelines and reviews 
published in reliable, peer-reviewed and indexed journals as described below. The 
specimen collection, handling and transport were evaluated per individual request. 
 
The criteria used for the assessing and determination of appropriateness of 
microbiological test requests and the appropriateness of sputum microbiological 
investigation is based on the criteria recommended by the British Thoracic Society 
guidelines in 2001, updated version in 2004 and 2009 guidelines as described in 
section 1.2.8 in the review of literature. The second criteria used were the BLT 
guidelines prepared by the respiratory and medical microbiology departments in 
2003. The BLT guidelines provide a rational approach to the microbiological 
investigation of respiratory specimen and it is attached in the appendix section 
(Appendix 2.3).  
 
In addition to these UK-based guidelines, other guidelines were taken into account. 
These included the other internationally recommended guidelines, including the 
recently updated guidelines of the Infectious Diseases Society of America/American 
Thoracic Society (IDSA/ATS) released in September 2007 (Mandell et al. 2007) 
and European Respiratory Societies (ERS) in 2005 (Woodhead et al. 2005) as 
explained in section 1.2.8 in the review of literature. The overall means of 
evaluation criteria based on the guidelines for microbiology laboratory testing 
(Murray 1999) and UK national guidelines as stated previously. Finally, the 
following key criteria have been used in this study which were based on the above 
stated guidelines, and recommendations.  
 
1. Type of microbiology test ordering or requisition for example routine 
bacteriology for culture and sensitivity (C & S), TB investigation, fungi 
investigation and cystic fibrosis microbiology. 
2. An accurate clinical detail to accompany any request for microbiological 
investigation since this determines the choice and conduct of laboratory tests. 
3. Previous antibiotic exposure or therapy. 
4. Quality of the sputum sample and contamination by normal oropharyngeal flora. 
5. Delays in specimen transportation and age of the specimen. 
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In addition to these criteria, the study investigator used other criteria to investigate 
the clinical relevance, cost-effectiveness of clinical microbiology and 
appropriateness of microbiology test results using respiratory tract specimens as a 
model. These criteria are the following: 
 
1.   Microbiology laboratory findings and cultures. 
2.   Reporting of microbiology test results and final reporting appropriateness. 
3.   Interpretation of actual test results and use of interpretative comments. 
4.   Expected reporting times and test TAT for microbiology tests. 
 
2.8 Data processing and statistical analysis 
 
A Chi-square (X2) test was used to compare the observed data with data we would 
expect to obtain according to a specific data analysed. This standard statistical 
method for categorical variables was used to detect significant differences between 
factors studied. It tests the null hypothesis that the intervention of Phase 3 of the 
study had no effect.  Associations were considered statistically significant if the P 
value was < 0.05 which means that the null hypothesis was rejected at the 5% 
level.  
 
The study investigated the cost implication of inappropriate test utilisation by 
conducting cost assessment. Microbiology laboratory costs were calculated by 
estimating the total pay cost/request and total non-pay cost/request of for each 
microbiology request. The total pay cost/request includes the medical salaries cost, 
clinical scientist salaries, biomedical scientist’s salaries and other staff salaries 
cost. The total non-pay cost/request includes the cost of supplies, equipment, and 
overhead charges.  
 
The microbiology laboratory charge fee of each laboratory test was obtained from 
the hospital finance department pricing list. However, the real microbiology test cost 
would not be disclosed due to confidentiality issues. For general microbiology test 
cost analysis, cost data was obtained from The Keele University microbiology 
benchmarking report (National Pathology Benchmarking Review 2005, National 
Pathology Benchmarking Review 2006, National Pathology Benchmarking Review 
2007, National Pathology Benchmarking Review 2008), Lord Carter NHS Pathology 
Reviews Reports (Lord Carter of Coles 2006, Lord Carter of Coles 2008) and 
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Healthcare Commission’s Report (CQC) in 2007 were used for data analysis where 
possible. 
 
2.9 Evaluation of microbiological quality indicators 
 
This study used a framework of microbiology quality indicators for the case of lower 
respiratory tract infection in a microbiology laboratory. The evaluation of 
microbiology quality indicators was based on the assessments of the key criteria’s 
described in the data evaluation section (2.7) and summarised in Table 2.4. For 
each key area of the practice, data on a series of quality indicators was collected 
and defined to evaluate the current practice of microbiological test appropriateness 
as explained in Table 2.4.  The definition of the microbiological quality indicators 
were described in the definition section (2.10).  
 
2.10 Definition of microbiological quality indicators   
 
Microbiological test utilisation and quality indicators results were described as 
“appropriate” if they were diagnostic or supportive of clinical diagnosis, a useful 
negative, or used in monitoring of treatment or disease progress.  
 
1. Test requisition: The microbiology tests requisition form has been completed 
and provided all relevant details by the user and particularly stated the required 
microbiology test including the test name or name of test requested, for example C 
& S. The test requisition was considered as an appropriate microbiological test 
requisition. 
 
2. Clinical diagnosis: Similarly, if the microbiology tests requisition form was 
completed and provided all relevant details by the user and particularly stated the 
patient’s working clinical diagnosis and clinical indications for the pre-test 
probability of the condition being sought to indicate that a test result would be 
abnormal or positive. The test requisition was considered as appropriate 
microbiological test requisition. 
 
3. Antibiotic use: The microbiology tests requisition form was completed and 
provided all relevant details by the user and particularly stated the patient’s 
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previous antibiotic exposure or antibiotic use. The test requisition was considered 
as appropriate microbiological test requisition. 
 
4. Quality of the specimen: The specimen has good quality with relevant test 
request and passed microbiology laboratory acceptability criteria, collected, 
selected appropriately and transported to the microbiology laboratory and received 
at the right time. The quality of specimen was considered as appropriate 
microbiological specimen. 
 
5. Specimen age: The specimen has good quality with relevant test request and 
was collected appropriately, transported to microbiology immediately, and received 
by the laboratory in a reasonable time to process. The quality of specimen was 
considered as appropriate microbiological specimen. 
 
6. Test turnaround times: If the turn-around times for each request were 
decreased and result reported in appropriate time. The TAT is considered 
appropriate. 
 
7. Reporting results: The laboratory report is precise and clear. The test report is 
considered appropriate. 
 
8. Result interpretation: The microbiological report has relevant comments and 
provides appropriate explanation of elements of the report and test to the clinician. 
The test report is considered appropriate. 
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Table 2.4: Evaluation of microbiological quality indicators  
 
No Appropriate quality indicators  Inappropriate process indicators 
 
 
1 
Test requisition: The microbiology tests 
requisition form has been completed and 
provided all relevant details by the user 
and the required microbiology test name 
has been stated, for example  C & S.  
The microbiological test requisition does not include 
the name of tests requested on the patients request 
form. This means, the patient’s sample has no test 
requested.  
 
 
2 
Clinical diagnosis: The microbiology 
tests requisition form was completed and 
provided all relevant details by the user 
and the patient’s clinical diagnosis and 
clinical information has been stated, for 
example pneumonia.  
The microbiology test requisition does not include 
the patient’s clinical diagnosis and relevant clinical 
information on the request form. This means, the 
patient’s clinical diagnosis is unknown.  
 
3 
Antibiotic use: The microbiology 
specimen has been collected before the 
start of the antimicrobial therapy.  
The microbiological requisition stated that the 
patient has been receiving antimicrobial treatment 
before the specimen collection. 
 
4 
Specimen age: The microbiology 
specimen has been transported properly 
and delivered to the laboratory as soon 
as possible after its collection. 
The microbiological specimen is not transported 
properly to the laboratory within 24hoursof its 
collection. This means, the patient’s specimen is too 
old to be processed.  
 
5 
Quality of the specimen: The    
microbiology specimen has been 
selected properly, collected properly and 
therefore has a good quality. 
The macroscopic quality assessment of specimen 
has found that the sample has poor quality and 
therefore the specimen is unsuitable for 
microbiological investigation.  
 
6 
Test turnaround times: The result of 
microbiology test has been reported as 
soon as possible and has a decreased 
TAT for each request. 
The reported microbiological test result has 
increased test turnaround times of more than 3 
days, the reported test results is too late and has a  
less microbiological significance. 
 
7 
Reporting results: The microbiology test 
result has been reported clearly, precisely 
and in a standardised format in which 
clinicians able to understand easily. 
The laboratory report is not clear, concise, and 
timeless and lacks clarity; the microbiology report 
creates confusion and misunderstanding for the 
clinicians and test users. 
 
8 
Result interpretation: The reports of  
 microbiological test result has been 
interpreted with relevant comments which 
provide    an appropriate explanation of 
the report to clinician.  
The microbiological test result does not being 
properly interpreted for their significance and 
instead reported to the clinicians in all 
microbiological findings, the test results is difficult 
and clinicians could not able to use it. 
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Chapter 3  Results      
  
3.1 Introduction  
 
During the 12 month retrospective study period, a total of 15,941 respiratory 
cultures were processed by the microbiology laboratory, and 6,396 respiratory 
cultures (40.1%) were reported as positive (definition of positive report, see section 
3.3). Of these respiratory cultures, 9,566 (60.0%) were sputum specimens, and 
3,730 sputum cultures (39.0%) were reported as positive.  During the three month 
period of detailed microbiological evaluation, a total of 700 respiratory specimens 
were studied, and 221 (31.6%) specimens were one day old and 81 (11.6%) were 
received after two days of collection. Of these respiratory specimens, 511 (73.0%) 
were sputum specimens, and a total of 306 (59.9%) of 511 sputum samples were 
considered to be of poor quality. During the two week period of post evaluation and 
follow up studies, a total of 133 respiratory samples were studied, and 119 (89.5%) 
were sputum specimens. Of these sputum samples, a total of 82 (68.1%) of 119 
samples was considered of good quality and appropriate for bacteriology culture.  
 
3.2  Evaluations for appropriateness of microbiology test ordering 
 
The analysis of the findings from the microbiological variables studied and 
information from the microbiology laboratory request forms is based on the 
microbiology quality indicators criteria described in Section 2.9. The evaluation of 
respiratory tract specimens for appropriateness of microbiological investigations by 
the designated quality indicators criteria are summarised in Table 3.1.  Similarly, 
the summaries of the results from the respiratory tract specimens due to 
inappropriate test ordering practice are presented in Table 3.2. The analysis of 
these results is based on the detailed microbiological evaluation of representative 
respiratory specimens during the three month period in Phase 2 of this study.  
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Table 3.1: Evaluation for appropriateness of microbiology test utilisation 
_________________________________________________________________ 
Evaluation criteria  Total RTS       Sputum  T/S          E/S                 
                                                 n (%)              n (%)_____    n %)___          n (%)__        
1. Test request:   
 C&S requested:  641 (91) 463 (91) 93 (93)  60 (95) 
 No test requested:   59   (9)  48   (9)  7   (7)  3   (5) 
Total number:   700  511  100  63  
2. Clinical diagnosis: 
With clinical diagnosis: 660 (94) 479 (94) 97 (97)  60 (95) 
Without clinical diagnosis: 40    (6) 32   (6)  3    (3)  3   (5) 
Total number:   700  511  100  63 
3. Antibiotic use: 
With antibiotic treatment: 277 (40) 214 (42) 35 (35)  25 (40) 
No antibiotic treatment: 188 (27) 135 (26) 33 (33)  12 (19) 
Not stated treatment:  235 (34) 162 (32) 32 (32)  26 (41) 
Total number:   700  511  100  63 
4. Specimen age: 
Same day received:  398 (57) 309 (61) 32 (32)  42 (67) 
I day old received:  221 (31) 145 (28) 46 (46)  19 (30) 
≥ 2 days old received:  81   (12) 57   (11) 22 (22)    2 (3) 
Total number:   700  511  100         63 
5. Sputum quality: 
Good quality specimen:   205 (40) 
Poor quality specimen:   306 (60) 
Total number:    511 
6. TAT: 
< 3 days results reported: 322 (46) 251 (50) 35 (35)  27 (43) 
Within 4 days reported: 127 (18) 94   (18) 23 (23)  5   (8) 
≥ 5 days results reported: 251 (36) 166 (32) 42 (42)  31 (49) 
Total number:   700  511  100  63 
________________________________________________________________ 
  
RTS: Respiratory tract specimen    T/S:   Throat swab       E/S:  Ear swab                 
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Table 3.2: Summary of inappropriateness of microbiology test utilisation 
__________________________________________________________________ 
Inappropriate test   Total RTS  Sputum  T/S                E/S                 
ordering practice due to:       n (%)    n (%) _____   n (%) __        n (%) ____       
 
1. No test requested:  59   (9)  48   (9)  7   (7)  3   (5) 
 
2. No clinical diagnosis: 40    (6) 32   (6)  3    (3)  3   (5) 
 
3. With antibiotic treatment:  277 (40) 214 (42) 35 (35)  25 (40) 
 
4. Prolonged transit time:  81   (12) 57   (11) 22 (22)    2 (3) 
 
5. Poor quality specimen:  0  306 (60) 
 
6. Increased TAT:   251 (36) 166 (32) 42 (42)  31 (49) 
_______________________________________________________________ 
  
RTS: Respiratory tract specimen    T/S:   Throat swab       E/S:  Ear swab                 
 
3.2.1 Microbiology test requisitions  
 
On the examination of microbiology laboratory request forms in Phase 2 of 
representative respiratory tract specimens, overall, 641 (91 %) of 700 respiratory 
tract samples were requested the microbiology test of C and S.  On the remaining 
59 (9%) no request was made as shown in Tables 3.1 and 3.2. The data from these 
results indicates that sputum specimens have the highest proportion of specimens 
that have no test requested (9%) during the microbiological test requisitions. The 
ear and throat swabs have the lowest number of specimens with no test requested.  
 
On further examination, it was found that the total number of respiratory tract 
specimens that were without microbiology test requests in the representative 
specimens that were assessed during the course of Phase 2 of this study have 
similar figures to that of the annual total workload; the difference found was only 1% 
(Table 3.25). 
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3.2.2 Patient’s clinical diagnosis  
 
On the examination of microbiology laboratory request forms in Phase 2 of 
representative respiratory tract specimens, overall, 660 (94.0 %) of 700 respiratory 
tract samples had the clinical diagnosis stated on the request form. In the remaining 
40 (6.0%) of 700 samples, patients clinical diagnosis was not stated on the request 
form, as shown in Tables 3.1 and 3.2.  
 
On further examination of sputum specimen requests, 479 (94.0%) of 511 patient 
requests for sputum microbiology had their clinical diagnosis on the request forms 
and 32 (6.0%) patients had not stated their clinical diagnosis. Where the patient’s 
clinical diagnosis was stated, 14 (3.0%) patient’s clinical diagnosis was illegible as 
explained in Table 3.3. The number of patients where their clinical diagnosis either 
was not stated or was illegible was 46 (9.0%) patients in total. The remaining 465 
(91.0%) of the 511 patient’s had stated their clinical diagnosis clearly. 
Total number of patients with respiratory tract infections where only 65 (13%) out of 
the 465 patients stated their clinical diagnosis. There were only a few patients with 
the clinical diagnosis of pneumonia; most of the respiratory tract infections were 
patients with chest infections, bronchitis, URTI, throat infections, haemoptysis and 
coughs. This analysis of the results showed that (87%) sputum specimens showed 
no evidence of respiratory tract infections (Table 3.3).  
The majority of the sputum specimens were from patients unlikely to have LRTI’s and 
samples were collected from patients with respiratory tract conditions such as COPD, 
bronchiectasis, respiratory failure and asthma. The post-surgery patients had highest 
sputum culture request followed by the oncology/cancer patients. 
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Table 3.3: Patient’s clinical diagnosis in sputum specimens in phases 2 and 3 
_________________________________________________________________ 
 Clinical diagnosis                                    Sputum culture          Sputum culture 
                               in Phase 2      in Phase 3  
                         (n = 511)   (n = 119) 
                                     No. (%)                No. (%)    
________________________________________________________________ 
 
Respiratory tract infections   65   (13)  19 (16) 
Pulmonary TB/TB    17   (3)   3   (2.5) 
Respiratory conditions   101 (20)  38 (32) 
Non-respiratory tract infections  24   (5)   7   (6) 
Oncology/Cancer    89   (17)  3   (2.5) 
Surgery and trauma    32   (6)   5   (4) 
Post-surgery     123 (24)  10 (8) 
Other conditions    14   (3)   27 (23) 
Illegible     14   (3)   1   (0.8) 
No clinical diagnosis given   32   (6)   6   (5) 
 
Total numbers:     511   119 
_____________________________________________________________ 
 
For throat swab specimens, in 95 (95.0%) of 100 samples the clinical diagnosis 
was stated, and only three (3.0%) had not stated patient’s clinical diagnosis. For 
two (2.0%) of the throat swab samples, it was not possible to read information in 
the request form. The majority of throat swabs have clinical conditions associated 
with throat conditions as presented in Table 3.4. More than 40% of the throat swab 
specimens were from patients with tonsillitis followed by patients with sore throats, 
and there were a few from patients with pharyngitis.  
 
For ear swab specimens, in 57 (90.0%) of 63 samples had stated their clinical 
diagnosis and 3 (5.0%) were not stated while another 3 (5.0%) specimens 
contained their clinical conditions, but they were illegible. The majority of ear swab 
specimens have been collected from patients with clinical conditions related to ear 
conditions such as ear discharge, ear infections and otitis media as presented in 
Table 3.5. 
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Table 3.4: Patients diagnosis in throat swab specimens in phases 2 and 3 
_________________________________________________________________ 
 Clinical diagnosis                             Throat swab culture    Throat swab culture 
                               in Phase 2          in Phase 3  
                   (n = 100)           (n = 11) 
                                No.  (%)                       No.  (%)    
________________________________________________________________ 
 
Throat infections    5   (5)   0 
Sore throat     27 (27)   1   (9) 
Pharyngitis     4   (4)   0 
Tonsillitis     44 (44)   2   (18) 
Throat conditions    2   (2)   0 
Non-throat infections    2   (2)   4   (36) 
Upper respiratory tract infections  3   (3)   2   (18 
Other conditions    8   (8)   1   (9) 
Illegible     2   (2)   0 
No clinical diagnosis given   3   (3)   1   (9) 
 
 
 
Table 3.5: Patients diagnosis in ear swab specimens in Phase 2 
____________________________________________________________ 
 Clinical diagnosis                                     Ear swab culture in Phase 2                 
                                    (n = 63) No.  (%)                    
____________________________________________________________ 
                      
Ear infections      11   (17) 
Ear discharge      32   (50) 
Otitis media      11   (17) 
Ear conditions      2     (3) 
Non-ear infections     0 
Other conditions     1     (1) 
Illegible      3     (4) 
No clinical diagnosis given    3     (4) 
______________________________________________________________ 
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3.2.3 Antibiotic use   
 
On the examination of microbiology laboratory request forms in Phase 2 of 
representative respiratory tract specimens, overall, 188 (27.0%) of 700 respiratory 
tract specimens were obtained before antibiotic treatment was given to the patients 
and for 235 (33.0%) of 700 samples it was not stated whether patients were given 
or not treated with antibiotics while 277 (40.0%) of 700 samples were collected from 
patients treated with antibiotics as presented in the Table 3.1. 
 
The total number of patients that were either on antibiotic treatment or their 
antibiotic treatment status have not been stated on their microbiology request forms 
was 512 (73.0%) patients as compared to 188 (27.0%) patients that has been 
stated on their request form no prior antibiotic treatment.  In sputum specimens, the 
total number of patients that were either on antibiotic treatment or not stated were 
376 (74.0%) patients of the 511 sputum samples collected and only 135 (26.0%) 
patients has no antibiotic treatment. 
 
The analysis of patient’s antibiotic usage results has found that, if the microbiology 
specimen was collected before the start of the antimicrobial treatment and the 
microbiology laboratory request form stated the patient’s previous antibiotic 
exposure or antibiotic use, then the test requisition was considered as appropriate 
microbiological test requisition. It has been also found, if the microbiology 
laboratory requisition form states that the patient’s has been receiving antimicrobial 
treatment before the specimen collection, this practice was considered as 
inappropriate test requisition and would have no value for patients management. 
 
3.2.4 Specimen age   
 
On the examination of microbiology laboratory request forms, in Phase 2 of 
representative respiratory tract specimens, it was found that 398 (57.0%) of 700 
specimens were transported to the microbiology laboratory within the day of sample 
collection and received by the laboratory on the same day and 221 (31.0%) of 700 
specimens were transported to the laboratory after one day of sample collection, 
while 81 (12.0%) of 700 specimens were transported to the laboratory specimens 
aged more than two days after the day samples were collected from the patients as 
presented in the Table 3.1.  
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With regard to sputum samples, 309 (61.0%) of 511 sputum samples have been 
transported to the laboratory within the day of sample collection and 145 (28.0%) of 
511 sample were received by the laboratory after one day of sample collection 
while 57 (11.0%) of 511 specimens were transported to the laboratory a more than 
72 hours after the day collected from the patients. Total number of respiratory tract 
specimens that were received and processed by the microbiology laboratory either 
within hours or within 24 hours of sample collection were 619 (88.0%) of the 700 
specimens in Phase 2 study.   
 
The distribution of sputum specimen ages were similar to the total rate of 
respiratory tract specimens stated previously. However, the total number of sputum 
specimens that were received and processed by the microbiology laboratory either 
within hours or within 24 hours of sample collection were 92.0 % as presented in 
Table 3.6 in phases 2 and 3 studies. 
 
On further examination, the age of specimen in throat swab and ear swab 
specimens indicates that 78 (78.0%) of throat swab were received within 24 hours 
and 22 (22.0%) received greater than 48 hours of sample collection. In ear swab, 
specimens received within 24 hours of sample collection was 61 (97.0%) and 2 
(3.0%) of the specimens received greater than 48 hours of sample collection. 
 
Table 3.6: Results of sputum specimen age (days) in phases 2 and 3 study 
________________________________________________________________ 
Specimen age   Sputum specimens   Sputum specimens                          
 days    in Phase 2     in Phase 3 
          (n = 511)     (n = 119)  
    No.  (%)                No.  (%)                 
_______________________________________________________________ 
0   309   (61)    62   (52)  
 
1   145   (28)    48   (40)  
 
≥ 2   57     (11)    9     (8)   
 
Chi-square test analysis of sputum specimens age results has shown that the 
specimens received either 24 hours or more than 48 hours were more than 40% of 
patient’s specimens as compared to those received within same day hence those 
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specimens were too old to process, X2 = 7.29 (P = 0.026) and transported to the 
laboratory more than 24 hours after the date of sample collection (Table 3.6).  
 
The analysis of specimen age results has shown if the specimen has good quality 
and is transported to the microbiology laboratory immediately and received by the 
laboratory in reasonable time to process, and then the quality of specimen was 
considered as appropriate microbiological specimen. It has been also found that if 
the microbiological specimen has not been transported properly to the laboratory 
within hours of its collection. The patient’s specimen is too old to process and this 
practice was considered as inappropriate test requisition and would have no value 
for patient management. 
 
3.2.5 Quality of sputum specimens 
 
Of the 511 sputum samples macroscopically evaluated for quality by the 
microbiology laboratory, in  463 (92.0%) their gross appearance were described 
and 48 (8.0%) sputum samples had no macroscopic description as presented in 
Table 3.7. On further examination, a total number of 306 (60.0%) of 511 sputum 
samples were considered of poor quality and inappropriate microbiologically to 
process. The sputum specimens described as poor quality included those 
described as mucoid, salivary and sputum specimens that have no description.  
 
The number of sputum specimens that were suitable for processing was obtained 
only from 205 of 511 patients (40.0%) and was considered of good quality and 
appropriate for microbiological investigation. Good quality sputum specimens 
included those described as mucopurulent and purulent sputum specimens. 
 
The rate of good quality sputum specimens received and processed by the 
microbiology laboratory was improved in 2006 as data from Phase 3 study shows 
from 40% to 69% and the rate of inappropriate or poor quality sputum specimens 
received and processed by the microbiology laboratory decreased from 60% to 
31% as presented in Table 3.7. Sputum specimens that were processed in Phase 3 
study were of good quality and considered appropriate as compared with sputum 
specimens processed in Phase 2 studies. 
 
Statistical analysis of results from sputum specimens quality description showed 
that there were significantly large differences between the quality of sputum 
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specimens in Phase 2, 40% (good quality)  and those in Phase 3, 69% (good 
quality),  X2= 35.04 (P = 0.0001) as presented in Table 3.7.  
 
Table 3.7: Results of sputum macroscopic description in phases 2 and 3 
_________________________________________________________________ 
Description   Sputum specimen               Sputum specimen  
    in Phase 2                      in Phase 3  
          (n = 511)            (n = 119) 
            No. (%)                        No.  (%)   
_________________________________________________________________ 
Salivary   35     (7)   13   (11) 
 
Mucosalivary   2       (0.5)   6     (5) 
 
Mucoid   186   (36)   13   (11) 
 
Blood stained   35     (7)   0 
 
Mucopurulent   155   (30)   80   (67) 
 
Purulent   50     (10)   2     (1) 
 
No description   48     (9.5)   5     (4) 
__________________________________________________________________ 
    2004 Phase 2 (n = 511)   2006 Phase 3 (n = 119) 
 
Appropriate   205    (40%)   82   (69%) 
 
Inappropriate   306    (60%)   37   (31%) 
 
 
The analysis of patient’s specimen quality results has shown that if the microbiology 
specimen has been selected properly, collected properly and has a good quality, 
the quality of specimen was considered as good and appropriate microbiological 
specimen.  
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3.2.6 Microbiology  test results turn round times  
 
15,941 respiratory tract specimens were received by the microbiology laboratory, 
15,718 (99.0%) of these specimens were reported their expected TAT and 223 
(1.0%) of the total specimens were not reported to requested clinicians due to 
unknown reasons. The expected TAT of results was reported in all of the 700 
respiratory tract specimens studied in Phase 2 of the study. 251 (36.0%) of 700 
respiratory tract specimens their culture and sensitivity results were reported more 
than five days of received sample by the microbiology laboratory as presented in 
the Table 3.8. 
 
Table 3.8 shows the overall TAT of respiratory tract specimens in all phases of the 
study. The data from Phase 3 study shows the decreased TAT in all days (from one 
to more than 5 days) as compared to the data from other phases of the study. Over 
30.0% of microbiology results were reported more than five days in study Phases 1 
and 2.  While the 39.0% of results were reported in two days and 27.0% were 
reported in three days in Phase 3 study. The reported results in Phase 3 in more 
than five days were only 17.0% as compared to other two phases. 
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Table 3.8: Results of respiratory tract microbiology TAT (in all phases) 
__________________________________________________________________ 
Turn around times  Respiratory tract       Respiratory tract Respiratory tract 
(Days)    specimens                specimens                  specimens   
    Phase 1  Phase 2   Phase 3  
(n =15941)   (n = 700)   (n = 133) 
No.  (%)              No.  (%)               No.(%)             
__________________________________________________________________ 
0   223 (1)                          0   0 
 
1   1511 (9)  68 (9)   16 (12)        
 
2   3099 (19)  112 (16)  52 (39)     
 
3   3371 (21)  142 (20)  36 (27)  
    
4   3025 (19)  127 (18)  6 (5)      
 
≥ 5   4712 (30)  251 (36)  23 (17)      
_________________________________________________________________ 
 
Table 3.9 shows the details of the results of sputum specimen reported TAT in all 
phases of the study. 2,563 (27.0%) of the sputum specimens test results were 
reported after more than five days of received sample by the microbiology 
laboratory in phase 1 and 166 (32.0%) in Phase 2 of the study while in Phase 3 
only 16.0%  were reported after more than five days. Among the individual 
specimens of throat swab and ear swab their microbiology results TAT results were 
presented in Appendices 3.1 and 3.2. 
 
Comparing the TAT results of all phases of the study, phases 1 and 2 has more or 
less similar pattern of TAT both in total respiratory specimens and among the 
individual specimens. The lowest TAT has been found in ear swab culture results in 
both phases where in Phase 1 40.0% of test results were reported more than five 
days and in Phase 2 49.0% of test results were reported more than five days. 
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Table 3.9: Results of sputum microbiology TAT (in all phases) 
____________________________________________________________ 
Turn around times Sputum            Sputum             Sputum   
(Days)              specimen                  specimen             specimen  
   Phase 1            Phase 2                       Phase 3 
   (n = 9566)           (n = 511)                     (n = 119) 
   No.  (%)                    No.  (%)                       No.(%)              
____________________________________________________________ 
0    0  0   0   
 
1   1374 (14)   63 (12)   11 (9)  
 
2   1934 (20)  88 (17)   50 (42)  
 
3   1939 (20)  100 (20)  33 (28)  
       
4   1756 (18)  94 (18)   6 (5)  
       
≥ 5   2563 (27)   166 (32)     19 (16)  
_____________________________________________________________ 
 
 
Statistical analysis of results (Table 3.9) from sputum specimens TAT showed that 
there were significantly difference between the TAT  of sputum specimens in Phase 
2 and those in Phase 3, X2= 58.86 (P = 0.0001). 
 
The analysis of patients expected TAT of results has shown that if the TAT for each 
microbiology request was decreased and results reported the expected TAT. Then 
the TAT is considered an appropriate. It has been also shown that if the reported 
microbiological test result has increased test TAT of more than three days, the 
reported patients test results is too late and has a less microbiological significance 
and was considered as inappropriate test requisition and would have no value for 
patient’s management. 
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3.3 Microbiological results of respiratory tract culture  
 
Over the 12 month study period, the results of a total of 15,941 respiratory tract 
specimens were analysed. The microbiological findings and their cultural results 
were reported in each specimen type in their respected tables and figures both in 
this section and in the appendix section. Microbiology laboratory cultured the 
respiratory tract specimens and reported the culture results findings according to 
the growth of micro-organisms either positive or negative. This study defined and 
assumed that for the positive culture, if the cultured organisms have been 
performed with full identification testing, antimicrobial susceptibility testing on 
relevant organisms and the test result were reported to the clinicians. For the 
negative culture, the cultured organisms no further identification and susceptibility 
testing have been performed on the organisms and then test results were reported 
to the clinicians.  
 
Overall, the average respiratory tract cultures were reported positive in 40.0% and 
negative in 60.0% for the cultured specimens in all phases of the study. Table 3.10 
explains the summary of the culture results from main specimen groups in Phase 1.  
 
The detailed microbiology culture results findings from the sputum specimens in all 
phases are presented in this section and the results from throat, ear and nose 
swabs are described here briefly. All microbiological findings from the other 
respiratory tract specimens are reported in the Appendix section of the thesis 
(Appendixes 3.3, 3.4 and 3.5). 
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Table 3.10: Summary of respiratory tract culture results in phase 1 
 
Type of respiratory 
 sample  
Number of specimens  
 studied  
Number of positive 
cultures (%) 
Number of negative          
cultures (%) 
BAL  
   
Ear swab  
  
ETT  
   
Mouth swab  
  
Nose swab  
  
NPA  
   
Sputum 
   
Throat swab  
  
Tongue swab  
 
Tracheal aspirate 
  
 
Total   
 
 
Percentage 
  
107 
 
1393 
 
431 
 
163 
 
410 
 
211 
 
9566 
 
3549 
 
60 
 
51 
 
 
15,941 
 
 
100 
44 (41%) 
 
996 (72%) 
 
249 (58%) 
 
41 (25%) 
 
183 (45%) 
 
128 (61%) 
 
3730 (39%) 
 
965 (27%) 
 
22 (37%) 
 
38 (75%) 
 
 
6,396 
 
 
40 
63 (59%) 
 
397 (28%) 
 
182 (42%) 
 
122 (75) 
 
227 (55%) 
 
83 (39%) 
 
5836 (61%) 
 
2584 (73%) 
 
38 (63%) 
 
13 (25%) 
 
 
9,545 
 
 
60 
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3.3.1 Sputum microbiology culture results 
 
In this study, 9,566 sputum specimens were cultured for lower respiratory tract 
infections investigation in phase 1 of the study, 3,730 (39.0%) sputum culture 
results were reported as positive culture and the remaining 5,836 (61.0%) sputum 
culture results were reported as negative test. The overall sputum microbiology 
culture results of all phases presented in the Table 3.11.   
 
Table 3.11: Summary of sputum microbiology culture results in all phases  
_________________________________________________________________ 
Culture results  Sputum             Sputum   Sputum    
   culture                        culture              culture   
         in Phase 1                  in Phase 2        in Phase 3  
   (n = 9,566)   (n = 511)  (n = 119)   
   No.  (%)              No.  (%)            No.(%)                 
_________________________________________________________________ 
Positive  3,730 (39)  161 (32) 48 (40)     
 
Negative  5,836 (61)  350 (68) 71 (60)      
_________________________________________________________________ 
 
Table 3.12 shows the number of positive culture sputum samples and the types of 
organisms isolated in each phase of the study. Based on data obtained from the 
Phase 1, the bacterial isolates from the positive cultures of 3,730 (39.0%), only less 
than 18.0% were respiratory tract pathogens while the other 72.0% were non-
respiratory tract pathogens. The primary respiratory tract pathogenic species 
reported were Streptococcus pneumoniae (4.0%), Haemophilus influenzae (7.0%) 
and Moraxella catarrhalis (3.0%). Among the culture positive sputum samples the 
most commonly isolated non-respiratory pathogens were coliforms (27.0%), 
Pseudomonas species (17.0%), Candida albicans (12.0%), MRSA (8.0%) and 
Staphylococcus aureus (6%).  
 
The micro-organisms listed in Table 3.12 were cultured from the sputum 
specimens; full identification testing and antimicrobial susceptibility testing has 
been performed. All were reported as possible potential respiratory pathogens with 
release of their susceptibility results. The microbiology reports were direct reporting; 
no comments or interpretations were used for results.   
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The analysis of frequency isolation of possible pathogens in all study phases 
remains very similar, and there were no significant differences and changes in 
proportion of positive sputum cultures, X2= 0.042 (P = 0.838) as presented in Table 
3.11.  
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Table 3.12: Sputum culture results reported as positive test in all phases 
_________________________________________________________________ 
 Microorganism/s          Sputum culture           Sputum culture     Sputum culture 
             in phase 1          in Phase 2     in Phase 3  
          (n = 3730)           (n = 161)    (n = 48) 
           No. (%)                       No. (%)               No. (%)   
_________________________________________________________________ 
Respiratory tract pathogens: 
Streptococcus pneumoniae  157 (4.2) 6 (3.7)   2 (4.2)  
Haemophilus influenzae  275 (7.4) 20 (12.4)  5 (10.4) 
Moraxella catarrhalis   102 (2.7) 2  (1.2)   0 
 
Doubtful non-respiratory  pathogens: 
Staphylococcus aureus  241 (6.5) 15 (9.3)  4 (8.3) 
MRSA     317 (8.5) 20 (12.4)  2 (4.2) 
Beta-haem.streptococcus A  31 (0.83) 2  (1.2)   0 
Klebsiella species   76 (2)  1 (0.6)   1 (2.1) 
Pseudomonas species  636 (17) 40 (24.8)  8 (16.7) 
Beta-haem.streptococcus B  9 (0.24) 0   1 (2.1) 
Beta-haem.streptococcus C  8 (0.21) 2 (1.2)   1 (2.1) 
Beta-haem.streptococcus D  4 (0.11) 0   0 
Beta-haem.streptococcus F  1 (0.03) 0   0 
Beta-haem.streptococcus G  16 (0.43) 0   0 
Streptococcus constellatus  1 (0.03) 0   0 
 
Non-respiratory pathogens: 
Acinetobacter species  66 (1.8) 1 (0.6)   4 (8.3) 
Aeromonas species   1 (0.03) 0   0 
Aspergillus species   17 (0.46) 0   0 
Bacillus species   2 (0.05) 0   0 
Candida albicans   444 (12) 11 (6.8)  4 (8.3) 
Candida glabrata   5  (0.13) 0   0 
Candida tropicalis   6 (0.16) 0   0 
Citrobacter species   2 (0.05) 0   0 
Coag. neg. staphylococcus  115 (3)  2 (1.2)   0 
Organism of coliform group  1002 (27) 31 (19.2)  14 (29.2) 
Corynebacterium species  4 (0.11) 0   0 
Enterobacter species   19 (0.5) 0   0 
Enterococcus species  24 (0.64) 0   0 
Escherichia coli   15 (0.40) 2 (1.2)   0 
Haemophilus species   3 (.08)  0   0 
Haemophilus parainfluenzae  24 (0.64) 4 (2.5)   0 
Haemophilus aegyptius  0  1 (0.6)   0 
Moraxella species   5 (0.13) 0   0 
Morganella morganii   4 (0.11) 0   0 
Proteus species   66 (1.8) 1 (0.6)   2 (4.2) 
Serratia marcescens   5 (0.13) 0   0 
Stenotrophomonas maltophilia 27 (0.72) 0   0 
_______________________________________________________________ 
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Table 3.13 shows the sputum culture results from 5,836 (61.0%) patients that were 
reported as negative culture results. 5,445 (93.0%) of these cultures grew normal 
respiratory tract flora, while the 391 (7.0%) of the sputum grew no organism.  
 
The most common organisms isolated from the sputum cultures in phase 1 of the 
study were mouth organisms, otherwise known as throat flora, and there were no 
differences in all phases. 
 
Table 3.13: Sputum culture results reported as negative test in all phases 
________________________________________________________________ 
 Microorganism/s          Sputum culture           Sputum culture     Sputum culture 
             in phase 1          in Phase 2     in Phase 3  
          (n = 5836)           (n = 350)    (n = 71)    
           No. (%)                      No. (%)                 No. (%) 
_________________________________________________________________ 
Coag. neg. staphylococcus 1 (0.33)  0   0 
Corynebacterium species 1 (0.02)  0   0 
Enterococcus species 2 (0.03)  0   0 
Mixed coliform   8 (0.14)  0   0 
Mouth flora/Throat flora 5194 (89)  320 (91.4)  56 (78.9) 
No growth   391 (6.7)  23 (6.6)  6 (8.5) 
Organism of the coliform 155 (2.7)  1 (0.3)   3 (4.2) 
Pseudomonas species 9 (0.15)  0   0 
Yeast  species  57 (1)   6 (1.7)   1 (1.4) 
Not processed   0   0   5 (7) 
________________________________________________________________ 
 
Table 3.14 shows the relationship between the quality of the sputum specimen and 
the types of organisms isolated. In Phase 2 of the study, out of the 511 sputum 
culture reports analysed, sputum culture reported as positive were 161 (32.0%) 
sputum samples.  Out of the culture positive samples only 67 (42.0%) were from 
good quality sputum specimens while the remaining 94 (58.0%) sputum sample 
reported positive cultures were from poor quality sputum specimens. 
 
There were six samples positive for Streptococcus pneumoniae, only one isolated 
from the good quality specimen and five were isolated from poor quality specimen 
sputum. Whilst twenty sputum samples were positive for Haemophilus influenzae, 
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thirteen were cultured from good quality sputum and seven were from poor quality 
specimens.  Out of the culture positive samples reported in both good and poor 
quality sputum samples, the commonest group of organisms isolated were 
organism of Coliform group and Pseudomonas species, both group are non-
respiratory pathogens. 
 
The majority of possible potential respiratory tract pathogens were cultured from 
poor quality specimens. This raises the question of whether they were significant or 
normal throat flora. 
 
Table 3.14:  Sputum quality and results reported as positive in Phase 2 study  
 
Organisms reported  Good quality sputum   Poor quality sputum 
    (n = 67)    (n = 94) 
    No. (%)   No. (%) 
_________________________________________________________________ 
 
Streptococcus pneumoniae 1   (0.5)   5  (5) 
Haemophilus influenzae 13 (6)    7  (7)  
Moraxella catarrhalis  1  (0.5)    1  (1) 
Staphylococcus aureus 8  (4)    7  (7) 
MRSA    7  (3)    13 (14) 
Beta-haem.streptococcus A 0       2   (2)  
Klebsiella species  1  (0.5)    0 
Pseudomonas species 16 (8)    24  (26) 
Beta-haem.streptococcus C 0    2    (2) 
Acinetobacter species 0    1    (1)   
Candida albicans  5  (2)    6   (6)  
Coag. neg. staphylococcus 0    2   (2) 
Organism of coliform group 11 (5)    20 (21) 
Escherichia coli  0    2   (2)  
Haemophilus parainfluenzae 2  (1)    2   (2)   
Haemophilus aegyptius 1 (0.5)    0 
Proteus species  1 (0.5)    0 
Total    67 (42)    94 (58) 
___________________________________________________________ 
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Table 3.15 shows the relationship between the sputum quality and culture results. 
Only 138 (39.0%) sputum cultures reported as negative tests were cultured from 
good quality sputum specimens and 212 (61.0%) reported culture negative were 
cultured from poor quality specimens.   
 
There were 130 (94.0%) mouth flora or throat flora cultured from good quality 
sputum and 190 (90.0%) mouth flora cultured from poor quality sputum specimens. 
Yeast isolates were cultured in six sputum samples, one was from a good quality 
sample and the other five were from poor quality specimens. 
 
Table 3.15: Sputum quality and results reported as negative in Phase 2 study  
 
Organisms reported  Good quality sputum   Poor quality sputum 
    (n = 138)    (n = 212) 
    No. (%)   No. (%) 
________________________________________________________________ 
Organism of coliform group 1    (1)    0 
Mouth flora    130 (94)   190 (90) 
No growth   6      (4)   17 (8)  
Yeast isolated   1      (1)   5   (2) 
 
Total    138 (39)   212 (61) 
______________________________________________________________ 
 
 
3.3.2 Throat swab culture results 
 
In this study, 3,549 throat swab specimens were cultured for throat associated 
infections investigations in Phase 1 of the study, 965 (27.0%) throat swab culture 
results were reported as positive culture and the remaining 2,584 (73.0%) were 
reported as negative tests. The overall throat microbiology culture results of all 
phases presented in Table 3.16. 
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Table 3.16: Summary of throat swab culture results in all phases  
____________________________________________________________ 
Culture results  Throat swab   Throat swab Throat swab    
   culture                         culture             culture   
         In Phase 1                   in Phase 2         in Phase 3  
   (n = 3549)   (n = 100) (n = 11)   
   No.  (%)              No.  (%)             No.  (%)                 
______________________________________________________________ 
Positive  965 (27)  29 (29)  2 (18)     
 
Negative  2584 (73)  71 (71)  9 (82)      
______________________________________________________________ 
 
The bacterial isolates from the positive cultures of phase 1, 67.0% were throat 
pathogens while the other 33.0% were non-throat pathogens. The primary throat 
pathogenic species reported was beta-haemolytic streptococcus A (67.0%) which is 
generally known as Group A streptococcus. There were two other possible throat 
pathogens reported, beta-haemolytic streptococcus C (9.0%) and beta-haemolytic 
streptococcus G (8.0%) (Table 3.17). The frequency isolation of beta-haemolytic 
streptococcus A in all study phases remains very similar and there were no much 
differences.  
 
Among the culture positives throat samples, the most commonly isolated non-throat 
pathogens were Candida albicans (4.0%), Organism of coliform group (4.0%), 
Staphylococcus aureus (3.0%), Streptococcus pneumoniae (2.0%), beta-
haemolytic streptococcus B (2.0%) and beta-haemolytic streptococcus F (1.0%). 
The other organisms reported as positive culture from throat culture included 
Coagulase negative staphylococcus, MRSA, Pseudomonas species, Haemophilus 
influenzae, Moraxella catarrhalis and Enterococcus species. These organisms are 
known common throat flora and normaly isolated from throat swab cultures.  
 
The micro-organisms listed in Table 3.17 were cultured from the throat specimens 
and full identification testing and antimicrobial susceptibility testing has been 
performed. All were reported as possible potential throat pathogens with release of 
their susceptibility results. The microbiology reports were direct reporting and no 
comments or interpretations were used for test results.  
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Table 3.17: Throat swab culture results reported as positive test in all phases 
_______________________________________________________________ 
 Microorganism/s          Throat culture           Throat culture       Throat culture 
             in Phase 1         in Phase 2  in Phase 3  
          (n = 965)          (n = 29)   (n = 2) 
           No. (%)                     No. (%)              No. (%)    
________________________________________________________________ 
 
Possible Throat Pathogens 
 
Beta-haem.streptococcus A 644 (66.7)  21 (72.)   1 (50) 
Beta-haem.streptococcus C 87 (9)   0    1 (50)     
Beta-haem.streptococcus G 74 (7.7)  1 (3.5)    0 
Corynebacterium diphtheriae 2 (0.2)   0    0 
 
Non-Throat Pathogens 
 
Beta-haem.streptococcus B 12 (1.2)  1 (3.5)  0 
Beta-haem.streptococcus D 0   0  0 
Beta-haem.streptococcus F 3 (0.3)   1 (3.5)  0 
Candida albicans  36 (3.7)  1 (3.5)  0 
Streptococcus pneumoniae 16 (1.7)  0  0 
Haemophilus influenzae 1(0.1)   0  0 
Moraxella catarrhalis  3 (0.3)   0  0 
Staphylococcus aureus 31 (3.2)  3 (10.4) 0 
MRSA    9 (0.9)   0  0 
Pseudomonas species 8 (0.8)   0  0 
Streptococcus species 1 (0.1)   0  0 
Aspergillus species  2 (0.2)   0  0 
Coag. neg. staphylococcus 1 (0.1)   0  0 
Organism of coliform group 29 (3)   1 (3.5)  0 
Enterobacter cloacae  1 (0.1)   0  0 
Enterococcus species 1 (0.1)   0  0 
Escherichia coli  1 (0.1)   0  0 
Neisseria meningitides 3 (0.3)   0  0 
_________________________________________________________________ 
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Table 3.18 shows the throat culture results from 2,584 (73.0%) patients that were 
reported as negative culture results. 2,543 (98.0%) of these cultures grew normal 
throat flora and no beta-haemolytic streptococcus (NBHS) was isolated. The 
remaining 41 (2.0%) grew no organisms.  
 
Table 3.18: Throat swab culture results reported as negative test in all phases 
________________________________________________________________ 
 Microorganism/s          Throat culture           Throat culture       Throat culture 
            in Phase 1         in Phase 2  in Phase 3  
         (n = 2584)          (n = 71)   (n = 9) 
         No. (%)                   No. (%)                No. (%)    
________________________________________________________________ 
Throat flora   2123   (82)            71   (71) 5    (55.5) 
NBHS    401     (15.5)  0  4     (44.4) 
No growth   41       (1.6)  0  0 
Organism of coliform group 19       (0.74)  0  0 
 
3.3.3 Ear swab culture results 
 
In this study, 1393 ear swab specimens were cultured for ear associated infection 
investigations in phase 1 study, 996 (72.0%) ear swab culture results were reported 
as positive culture and the remaining 397 (28.0%) were reported as negative tests.  
The overall ear microbiology culture results of all phases are presented in Table 
3.19. 
 
Table 3.19: Summary of ear swab culture results in phases 1 and 2  
_____________________________________________________________ 
Culture results  Ear swab culture   Ear swab culture     
    in Phase 1                              in Phase 2                      
          (n = 1393)                              (n = 63)      
                  No.  (%)                                   No. (%)  
____________________________________________________________ 
Positive  996   (72)   43   (68)      
 
Negative  397   (28)   20   (32)   
_______________________________________________________________ 
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Of bacterial isolates from the 996 (72.0%), positive cultures of the most commonly 
isolated pathogens were Streptococcus pneumoniae (7.0%), Haemophilus 
influenzae (3.0%), beta-haemolytic streptococcus A (5.0%), Staphylococcus aureus 
(25.0%) and Pseudomonas species (38.0%) (Table 3.20). 
 
Most of the other micro-organisms listed in the Table 3.20 are normally known to be 
doubtful pathogens and their clinical relevance is obviously difficult and case 
dependant, but those shown as of dubious significance are where clinical 
summaries did not indicate sensitivity according to Standard Operating Procedures 
for microbiological investigation of respiratory tract specimens. There were a few 
possible secondary pathogens that seldom cause ear associated infections in 
patients with normal ear. These include Aspergillus species, Proteus species, 
organisms of coliform groups and Candida albicans.  
 
A total of 800 (80.0%) organisms were considered possible pathogens and reported 
with their susceptibility test results out of an overall total of 996 ear culture results 
reported as positive test from the total of 1,393 (72.0%) ear specimen processed in 
Phase 1. A total of 185 (18.0%) organisms reported with their susceptibility test 
results were of questionable value out of an overall total of 996.  A total number of 
11 (~2.0%) organism reported with their susceptibility had no microbiological values 
and were inappropriate to report as a positive test. 
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Table 3.20: Ear swab culture results reported as positive in phases 1 and 2 
________________________________________________________________ 
 Microorganism/s                 Ear swab culture                Ear swab culture     
                     in  Phase 1                in Phase 2      
                  (n = 996)                            (n = 43)   
                   No. (%)                          No. (%) 
________________________________________________________________ 
Possible Ear Pathogens: 
Beta-haem.streptococcus A  52  (5.2)  3  (7)   
Beta-haem.streptococcus B  4    (0.4)  0 
Beta-haem.streptococcus C  1    (0.1)  0 
Beta-haem.streptococcus D  3    (0.3)  0 
Beta-haem.streptococcus F  0   0 
Beta-haem.streptococcus G  6    (0.6)  0 
Streptococcus pneumoniae  70   (7)   0 
Haemophilus influenzae  33   (3.3)  1  (2.3) 
Moraxella catarrhalis   1     (0.1)  1  (2.3) 
Staphylococcus aureus  246  (24.7)  9  (21) 
MRSA     8      (0.8)  1  (2.3) 
Pseudomonas species  376  (37.8)  14 (32.7) 
Doubtful Ear Pathogens: 
Organism of coliform group  90    (9)  7  (16.3) 
Candida albicans   16    (1.6)  1  (2.3) 
Streptococcus species  2      (0.2)  0 
Aspergillus species   24    (2.4)  2  (4.7) 
Mixed anaerobes   9      (0.9)  1  (2.3) 
Escherichia coli   1      (0.1)  0 
Proteus species   42    (4.2)  1  (2.3) 
Klebsiella species   1      (0.1)  0 
Non-Ear Pathogens: 
Corynebacterium species  3      (0.3)  2  (4.6) 
Coag. neg. staphylococcus  4      (0.4)  0 
Enterococcus species  3      (0.3)  0 
Bacillus species   1      (0.1)  0 
________________________________________________________________ 
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Table 3.21 shows the ear swab culture results from 397 (28.0%) patients that were 
reported as negative culture results. 239 (60.0%) of these cultures grew normal 
skin flora, and the remaining 115 (30.0%) grew no organism.  
 
Table 3.21: Ear swab culture results reported as negative in phases 1 and 2 
__________________________________________________________________ 
 Microorganism/s          Ear swab culture                       Ear swab culture     
             in Phase 1                        in Phase 2    
          (n = 397)                         (n = 20)      
            No. (%)                       No. (%)                         
_______________________________________________________________ 
No growth   115   (29)  8   (40) 
No significant growth  11     (2.8)  0 
Pseudomonas species 3       (0.8)  0    
Coag. Neg. staphylococcus 3       (0.8)  0    
Skin flora   239   (60.2)  11   (55)    
Proteus species  0   1     (5) 
Organism of coliform  5       (1.7)  0    
Yeast  species  21       (5.3)  0    
________________________________________________________________ 
 
3.3.4 Reporting and interpretation of respiratory tract culture results 
 
The report in Table 3.22 shows the typical microbiology result report from sputum 
culture. The left hand side (a) of the report shows a microbiological report from 
positive sputum culture, results that have been sent to clinicians and other 
microbiology laboratory service users. In addition to the patient’s demographic data, 
the test report of Escherichia coli with a susceptibility report of relevant antibiotics 
was reported. The report indicates that this bacterium was isolated from the sputum 
culture with full identification and susceptibility of this bacterium to a number of 
different antibiotics. 
 
No interpretation was offered on the significance of this finding. The report does not 
indicate whether this cultured bacterium was probably a potential pathogen or 
normal bacterial contamination due to bacterial colonisation of the upper respiratory 
tract. Similarly, it is not stated why antimicrobial susceptibility was performed and 
reported. The report generated by the microbiology laboratory should be written in a 
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way clinicians would understand and should be interpreted in the light of clinical 
diagnosis and culture findings. 
 
The right hand side (b) of the report shows a microbiological report from a negative 
sputum culture, results that have been sent to clinicians and test results of throat 
flora was reported. The report indicates that this throat flora was isolated from the 
sputum culture and reported directly without any interpretation and further 
comments. The negative report generated by the microbiology laboratory should be 
written in a way clinicians would understand and should be explained in the light of 
clinical diagnosis and indicating why this culture is negative. 
 
Table 3.22: non-interpreted microbiology report from sputum culture 
 
Source: Sputum specimen (a)  Source: Sputum specimen (b)  
▪ Status: Final 
▪ Clinical diagnosis: Pneumonia  
 
▪ Macroscopic description:  Mucopurulent 
 
▪ Culture: Escherichia coli 
 
▪ Susceptibilities:  
 
- Sensitive:  cefuroxime, gentamicin, 
augmentin, tazobactin, ciprofloxin 
 
 - Resistant: ampicillin 
 
 
 
▪ Status: Final 
▪ Clinical diagnosis: Pneumonia  
 
▪ Macroscopic description:  Purulent 
 
▪ Culture: Throat flora 
 
 
 
 
(a):  Final microbiology report from positive sputum culture. 
 
(b): Final microbiology report from negative sputum culture. 
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3.3.5   Microbiology cost per request test 
 
Table 3.23 shows the total cost per microbiology test request, including the total 
pay cost per request, the total non-pay cost per request, and the total capital 
charge cost per request where applicable (Table 3.23). The cost data used in this 
study were derived from the local hospital microbiology benchmark reports over the 
years, since the local cost data could not be used here due to confidentiality issues 
(National Pathology Benchmarking Review 2006, National Pathology 
Benchmarking Review 2007, National Pathology Benchmarking Review 2008, 
National Pathology Benchmarking Review 2005) 
 
Table 3.23: Total expenditure cost per request 
________________________________________________________________ 
Sources of the cost   Data years  Data years  Data years 
2005/2006  2006/2007 2007/2008  
_______________________________________________________________ 
Total pay Cost/request  £5.91  £7.28  £4.57 
 
Total non-pay Cost/request  £4.02  £4.69  £4.27 
 
Capital charge Cost/request  £0.00  £0.00  £0.04 
 
Total Cost/request   £9.94  £11.97  £8.88 
______________________________________________________________ 
 
The cost data indicated that during 2005 to 2007, the microbiology cost per test 
request was higher than cost data in 2007/2008. The salary increase of healthcare 
professionals was one of the reasons due to the Agenda for Change implemented 
from July 2005. The later data shows since increased productivity has led to 
reduction in overall cost per request of around 10%. The cost analysis of this study 
will be based on cost data from 2005/2006, total cost per microbiology test request 
of £9.94 (National Pathology Benchmarking Review 2006). 
 
 
 
 -   111 
3.4 Impact of results on the NHS both locally and nationally  
 
The current study results have major relevance to the NHS, both locally and 
nationally. It has an impact on microbiology workload activities, associated cost and 
clinical implication of patient care. The decreased workload activities indicate the 
reduction of inappropriate microbiology test utilisation. The appropriate test 
orderings practice reduces unnecessary tests, wasted costs and increases 
processing of properly collected good quality microbiology specimens which results 
in appropriate test results report.  
 
3.4.1 Impact on microbiology workload activities 
 
Table 3.24 shows microbiology benchmarking data for this Trust. This serves as a 
guide for optimal use of the microbiology laboratory service, indicating the total 
workload of respiratory microbiology activities from 2004 to 2008 and the gradual 
decreased number of specimens processed per year (Table 3.24). This study 
initiated and encouraged the use and application of microbiology quality indicators 
for the evaluation of specimen processing to minimise the processing of 
inappropriate specimens and performing unnecessary further testing. 
 
Since the presentation of this study in the local hospital, the unnecessary workload 
decreased due to the new management rules that have been put in place. The first 
strategy was the rejection of duplicate sputum cultures and the use of comments for 
reporting duplicate sputum specimens received daily by the microbiology laboratory 
such as:  “This test has been performed within the last three days. Therefore, in 
accordance with laboratory protocols it will not be tested again. If the patient's 
condition has changed since last testing, please contact one of the microbiology 
SpRs to request this sample is tested”. 
 
The second strategy was the rejection of poor quality sputum specimens and 
issuing the appropriate statement, for instance, “mucoid sputum or salivary sputum 
specimen received, therefore, unsuitable for culture due to poor quality of the 
sample, please repeat if clinically required”. In addition to this, this policy became 
routine practice and is used daily presently at local hospital, BLT. Similarly, it has 
been also applied to other microbiology specimens including faeces.  
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Table 3.24: Total workload of respiratory tract microbiology activity 
______________________________________________________________ 
Workload Data  Respiratory tract           Changes No. (+/-%)   
 (years)   specimen                
_______________________________________________________________ 
2004/2005   18,915      
 
2005/2006    19,618     703     (+4)  
    
2006/2007   18,166    1452   (-7) 
  
2007/2008   16,651     1515   (-8)  
_________________________________________________________________ 
 
+/- indicates the % of increase or  decrease for the workload 
 
The respiratory microbiology workload decreased during the course of later years 
from 2006/2007 to present. This has been a significance development for the 
reduction of inappropriate microbiology test utilisation and if applied to other NHS 
hospitals in the country will decrease the processing of unnecessary microbiology 
specimens as well as wasted test costs. 
 
3.4.2 Impact on cost to the local NHS and nationally 
 
The rate of respiratory tract specimen received without microbiology test requests 
was 8%, which means that 1,594 of patients submitted respiratory tract specimens 
without stating the required microbiology test requested. This is described in Table 
3.25. These figures and data were obtained from the main respiratory tract 
specimens assessed during the course of phase 1 of the study and specimens for 
TB investigation and cystic fibrosis microbiological tests were not included. 
 
The results shown in Table 3.26 indicate the reasons for test inappropriateness and 
unnecessary number of respiratory tract microbiology specimens tested in the local 
hospital for various reasons. The data presented in this table was derived from the 
local hospital figures based on 2004/2005, 18,915 respiratory tract specimens and 
the study estimated the associated cost lost for the processing of inappropriate test 
orders. 
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Table 3.25: Total result of RTSs for microbiological test requisitions 2004-05 
_________________________________________________________________ 
Test request  Respiratory tract  Sputum Throat swab  Ear swab 
specimen   specimen specimen specimen 
   (n = 18915)             (n = 9566)       (n = 3549)       (n=1393) 
   No. (%)  No. (%) No. (%) No. (%) 
________________________________________________________________ 
C & S requested 17321  (92)  8667  (91) 3301 (93)        1327 (95) 
 
No test requested  1594  (8)  899   (9) 248   (7) 66   (5) 
     
Total workload 18915 (100)  9566   (100)   3549 (100)     1393 (100) 
________________________________________________________________ 
 
 
Table 3.26: Summary of reasons for microbiology test inappropriateness 
_______________________________________________________________ 
Reasons for test    RTS    RTS                  
Inappropriateness    local    national 
       No.      No.   __  _      
No test requested    1,594     182,931 
 
No clinical diagnosis stated    1,081     124,124 
  
Too old specimen received   2,188   251,069  
 
 Poor quality specimen received   5,728   1,306,123  
 
Increased test turn around times   4712   540,547  
_______________________________________________________________ 
Total       9,575   2,153,977 
________________________________________________________________ 
 
RTS: Respiratory tract specimen     
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In addition to the data shown in Table 3.25, the total number of bacteriology 
workload at local hospital and other associated hospitals was 436,151 samples 
during 2004/2005. The total number of respiratory tract workload was 18,915 
(4.3%) out of the total bacteriology workload volume. Therefore, the respiratory 
tract specimen per bacteriology specimen from the hospital was 4.3% 
(18,915/436,151) respiratory request per bacteriology specimen. 
 
As there are no national statistics for request rates within the NHS, it has been 
assumed that the request rate at this local hospital was representative of the NHS 
and extrapolated accordingly. Total microbiology request in England in a year 2005-
2006 was 50 million requests (Lord Carter of Coles 2006.). The estimate of 
respiratory tract specimen requests in England from microbiology service users in 
that year was 2,170,000 (50,000,000 X 0.0434).  
 
If we can assume that number of microbiology tests request rate of 8.4% is a typical 
representation, therefore, the number of respiratory tract specimens that has no 
microbiology test request in England in a year was 182,931 (2,170,000 X 0.0843). If 
these 182,931 respiratory tract specimens without microbiology test request 
assumed as inappropriate test order due to their lack of test request then this was 
an example of inappropriate utilisation of the microbiology laboratory service. 
 
The average cost of processing microbiological specimens, including respiratory 
tract specimens, at local hospital microbiology departments was £9.94 as 
previously stated in Section 3.3.5. It has again been assumed that the missing test 
request rates within the department of microbiology at the local hospital was the 
same across the NHS hospitals and therefore the average cost of a respiratory tract 
test was the same across the NHS microbiology laboratories. 
  
The cost of respiratory tract specimens without microbiology test request that has 
been processed in a year from microbiology services users in England was 
£1,818,334 (182,931 X £9.94). Similarly, the local cost of processing of 
unnecessary respiratory tract specimens was £15,844 (1,594 X 9.94) in the year 
2004-2005. 
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On further cost analysis, it has been found that the cost of other inappropriate tests 
was similar to that of microbiological test requisitions as indicated the data 
presented in the Tables 3.26 and 3.27. 
 
Table 3.27: Summary of cost for inappropriate microbiology test  
_________________________________________________________________    
  Cost for inappropriate test  local NHS  national NHS  
Cost/test   Cost/test 
X (£9.94)  X (£9.94) 
       _____________________________ ____   
 
No test requested   £15,844  £1,818,334  
    
No clinical diagnosis stated   £10,745  £1,233,793  
    
Too old specimen received  £21,749  £2,495,626  
    
 Poor quality specimen received  £56,936  12,982,862  
 
Increased test turn around times  £46,837  £5,373,037  
____________________________________________________________ 
Total      £152,111  £23,903,652   
____________________________________________________________ 
  
In terms of cost reduction, since this study began, the data from Phase 3 of this 
study has indicated good improvement in specimen transport, specimen quality and 
TAT of the test results. A significant amount of cost could be saved from this 
improvement as found in good quality of the sputum specimens from 40.0% to 
69.0% (Section 3.5, (Table 3.7)). Hence, the rate of inappropriate or poor quality 
sputum specimens received and processed by the microbiology laboratory 
decreased from 60% into 31%. 
 
The local costs associated with the processing of these inappropriate sputum 
specimens was decreased from £56,936 to £29,443 (2974 X £9.94) in 2006. 
Therefore, the local cost saved from the processing of appropriate and good quality 
specimen was a sum of £27,493 (£56,936 - £29,443) in 2006 after the intervention 
and staff education initiated. 
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3.4.3 Clinical implications for the patient’s care 
 
Further analysis of the study results indicates the clinical implications for patients 
care. Results from patients, clinical diagnoses and the quality of the sputum 
specimens indicates that 33.0% of patients with respiratory tract infections or 
respiratory conditions have produced a good quality sputum specimen, while a 
similar number, 35.0%, of these patients sent a poor quality sputum specimen to 
the laboratory (Table 3.28). 
 
Table 3.28:  Clinical diagnosis and sputum specimen quality in Phase 2 study  
 
Clinical diagnosis    Sputum quality Sputum quality  
      good   poor 
(n = 205)   (n = 306)  
      No. (%)  No. (%)  
Respiratory infection or condition  68     (33)  108   (35) 
 
Other clinical diagnosis   137   (67)  198   (65) 
 
Total      205   (100)  306   (100) 
________________________________________________________________ 
 
Looking at antibiotic use, results indicated that the majority of the respiratory tract 
possible pathogens have been cultured from the sputum specimens from patients 
that had no prior antibiotic treatment, whilst Staphylococcus aureus, MRSA, 
Pseudomonas species, organisms of coliform group, Candida albicans and yeasts 
were cultured from patients who had started antibiotic treatment before sample 
collection (Table 3.29).   
 
This data indicated that the use of antibiotic treatments before sample collection 
reduces recovering of the possible respiratory tract pathogens while increasing the 
colonisation with non pathogenic organisms such as yeasts. 
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Table 3.29:  Sputum culture results and antibiotic usage in Phase 2 study  
 
Organisms recovered  No antibiotic    With antibiotic          Not stated 
    treatment   treatment           treatment 
    (n = 135)   (n = 214)  (n = 162) 
    No. (%)  No. (%)  No. (%) 
_________________________________________________________________ 
Streptococcus pneumoniae 3   (2)   1  (0.5)   2 (1) 
Haemophilus influenzae 6 (4)   4  (2)   10 (6) 
Moraxella catarrhalis  1  (0.7)   0   1 (0.6) 
Staphylococcus aureus 3 (2)   4  (2)   8 (5) 
MRSA    3  (2)   10 (5)   7 (4) 
Beta-haem.streptococcus A 0      1   (0.5)  1 (0.6) 
Klebsiella species  0   1 (0.5)   0 
Pseudomonas species 7 (5)   23  (11)  10 (6) 
Beta-haem.streptococcus C 1 (0.7)   0   1 (0.6) 
Acinetobacter species 0   1    (0.5)  0 
Candida albicans  0   11  (5)   0 
Coag. neg. staphylococcus 0   2   (1)   0 
Organism of coliform group 8 (6)   14 (7)   9 (5) 
Escherichia coli  1 (0.7)   1   (0.5)  0 
Haemophilus parainfluenzae 2  (1)   0   2 (1) 
Haemophilus aegyptius 1 (0.7)   0   0 
Proteus species  1 (0.7)   0   0 
Organism of coliform group 1 (0.7   0   0 
Mouth flora    93 (69)   122 (57)  105 (65) 
No growth   3 (2)   16 (7)   4 (2) 
Yeast isolated   1 (0.7)   3 (1)   2 (1) 
____________________________________________________________ 
 
Nearly all (94.0%) of the sputum specimens were collected from in-patients who 
had already been treated with antibiotics, as compared with specimens received 
from the out-patients department, where only 6.0% had received antimicrobial 
treatment, the results are present in Table 3.30. 
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Table 3.30:  Type of patients and antibiotic usage in Phase 2 study  
 
Type of patients   No antibiotic   With antibiotic           Not stated 
(patients location)    treatment  treatment           treatment 
      (n = 135)  (n = 214)           (n = 162) 
     No. (%) No. (%)           No. (%) 
Accident & emergency (AE)  1 (1)  0   1 (1) 
 
Chest/specialist clinics (CL)   2 (1)  0   5 (3) 
 
General practice (GP)   1 (1)  0   8 (5) 
 
Inpatients (IP)    107 (79) 202 (94)  118 (73) 
 
Outpatients (OP)   24 (18)  12 (6)   30 (18) 
_________________________________________________________________ 
Total      135 (100) 214 (100)  162 (100) 
_________________________________________________________________ 
 
Assessing the age of specimens, the result in the Table 3.31 indicates that the 
majority of respiratory tract potential pathogens have been cultured from sputum 
specimens that had been received by the laboratory within day of sample collection. 
While Staphylococcus aureus, MRSA, Pseudomonas species, organism of coliform 
group and Candida albicans were cultured from the patients where their sample 
had been received more than one to three days after collection.   
 
These specimens have questionable and limited microbiological value as the 
sample has been delayed either more than 24 or 48 hours of sample collection and 
it was too old to process. 
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Table 3.31:  Sputum culture and effect of specimen age in Phase 2 study  
 
Organisms recovered  specimen  specimen  specimen  specimen  
    same day 1 day   2 days  >3 days 
    (n = 309)  (n = 145) (n = 27)  (n = 30) 
    No. (%) No. (%) No. (%) No. (%) 
_________________________________________________________________ 
Streptococcus pneumoniae 5   (2)  1 (1)  0    0 
Haemophilus influenzae 13 (4)  4 (3)  0  3 (10) 
Moraxella catarrhalis  1  (0.3)  1  (1)  0  0 
Staphylococcus aureus 6  (2)  4 (5)  2 (7)  0 
MRSA    9  (3)  11 (8)  0  0 
Beta-haem.streptococcus A 1  (0.3)    1 (1)  0  0 
Klebsiella species  0  0  1 (4)  0 
Pseudomonas species 29 (9)  10 (7)  0   1 (3) 
Beta-haem.streptococcus C 2  (1)  0  0  0 
Acinetobacter species 1 (0.3)  0  0  0 
Candida albicans  8  (3)  3 (2)  0  0 
Coag. neg. staphylococcus 2 (0.6)  0  0  0 
Organism of coliform group 17 (5)  6 (4)             4 (15)  4 (13) 
Escherichia coli  1 (0.3)  1 (1)  0  0 
Haemophilus parainfluenzae 3 (1)  1 (1)  0  0 
Haemophilus aegyptius 1 (0.3)  0  0  0 
Proteus species  1 (0.3)  0  0  0 
Organism of coliform group 1    (0.3) 0  0  0 
Mouth flora    186 (60) 93 (64)  19 (70)    22 (73) 
No growth   17    (5) 5 (3)  1 (4)  0 
Yeast isolated   5    (2)  1 (1)  0  0 
________________________________________________________________ 
 
Evaluating the quality of the specimen, the total number of sputum specimens that 
were judged macroscopically as appropriate (i.e. mucopurulent or purulent) and 
reported  positive results were only 67 (42.0%) of the 161 sputum specimens from 
205 described as good quality specimens. While 58.0% were from poor quality 
specimens as presented in Table 3.32. These 58.0% of the culture results reported 
positive were from poor quality sputum specimens. 
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Table 3.32:  Quality of sputum culture reported as positive in Phase 2 study  
 
Sputum quality    Positive culture report 
      (n = 161)      
      No. (%)    
Good quality sputum    67   (42) 
 
Poor quality sputum    94   (58) 
 
Total      161   (100) 
________________________________________________________________ 
 
Analysing the results of TAT, the results of respiratory tract specimens culture 
positive test results that were reported of more than five days was more than 30.0% 
in the phases 1 and 2 of the study. Since this study, the TAT of microbiology results 
has been decreased. The TAT in Phase 3 of the study, the results that were 
reported more than 5 days was 17.0% and decreased dramatically as compared to 
the other two phases as described in the previous Section 3.2.6 (Table 3.8).  
Microbiology results with increased TAT have no clinical values for the patients 
care. 
 
Since the presentation of the current study results, a new microbiology reporting 
system has been introduced and its interpretation is based on the clinical diagnosis 
of the patients, organism cultured and their clinical significance (Table 3.33). The 
introduction of comments and test result interpretation will improve the optimal 
utilisation of microbiology laboratory service.  
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Table 3.33: Interpreted microbiology report from positive sputum culture 
 
Source: Sputum specimen (a)  Source: Sputum specimen (b)  
▪ Status: Final  
▪ Clinical diagnosis: Pneumonia  
 
▪ Macroscopic description:  Mucopurulent 
 
 
▪ Culture: Escherichia coli 
 
▪ Antimicrobial susceptibility report:  
Antibiotic        Mic           Interpretation 
Cefuroxime     NP           Sensitive 
Gentamicin     NP            Sensitive 
Augmentin      NP            Sensitive 
Tazobactin     NP             Sensitive 
Ampicillin         NP           Resistant 
 
▪ Comment:  
 
The presence of coliforms may represent 
oral or upper airway contamination. 
Antibiotic therapy is only indicated in the 
presence of clinical signs of pneumonia. 
 
Contact (name/pager number of clinical 
microbiologist) if concerned. 
▪ Status: Final  
▪ Clinical diagnosis: Pneumonia  
 
▪ Macroscopic description: Mucoid 
 
 
▪ Culture: Throat flora 
 
 
 
 
 
 
 
 
 
▪ Comment:   
 
Normal flora, which is probably 
colonising this site.  
 
 
 
 
 
 
 
 
(a): Final microbiology report from positive sputum culture  
(b): Final microbiology report from negative sputum culture  
NP: Not performed 
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As previously stated in Section 3.3.4, the microbiology results were reported 
directly to the clinicians without interpretation comments (Table 3.22). The following 
microbiological comments have been introduced and have been in use for the last 
three years. 
 
1. The microbiology report from sputum culture specimen growing with non-
pathogenic organisms such as the organism of the coliform group, the following 
comments used with the report: 
 
 “The presence of coliforms may represent oral or upper airway contamination. 
Antibiotic therapy is only indicated in the presence of clinical signs of pneumonia.” 
For clinical advice please contact if concerned. 
 
2. The microbiology report from sputum culture specimen growing with 
Staphylococcus aureus or MRSA, this comments used with the report:  
 
“The presence of Staphylococcus aureus, including MRSA, may represent upper 
airway colonisation. Antibiotic therapy is only indicated in the presence of clinical 
signs of pneumonia”. For clinical advice please contact if concerned. 
 
3. The microbiology report from sputum culture specimen growing with 
Staphylococcus aureus or MRSA with relevant sensitivity report, this comments 
used with the report: 
 
 “The presence of Staphylococcus aureus, including MRSA, may represent upper 
airway colonisation. Antibiotic therapy is only indicated in the presence of clinical 
signs of pneumonia”. For clinical advice please contact if concerned. 
 
4. The microbiology report from sputum culture specimen growing with same 
organisms from the repeat culture, this comments used with the report:  
 
“Please refer to previous susceptibility test and as previously isolated”. For clinical 
advice please contact if concerned. 
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3.5 Summary of study results  
 
1. Ninety-one percent of the microbiology test requisition forms were 
completed by the service users provided in all relevant details and were 
considered as appropriate microbiology test requisitions. In 9% of the test 
requisition forms were not stated the name of the required test and this 
practice was considered as inappropriate test requisition. 
 
2. Ninety-four percent of the respiratory tract samples were stated the patient’s 
diagnosis and clinical details. The other 6% of the samples patients’ clinical 
diagnosis was not stated on the request form. The total number of patients 
with respiratory tract infections was only 13%. 
 
3. Twenty-seven percent of the microbiology specimens were collected before 
patients antibiotic treatment. 40% of samples were obtained from patients 
treated with antibiotics while the remaining 33% patient’s status of antibiotic 
usage was not stated on the request form.  
 
4. Fifty-seven percent of the specimens were transported to the laboratory 
within the day of sample collection. 31% of the respiratory tract specimens 
were received after one day of sample collection while the remaining 12% of 
the specimens were received by the laboratory after 2 days of sample 
collection. 
 
5. Forty percent of sputum specimens were considered of good quality while 
the remaining 60% were considered as poor quality specimen. 
 
6. The TAT of respiratory tract microbiology results was reported only 20% 
within three days in 2004/2005 and 27% in 2006. However, the total 
microbiology test TAT that was reported within three days in 2008/2009 was 
90%. 
 
7. Forty percent of the respiratory tract specimens were reported as positive 
based on the local hospital criteria of microbiology test reporting and 60% 
were reported as culture negative. In sputum culture, 39% were reported as 
positive and 61% were reported as negative. Of 39% of positive sputum 
specimens, less than 18% were positive with respiratory tract pathogens 
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while the remaining 72% were non-respiratory tract pathogens. The throat 
swab, 27% were reported as positive in which 67% were throat pathogens.    
 
8. Prior to the present study, there was no microbiology test comments 
interpretation. However, from mid 2006 and onwards test interpretation 
comments have been used in all microbiology test result reporting. 
 
9. The total cost/request of microbiology cost per request test was decreased 
from approximately £10.0 to £9.0 over the years from 2005/2006 to 
2007/2008. 
 
10. The total workload of respiratory tract microbiology activity was decreased 
from 18,915/year to 16,651/year over the years from 2004/2005 to 
2007/2008, which is nearly down in 8%. 
 
11. The total inappropriate RTS processed locally was 9,575, with 2,153,977 
estimated nationally as derived figures from local NHS hospitals in 
2004/2005. 
 
12. The total cost of inappropriate respiratory tract microbiology test use was 
£152,111 in local NHS hospitals and £23,903,652 in national NHS hospitals 
as derived data from local hospital. 
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Chapter 4  Discussion    
  
4.1 Introduction  
 
This study was explicitly directed at respiratory tract specimens received routinely 
in the clinical microbiology laboratory, based on microbiological investigations at the 
clinician’s requests. It provides insight into the importance of a rational approach to 
the microbiological investigation of lower respiratory tract specimens, particularly 
sputum samples. The study also addressed the rarely documented inappropriate 
utilisation of the clinical microbiology laboratory service by service users such as 
the clinicians and the other healthcare professionals. Several key factors 
responsible for the inappropriate utilisation of clinical microbiology laboratory test 
with reference to sputum cultures have been identified and studied in order to 
assess the ways to maximise the diagnostic yield from sputum cultures and other 
respiratory tract cultures. Finally this study illustrated cost control strategies in this 
clinical microbiology laboratory, the implications of the study outcome and the 
contribution of health economics to the evaluation of diagnostic strategies and 
microbiology testing both at the local health service level and the NHS at large, 
including the gaps, needs and challenges in UK clinical microbiology services. 
 
The present study demonstrates the limited value of sputum specimens and other 
respiratory tract specimens as a diagnostic tool in the initial evaluation of patients 
with respiratory tract infections admitted to NHS hospitals or treated in health 
centres. From this study, eight main limitations have emerged. These are: the 
failure to state the required microbiology test requisition, patient’s clinical diagnosis, 
to collect microbiology specimen prior patient’s antibiotic treatment, to obtain a 
good quality sputum sample from most patients, delay in collection and laboratory 
processing of samples, to explain value of microbiology test results, delay in test 
turnaround times and failure to interpret microbiological test results.  
 
All of these reported limitations cause low diagnostic yield and have minimal impact 
on therapeutic decisions. As no published results on the topic of microbiology 
laboratory test utilisation in UK are available, this study may serve as a departure 
point for discussion and future research.  
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4.2 Appropriate use of clinical microbiology tests 
 
This study is one of the largest audits in the UK addressing the issues of 
inappropriate use of clinical microbiology tests. The main findings were as follows: 
1) the clinicians and other healthcare professionals utilise the clinical microbiology 
service inconsistently by sending to the laboratory by inappropriate test requests 
and specimens; 2) in spite of numerous guidelines on appropriate specimens for 
microbiological examination, laboratories continue to receive and process large 
numbers of inappropriate sputum samples; 3) there was lack of adherence to 
specimen collections principles 4) lack of adherence to microbiology laboratory 
compliance with the laboratory working principles. 
 
4.2.1 Appropriateness of test requisition 
  
The results of this  study has found that the frequency of missed or not stated type 
of required microbiology test during the microbiology test requisition was found to 
be 9% in 2004-05, as shown on the examination of patient’s information on 
microbiology laboratory request forms. This disagrees with the fundamental 
requirement of test requisition. This study indicates that the value of stating proper 
microbiology test requisitions is underestimated whilst the importance of sending 
any microbiology specimen to the laboratory is overestimated. It is unfortunate how 
little attention is paid to the one process in clinical microbiology that has the most 
influence on accurate laboratory results and contributes so much to patient 
outcome and safety.  
 
When a clinician decides to order a microbiology or laboratory test, a requisition slip 
(microbiology request form) is completed in writing or electronically and submitted 
with the specimen to laboratory. Thus, the clinical microbiology laboratory request 
form performs a pivotal role between the clinician and the laboratory, and it is 
indeed surprising that very little appears to have been published regarding this 
rather important aspect.  It is the standard expectations of all clinical microbiology 
investigations should be requested the required tests. The microbiology test orders 
should be marked clear, specific, unambiguous and clearly marked on the 
requisitions and written legibly. The microbiology respiratory tract samples received 
without required test should be treated as an inappropriate test request and 
therefore the microbiology laboratory should not perform testing. Similarity, the 
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laboratory should not perform testing on any microbiology specimen without a valid 
order submitted in writing on the patient’s microbiology request form. 
 
Inaccurate or incomplete requisitions have been reported to be the sources of 
errors which can affect the quality of laboratory testing. The CAP Q-Probes study in 
the US found that the 12.8% of test requisitions were improperly filled including the 
missing of test requisitions (Valenstein and Meier 1999).  It also known that using a 
customised requesting of MC&S may result in the ordering of tests that are not 
required, reasonable or necessary. Hence, such requesting practice will increase 
the inappropriate utilisation of laboratory services and wasting millions of money. 
 
The request (requisition) forms whether a hard copy or an electronic version from 
clinicians is the most important means of communication and clinicians should 
provide their requests by indicating the clinical question and the type of test and 
other information on the patient, thus enabling the clinical laboratory to select the 
appropriate tests, or test cascade. The advantages and disadvantages of electronic 
requesting of laboratory tests is not the scope of this study. Here, it is particularly 
important to stress the potential role of ward order systems in encouraging 
clinicians to select the most appropriate tests, in facilitating dissemination of 
protocols and guidelines and in effecting real time consultation by health 
professionals regarding specimen type, sample timings, and providing any other 
information useful for a state of the art specimen collection. 
 
The microbiology laboratory requisition forms are designed to emphasise clinician 
choice. However, it is important that it only tests that are medically necessary for 
the diagnosis or treatment of the patient should be performed. The microbiology 
laboratory should deny the processing of specimens where there is insufficient key 
information to support the medical necessity of each of the ordered tests, as the 
information on the order forms can directly affect process and analysis of the 
specimens. The microbiology test requisitions are often made by the doctors; 
nurses are often responsible for providing patient’s information both on the request 
form and specimen. Therefore, clinicians are accountable for selecting and ordering 
the inappropriate microbiology test and should sequence the test request, problem, 
complaint or other reason for the encounter as principal.  
 
There should be developed a laboratory compliance programme or regular audit to 
ensure that regulatory policies for ordering, performing for microbiology laboratory 
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testing that are adapted and enforced. As part of the compliance programme, 
notice should be being provided to the service users to assist them in identifying 
their role in ensuring compliance. It should be outlined the shared responsibilities 
required of both service providers and service users to achieve compliance under 
the agreed guidelines for preventing of inappropriate test orders and specimens 
without required test.  
 
The Royal College of Pathologists recently suggested the concept of intelligent 
requesting. “If we could stop doing unnecessary laboratory tests, we could at a 
stroke make efficiency savings that are probably greater than those that are 
currently being demanded”. However, too often laboratories find it easier to do a 
test than to argue that it is not necessary (Royal College of Pathologists 2010). 
 
Apart from the clinical importance of test requisitions, there is a health and safety 
issue. The current study and other investigations have identified there has been a 
lack of sufficient relevant clinical details being provided on specimen request forms. 
This has resulted in samples being handled at the wrong biological containment 
level with resulting increased risk of infection to medical laboratory staff. In 
December 2011 the Health and Safety Executive (HSE) issued safety notice to alert 
health and social care services to potential risks to laboratory staff, if specimen 
request forms do not contain relevant details.  It is important that medical staff and 
other healthcare professionals should ensure that appropriate information, including 
relevant travel history, clinical details and other relevant are provided in order to 
alert laboratory staff of potential dangers (Health and Safety Executive 2011). 
 
 
4.2.2  Patients clinical diagnosis 
  
The present study has found 6% of microbiological test requests were submitted 
without the patient’s clinical diagnosis. Patient’s clinical diagnoses are very 
important to laboratory staff. This is because they play an important role in setting 
the context for the test. Laboratory managers believe that this contextual 
information improves the laboratory’s input. For instance, it may help a 
microbiologist detect the need for more tests, or perhaps identify when a doctor 
may have asked for an inappropriate test. In addition to this, it may cause a 
dilemma to microbiologists for results reporting and interpretation. Hence, this may 
lead to misinterpretation of microbiology laboratory results. 
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The clinical information/impression should always come first and should always be 
used for proper interpretation of laboratory results. The culture and sensitivity result 
should be taken into consideration when clinical impression and adequacy of 
specimen are fulfilled. After all, the aim is to treat the patient, not the organism! If an 
organism name and sensitivities appear on a laboratory result, it is often interpreted 
as being the cause of the clinical problem. 
 
This shows that providing appropriate clinical information, including the patient’s 
clinical diagnosis and required microbiology test, will help the microbiology 
laboratory to do the appropriate microbiological investigations work that the 
clinicians and their patients want. Similarly, providing better clinical information will 
help the microbiology laboratory and microbiologists to produce an improved 
interpretative report and include comments with a beneficial effect on diagnosis and 
treatment.  
 
The diagnosis of infectious disease conditions clinically starts with a good detailed 
history, followed by appropriate specimen collection and proper interpretation of 
results. The results of the present study show that there are still cases where a 
patient’s clinical diagnosis and good clinical history is lacking. The clinical diagnosis 
and travel history is extremely important for infectious diseases and microbial 
infections in their epidemiological investigations, but is not always taken and 
entered on the microbiology laboratory request forms. In multicultural UK, due to 
migration from, and travel to, the tropics and the developing world, this aspect of 
the history and clinical diagnosis is extremely important. 
 
It is well known that when proper clinical diagnosis is stated and appropriate 
investigation ordered, this would result in early patient treatment and where 
diagnosis was delayed or not started, would most likely cause patients to suffer with 
serious consequences and complications. Similarly, it is well known that inaccurate 
diagnosis leads to unnecessary deterioration of patients conditions leading to 
possible hospitalisation and prescription of inappropriate drugs. This adds 
enormous cost to already costly aspects of healthcare. Patients with correct clinical 
diagnoses lead to appropriate microbiological investigations and treatment. Hence, 
the diagnostic accuracy is the key for microbiological investigations (Wilson 2008).  
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This study underscores the important role that the provision and exchange of 
clinical information plays in microbiology laboratory processes. Clinical information 
helps to inform the laboratory of the type and urgency of tests required as well as 
assisting microbiology staff to add interpretative value to the information provided 
back to medical staff. The exchange and transfer of clinical information is 
underpinned by a complex variety of communication channels within the hospital. 
This study would suggest the use of computerised provider order entry (CPOE) 
systems. New CPOE systems can increase the efficiency of this process and 
enhance the richness of information exchange. To date, little attention has been 
provided to this issue. This study recommends that more research into this area be 
undertaken so as to make these channels of communication and information 
exchange more explicit, and as a means of providing information to enhance the 
design and implementation of CPOE systems (Wilson 2008). 
 
Adoption of laboratory CPOE systems may offer institutions many benefits, 
including reduced test turnaround time, improved test utilisation, reduced costs, 
fewer errors, promote appropriate laboratory test selection, enhance the accuracy 
and efficiency of the entire laboratory testing process and better adherence to 
practice guidelines (Baron and Dighe 2011). 
 
From the microbiological perspective, all microbiology tests require that the 
diagnostic information should be submitted in order to establish the medical 
necessity of diagnostic testing. The patient’s clinical diagnosis should be indicated 
for each test ordered. Clinical diagnosis should be provided to the highest degree 
of accuracy or certainty on all tests ordered, both when the diagnosis is known and 
when the diagnosis is unknown. History, signs and symptoms of the patient may be 
used when a definitive diagnosis has not been established. 
 
 
4.2.3 Specimen quality  
 
This study assessed the quality of sputum specimens and has found that only 40% 
of  samples were judged to be of good quality when standard macroscopic 
examination criteria were applied, thereby substantially reducing the number of 
sputum specimens appropriate for microbiology investigation. With reference to 
quality of sputum specimen, salivary and mucoid samples are unsuitable for culture 
and inappropriate in the investigation of pneumonia. Purulent or mucopurulent 
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sputum samples should ideally be collected before antibiotic therapy is started and 
should reach the laboratory with minimum delay; otherwise culture interpretation is 
difficult.  
 
In this retrospective study of sputum cultures at our institution, based on the local 
criteria, the poor quality of sputum specimens were found to be 60%, and they have 
been considered as unacceptable and inappropriate samples for microbiological 
investigations. Sputum samples submitted for culture are often improperly collected 
and contain predominantly upper respiratory or oropharyngeal flora. Further more, 
the results of this study show a limited value of sputum culture as a diagnostic tool 
in the initial evaluation of patients with chest infections, as a majority of patient’s 
sputum specimens has very poor quality and predominately consisted of saliva and 
were mucoid in their composition. 
 
Many other clinical studies have demonstrated similar results. Roson et al. 
concluded that a good quality sample could be obtained in 39% of the patients with 
CAP admitted to a University hospital (Rosón et al. 2000).  In a recent study, 
prospectively analysed hospitalised patients with CAP, a good quality sample was 
obtained in 36% of the patients admitted to hospital (Miyashita et al. 2008). This 
agrees with the rate of good quality sputum specimen as reported by the current 
study.  Ewig and co-workers (Ewig et al. 2002) have shown that in primary care 
hospitals sputum has low diagnostic yield (9%) and does not contribute significantly 
to patient management.  
 
If this initial requirement for specimen quality fails to be met, subsequent 
processing and culture work up becomes irrelevant for meaningful patient 
management. The adage “garbage in results in garbage out” can be used to 
descriptively refer to the issue of specimen quality in the clinical microbiology 
laboratory. Therefore, good quality sputum specimen is recommended. If poor 
quality sputum or spit received and specimen rejected (even processed) then the 
consequence is delay in diagnosis and treatment and repeat specimens collected 
after antimicrobial treatment. 
 
The results of the present study suggest that using the macroscopic criteria, a 
macroscopic purulent/mucopurulent appearance could be used to assess the 
quality of sputum for screening before accepting it to process for culture. It is also 
believed this method had a high true-positive rate of predicting validity and 
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appropriateness of subsequent growth in culture based on macroscopic 
appearance. However, in the present study there are no comparative studies with 
Gram staining reported. If these observations of macroscopic validation are 
confirmed with sputum Gram staining microscopic examination. Thus, it is simply 
possible to replace microscopic validation (Gram staining) by the use of more this 
readily available macroscopic criteria validation for assessing sputum quality. 
 
However, the usefulness of sputum Gram stain in the initial management of 
pneumonia is still a matter of controversy. Arguments against its use include the 
low yield, cited in many reports, described in the review of literature section, the 
belief that performing adequate sputum studies on a routine daily basis is a difficult 
task, and the low cost-effectiveness. Another argument against sputum Gram 
staining has been the lack of documentation of its value in terms of cost or 
outcomes. Although this study was not specifically designed to evaluate cost-
effectiveness of macroscopic and microscopic validation of sputum specimens, the 
macroscopic sputum observation is the most simple and cost effective method of 
sputum quality assessment. Like most of the UK other hospitals, at our institution, 
sputum Gram staining is rarely performed upon patients with suspected bacterial 
pneumonia unless medically requested (Roberts et al 2008).  
 
However, there are many studies in the literature on the value of sputum in the 
evaluation and management of LRTIs and, nevertheless, its role remains 
controversial. Recent studies have shown that the Gram staining of sputum is of 
limited value in the management of CAP in adult patients (Loens et al. 2009, Ferre' 
et al. 2011, Campbell and Forbes 2011). Evidence-based guidelines for interpretive 
reporting of the sputum Gram stain will allow laboratories to provide accessible, 
clinically relevant information to guide the management of pneumonia patients 
(Campbell and Forbes 2011). 
 
Proper specimen collection and handling is one of the most important factors, along 
with appropriate use of tests, in maximising the cost effectiveness and clinical 
relevance of microbiological testing. It is essential to appreciate that a microbiology 
laboratory report is only as good as the specimen collected. The microbiology 
laboratory would much prefer quality to quantity when it comes to specimen type, 
particularly lower respiratory specimens. 
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In addition to this, it is also important to indicate that litigation has now entered the 
sphere of microbiological diagnosis and patient treatment. A poorly collected 
specimen with an incorrect answer and inappropriate treatment resulting in patient 
dissatisfaction may be cause for legal examination and action. The indication for 
sputum culture is that sputum samples should be sent for culture and sensitivity 
from patients with pneumonia who are able to expectorate purulent sample and 
who have not received previously antibiotic therapy. Sputum microbiology is not 
indicated for specimens that are largely or wholly saliva which can only yield 
misleading information and should not be sent for culture. 
 
Lower respiratory secretions may result in more unnecessary microbiology 
laboratory effort than any other type of specimen. For example, in only 50-60% of 
patients with pneumococcal pneumonia can the organism be recovered from 
expectorated sputum samples, suggesting poor sensitivity of the culture (Isenberg 
2004). On the other hand, the absence of a pathogen does not exclude the 
presence of serious pulmonary infection. Therefore, the sputum culture 
undoubtedly is one of the most misleading of all specimens with regard to true 
clinical correlation. 
 
4.2.4 Specimen transport  
 
In the present study, the majority of the respiratory specimens were received by the 
microbiology laboratory within the first 24 hours of sample collection. However, the 
results of this study has found that the total rate of respiratory tract specimen 
received by the microbiology laboratory that were greater than 48 hours of sample 
collection was 12%. This indicates that these specimens have little microbiological 
value as the sample has been delayed and it is too old to process. 
 
 All microbiological specimens including sputum specimens should be transported 
to the microbiology laboratory as quickly as possible. Delay of microbiology 
specimens by more than 2-3 hours in transit time causes the overgrowth of 
commensal flora, resulting in false positives, and it also causes the loss of 
pathogen viability, again resulting in false negatives. Therefore, microbiology 
specimens such as the sputum specimens should be transported immediately to 
microbiology laboratory and cultured specimen as soon as possible. The other 
microbiology specimens have been suggested transportation in fewer two hours is 
recommended with refrigeration if delays anticipated. It should be transported the 
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specimen to the laboratory expeditiously or make sure that, if it must be stored, the 
storage conditions are appropriate for the suspected organism. 
 
Delays in collection have resulted in antimicrobial pre-treatment, thereby affecting 
the specificity of culture results, leading to an increased recovery of coliforms and 
non-fermenters. Although this study was not designed to define exactly the impact 
of processing delays on the sensitivity of sputum cultures, it is known that common 
respiratory pathogens such as S. pneumoniae and H. influenzae are easily missed 
when samples are processed after more than four hours. In addition, it was evident 
that delays in processing were associated with an increase in the isolation of 
Candida species. Thus, the isolation of Candida species in sputum samples of non-
immunosuppressed patients may be regarded as marker of overgrowth with 
colonising organisms and not true pathogens (Ewig et al. 2002). 
 
Specimen quality can be compromised during delivery by excessive delay, adverse 
temperature, and contamination of specimens collected for bacterial growth due to 
the delay. Each specimen type has standards for timely delivery and conditions for 
transport in order to maintain its integrity. Specimens for urgent test orders such as 
those collected in the emergency room need to be delivered to the laboratory 
immediately. Most micro-organisms die quickly after removal from the body and 
should be transported quickly. Transporting and processing delays can render a 
specimen invalid for analysis.  
 
The results of the present study have found that the adherence to specimen 
collection guidelines and specimen delivery to the microbiology laboratory within 2-
24 hours is not working and more action suggested addressing this issue of 
specimen transport is needed. Prompt processing of microbiology specimens 
minimises the loss in viability of potential pathogens and insures a more accurate 
appraisal of flora present particular sputum specimens. Reducing the delay in set 
up should give clinical more accurate results (less lost of viability due to transport 
delays to the). Bringing microbiology specimens to the laboratory quickly will be a 
physician satisfier, it will reduce turnaround time, and it will probably reduce length 
of stay, and processing such a specimen adds cost to the laboratory. 
 
The present study suggests that the most important contribution to the 
effectiveness of the microbiology laboratory is the specimen that is appropriately 
selected, collected and transported. Since specimens for microbiological analysis 
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are likely to contain living organisms, specimen collection, handling and transport to 
microbiology laboratory as soon as possible. The properly transported microbiology 
specimens are vital to obtaining the best results. 
 
The prompt transport of specimens to the microbiology laboratory is essential in 
order to optimise the yield of cultures and the interpretation of results. Delays in 
processing may result in the overgrowth of some microorganims or the death of 
more fastidious ones. Desiccation of the sample must also be avoided. Rapid 
transport to microbiology laboratory is indicated otherwise death of delicate 
organisms and overgrowth of normal flora that mask the pathogen. Delay more 
than 24 hours need transport media for certain specimen but delay of sputum 
samples more than 2 hours may need refrigeration as some school of thoughts 
believe (Sharp et al. 2004, Isenberg 2004). Specimen transport is one of the 
microbiological challenges.  
 
 
4.2.5  Antibiotic use 
 
The number of patients on antibiotic treatment in this study was found to be 40%, 
as stated on patient’s microbiology laboratory request forms, and therefore, the 
results of this study confirm the common belief in which microbiology suffers from 
prescribe first, test later. It is commonly assumed that most of the physicians prefer 
to prescribe (antibiotics) first and test second. Due to its slow turnaround time 
(usually more than 24 hours), an estimated 70% of all microbiology tests are not 
used to guide therapy (personal communication). The basic rules on how to take 
microbiological samples state that a sample should be taken before antibiotic usage 
starts.  
 
Obtaining a precise bacteriological diagnosis before starting antibiotic therapy is, 
when possible, of paramount importance for the success of therapeutic strategy 
during infection and sepsis. It has been demonstrated that the outcome of sputum 
Gram stain and culture for the detection of Strep, pneumoniae is inversely 
proportional to the duration of antibiotic treatment (Musher et al. 2004). Ewig et al, 
(2002) demonstrated that prior ambulatory anti-microbial treatment was associated 
with a four –fold reduction in sputum diagnostic yield.  
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The results of another study also demonstrated that prior anti-microbial treatment 
decreased the diagnostic yield (Miyashita et al. 2008).  In addition to this decrease, 
their results also demonstrated that Gram-negative bacilli were more frequently 
observed in patients who had taken antibiotic treatment compared with the entire 
group (71.0% vs 29.0%) (Miyashita et al. 2008). Thus, the sputum samples 
obtained after initiation of antibiotic therapy may be unreliable and should be 
interpreted carefully. In similar studies, it has been reported that sputum 
microbiological investigations added very little to the management and outcome of 
patients who received an appropriate initial antimicrobial regimen in different 
hospital settings (Woodhead et al. 1991, Ewig et al. 1996, Sanyal et al. 1999, 
Theerthakarai et al. 2001, Ewig et al. 2002). 
 
The results of the present study support that of other studies that one of the 
commonest reasons for false negative microbiological investigations is the sending 
of samples for culture or direct examination after commencement of antibiotic 
therapy. If possible, all such initial investigations should be sent before antimicrobial 
treatment is begun. In many cases and particularly in emergencies, culture results 
will not be timely enough to influence initial empirical therapy - i.e. antibiotic 
treatment may need to be commenced prior to obtaining such results. Indeed, it is 
national policy to administer antibiotics to patients with suspected meningitis at the 
earliest possible opportunity and not to delay this, even to initiate a laboratory 
investigation. However, in almost every other case, including emergencies, there is 
time to draw baseline pre-treatment tests. Sputum culture, blood cultures and other 
clinical pathology investigations can all be obtained from the patients. Similarly 
urine from urinary catheters, tracheal secretions from endotracheal tube, throat 
swabs, petechial aspirates/swabs, CAPD effluent, wound discharge etc. are 
frequently immediately available for direct microscopy and culture. Baseline 
investigations such as these may be sent in emergencies without delaying the 
institution of antibiotic therapy at all.  
 
The lack of productivity of post treatment cultures in comparison to those obtained 
prior to treatment cannot be over emphasised. Sending cultures prior to antibiotic 
treatment will save a lot of time and effort. It is also important to note that cultures 
from patients on inappropriate antibiotics may also be falsely rendered sterile, from 
a laboratory point of view. Such cultures, sometimes referred to as check cultures, 
may give a false sense of security. 
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4.2.6  Value of microbiology test results 
 
This study attempted to assess the value of respiratory tract microbiology test 
results based on the cultural results and reporting practices. The study found that 
there were unexplained bacteriology culture results and antimicrobial susceptibility 
testing results that were reported to the clinicians and other microbiology laboratory 
service users. The majority of the positive culture results that were reported 
consisted micro-organisms that had no microbiological significance and are normal 
respiratory tract flora in which their findings are sign of contamination or otherwise 
of colonisation of respiratory normal flora. The reporting of these organisms with 
their antimicrobial sensitivity results was unnecessary.  
 
For instance, the results of sputum culture would seem to indicate that the many of 
the reported micro-organisms were normally known to be doubtful pathogens or 
non-respiratory tract pathogens and their clinical relevance is obviously difficult and 
case dependant, but those shown as dubious significance are where clinical 
summaries did not indicate sensitivity according to Standard Operating Procedures 
for microbiological investigation of respiratory tract specimens (Table 3.12). There 
are a few possible secondary pathogens that seldom cause lower respiratory tract 
infections in patients with normal respiratory tracts, but are often occurring hospital 
acquired lower respiratory tract infections. These include Klebsiella species, Gram 
negative bacilli such as Enterobacter species, Citrobacter species, E.coli and 
Acinetobacter species and Pseudomonas species. 
 
Gram-negative bacilli and gram-positive cocci like Staphylococcus aureus and 
Streptococcus pneumoniae from the throat and mouth area may contaminate the 
specimen, especially if there is a prolonged transit time.  In this study, there were 
six Streptococcus pneumoniae that were isolated from the sputum culture out of the 
161 positive cultures from 511 samples. Only one was isolated from a good quality 
sputum sample, while the other five were cultured from poor quality sputum. 
 
Guidelines for identification and susceptibility testing of potential pathogens 
recovered in the culture are based on the relative numbers and types of bacteria 
that grow in conjunction with the direct Gram stain results. Even good quality 
specimens may be inconclusive. Previous antimicrobial therapy may alter yield of 
culture. In this study, of the six Streptococcus pneumoniae reported, only three 
were isolated prior to patient’s commencement on antibiotic treatments. MRSA, 
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Candida sp, coliform groups and Pseudomonas sp were cultured from post 
antibiotic treatments. Gram-negative bacilli often colonise the respiratory tract of 
patients who are treated with antibiotics (Craven and Hjalmarson 2010). Thus, 
sputum cultures positive for such bacteria should be interpreted with caution.  
 
This study was not designed to investigate the aetiology of lower respiratory tract 
infections, particularly the causative agents of pneumonia.  However, the isolation 
of primary pathogens from respiratory tract samples helps the diagnosis and proper 
antimicrobial treatments for patients with lower respiratory tract infection. Valid 
samples of sputum growing predominant micro-organisms were considered for a 
very probable bacteriological diagnosis.  
 
Other studies have reported that sputum culture is of little value in diagnosing 
community-acquired pneumonia (CAP).    According to the results of a cohort study 
published in the Sept. 13 issue of the Archives of Internal Medicine in 2004 (Garcia-
Vazquez et al. 2004).The investigators and editorialist recommend against routine 
use (Madison and Irwin 2004). "The role of sputum culture as a rapid diagnostic 
tool that could direct antimicrobial treatment of CAP is a matter of controversy," 
write Elisa Garcia-Vazquez, and colleagues from the Hospital Clinic in Barcelona, 
Spain. "Some of its limitations are the difficulty to obtain good quality samples, its 
lack of reliability due to possible sputum contamination by the flora of the upper 
airways, its low diagnostic yield (i.e, sensitivity), and, therefore, its low impact on 
treatment decisions." 
 
In an accompanying editorial, J. Mark Madison, and Richard S. Irwin, from the 
University Of Massachusetts Medical School in Worcester, describe routine Gram 
staining and culture of expectorated sputum as a "hallowed, time-honoured tradition 
of dubious value" (Madison and Irwin 2004). "We only order tests on expectorated 
sputum if organisms not covered by usual empiric therapy and clearly not 
contaminants, such as Mycobacterium tuberculosis, are suspected," the authors 
write. "Unless new strategies for applying and interpreting these sputum tests can 
be devised, what may be needed most are studies assessing the effects that these 
tests have on treatment delays, co-infection outcomes, and the over prescription of 
antibiotics. If such studies document significant negative effects in real-world 
clinical settings, then everyone might finally be able to retire these poorly 
performing tests." 
 
 -   139 
These reports and studies are very similar to the findings of the current study; the 
author of this study believes that there is a very limited value of sputum 
microbiological culture. 94% of the sputum samples processed in NHS local 
laboratories was collected from in-patients; most of these patients with non-
respiratory tract infection conditions, only 13% of patients have a diagnosis of LRTI 
including pneumonia, in this study. In addition, the majority of them were receiving 
antibiotic treatments. 
 
4.2.7  Interpretation of microbiological test results 
 
Subsequent to specimen analysis, the next step in microbiology testing is report 
interpretation and verification. However, the results of this study show that there is 
a lack of interpretative comments and backup information to help the clinicians to 
use the results appropriately. All microbiology laboratory test results are reported 
directly, regardless of whether they are positive or negative. This study has found a 
lot of non-interpretative microbiology reporting with release of susceptibility results 
instead of a lot of interpretative microbiology reporting with susceptibility results 
withheld. The present result is similar to one survey of microbiology laboratory 
users that found that microbiology reports were “more allied to the laboratory than 
to the busy clinicians” (Morgan 1995).  
 
When reports are released with antibiotic susceptibilities results, this may reflect a 
tendency to consider reports that include susceptibilities as warranting treatment, 
regardless of clinical indications. In microbiology there is rarely any interpretation of 
the microbiology results. This kind of reporting practice is causing confusion among 
the service users. The poor impact of microbiology reports on patients care may, in 
part, be due to confusion between accuracy and clinical relevance of results. A 
detailed report, such as the one shown in Table 3.33 in section 3.4.3 is entirely 
accurate. The organism is correctly named, the manner in which it was isolated is 
noted and qualitative susceptibility results are given. 
 
Sending of a specimen to the microbiology laboratory is in essence a request for 
consultation and should form part of the consultative process between the primary 
care/secondary care physician and the microbiologists/infectious disease (ID) 
physician. The report should transmit clinical useful information about the pathogen 
and sensitivities provide appropriate clinical and infection control advice and 
encourage the primary care clinician to seek further advice if required.   
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The interpretation of microbiology reports depends on a number of factors, 
including: source of the culture, Gram stain results, organism, and likelihood of that 
culture was contaminated based by the organisms that are isolated, number of 
organisms that grow, patient’s gender, patient’s age, and type of patient 
(immunocompromised, etc). The amount of organisms present, source of culture, 
and patient’s age may determine significance as pathogen. Post-analytical 
interpretation of the microbiological laboratory results, the microbiology results is 
put in the context with the patient’s symptoms as well as the general 
epidemiological situation of the ward. 
 
In addition, it has been found that the naming of a specific organism, in a situation 
where it was unlikely to be a pathogen (e.g. Staphylococcus aureus in a throat 
swab), often leads to inappropriate therapy, as does the reporting of susceptibilities 
for organisms of doubtful significance (Lee and McLean 1977). The turnaround time 
of results is very important, but so is an accurate result that provides useful 
information. It has been seen many times in culture results that list normal flora 
because there was not enough expertise to interpret the growth on the plate with 
the thought being “let the physician decide if it is important”. This thought process is 
not in the best interest of the patient, and lack of useful information is of no help to 
the physician. In most cases this increases turnaround time because of extensive 
work up. 
 
This study suggests that the microbiologists should think outside the traditional 
thoughts and patterns of reporting everything that grows from the cultured 
specimens. They should come to a middle ground that ultimately produces the best 
result at the right time for the interest of the patients.  
 
There may be a role for using interpretative reporting for negative reports. If a 
negative report has a high positive predictive value for the absence of infection, 
clinicians should be made aware of this. For example a negative throat swab could 
prompt the comments “a negative throat swab correlates with a very low likelihood 
of bacterial pharyngitis and antibiotic therapy is rarely indicated in this setting”. 
Interpretative reporting of microbiology results entails the addition of a comment to 
the report, giving the likely significance of the organism(s) isolated and, where 
necessary, specific advice on therapy. The use of interpretative comments 
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appended to microbiology reports has been shown to allow clinicians to make 
informed decisions based on such reports (Barnes 1980). 
 
The clinicians primary requirement of the microbiology laboratory as “what micro-
organism is responsible for my patients condition?” (Neu 1978). Answering this 
question is often difficult because microbiology reports do not have the same 
absolute validity as most biochemical or haematological reports (Ackerman et al. 
1980). Therefore, this study suggests that the inclusion of interpretative comments 
can compensate for confusing reporting practices and produce more clinically 
relevant reports. The lack of such interpretation may cause misinterpretation of 
microbiology results by clinicians. 
 
However, there may be reluctance on the part of some laboratories to add lengthy 
comments as they might be seen to make reports needlessly long. It has been 
suggested that longer comments, employing a conversational tone, are more likely 
to reflect clinical reality and therefore be accepted by microbiology laboratory users. 
Morgan found that 97% of hospital doctors approved of the inclusion of 
interpretative comments on microbiology reports and 72% requested more 
interpretation (Morgan 1995). 
 
The role of a microbiologist is to take an active role and make a difference because 
microbiology laboratory produces so much of the information that is used to make 
medical decisions. It is, therefore, important that microbiology reports are readable, 
accurate, and credible. Expertise of microbiologists is important, as both physicians 
and patients rely on him. However, in microbiology laboratories, there are less 
guidelines necessitating reporting and interpretations of microbiology cultural 
results. While most laboratories provide some form of interpretative comments in 
anatomic pathology reports, this is not always the case with clinical microbiology 
reports. Thus, this study indicates there is clearly a need for education of clinicians 
regarding indications for sending specimens and applying results to patient 
management. 
 
This study would suggest and encourage that the ideal microbiology laboratory 
report should be user friendly, employing terms that are readily understood and 
communicate clinically relevant information. The patient is the true end-user of the 
laboratory and this should be the guiding principle in ensuring that results are 
reported in a way that maximises clinical benefit. Nobody questions the fact that 
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radiology and anatomic pathology results are reported with interpretation and that 
further discussion is often required between the radiologist or pathologist and the 
primary care physician. Perhaps the clinical microbiologist should begin to think of 
microbiology results in the same way as radiologist or pathologist do.  
 
GPs and hospital doctors rely on accurate information from clinical pathology 
services to help them make the right treatment decisions that will deliver the best 
outcomes for their patients. They need to be sure they are able to interpret the 
results of pathology investigations correctly. Up until now, there has been no way of 
reporting pathology test results in a consistent, standardised way across the 
country, meaning that different names in different settings could mean the same or 
different things. The NHS will soon test the National Laboratory Medicine Catalogue 
(NLMC). This is a unique data set, which will standardise the way pathology tests 
are requested and reported electronically in hospitals, clinics and medical 
laboratories across the UK. It will address a number of quality and patient safety 
issues in both requesting and reporting, and improve the reliability and 
effectiveness of pathology services (Barnes and Batstone 2012). 
 
NLMC will be available from July 2012 and it is similar to the British National 
Formulary (BNF). NLMC is the first comprehensive standard for pathology services, 
enabling pathology test requests and results to be standardised in common and 
consistent formats.  It will define a common terminology so that doctors across the 
country will use the same words when ordering laboratory tests or receiving results. 
This means that hospital doctors, GPs, nurses and other health professionals can 
be certain they are requesting the right test every time and can safely interpret the 
results of pathology investigations eve when they come from more than one source.  
 
In addition to NLMC pathology data system, Electronic health record (EHR) 
systems are now a major topic in healthcare service. Use of EHRs in physician 
practices and in healthcare organisations directly impacts the communication and 
management of laboratory information in patient care, particularly reporting of 
laboratory results and test order management (Henricks 2011). Meaningful use of 
EHR and its relevance to laboratories will have substantial direct and indirect 
implications for laboratories and for pathology practice and this will lead to 
improved healthcare provision. There will be greater expectations for electronic 
interchange of laboratory information which will provide other opportunities for ways 
that laboratories can better serve their provider community. 
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4.2.8  Test turnaround times (TAT) 
 
The published TAT times in most of the NHS microbiological laboratories is a target 
of three days. However, this study has found that over 30% of respiratory tract 
microbiology results had a TAT of more than five days in the period of 2004-05. 
While the repeated follow-up study in 2006 found that 66% of cultural results were 
reported in three days. The average TAT of local NHS laboratory in 2009-2010 was 
more than 95% of all microbiology test results. 
 
The results of this study show there were increased TATs in the period 2004-05 
and decreased TAT in the last part of the study, in 2006 and onwards. The main 
reason for the decrease in 2006 was due to the introduction of a new IT system 
called Winpath system in the Trust at the end of the 2005. The possible second 
reason for the decrease of BLT TAT was due to the awareness of microbiology staff 
of the importance of TAT in microbiology as a result of this study. 
 
Typical expected TAT for microbiology, Gram stains, when appropriate, are 
resulted within 2 hours of receipt. Culture results are read and reported as pending 
everyday via computer. Results are finalised within 2-5 days depending on growth 
and organism isolated. For the diagnosis and management of bacterial infections, 
physician’s relay on the results of identification and antimicrobial susceptibility 
testing (ATS) provided by the clinical microbiology laboratory. As soon as results 
are reported, empirical therapy that was started in anticipation of culture results can 
be adjusted in order to achieve the highest treatment efficacy for the patients, 
prevent the development of antimicrobial resistance, and reduce the cost of 
antimicrobial therapy.  
 
Faster reporting of microbiological results enables the clinicians to start appropriate 
treatment sooner, which is associated with an improved clinical outcome 
(Barenfanger, Drake and Kacich 1999, Bruins et al. 2005). It has been shown that if 
results are available earlier, significantly more changes in therapy are made, 
resulting in either a more effective or a less expensive treatment. Therefore, 
shortening the TAT of microbiological procedures is associated with an improved 
clinical outcome. However, most TAT studies have focussed on inpatient and 
emergency care settings, though a few researchers have ventured to outpatient 
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and general practice settings. TAT varies depending on the location of the 
laboratory.  
 
TAT microbiology laboratory practices, and specimen characteristics such as the 
type of specimen and microbiological results findings. TAT varied substantially 
according to specimen type. Technically it is difficult to assess and determine TAT 
the difference between recorded starting times (test ordering) and ending points 
(test reporting time). Clinicians consider turnaround times from the time test is 
ordered to results reporting, whereas the laboratory professionals usually use 
specimen receipt to reporting of results as the turnaround times.  
 
Currently, the measurements of TAT do not reflect whether the microbiology 
services meet the expectations of the clinicians using the microbiology service. 
Also, improving TAT can be challenging, not only because of the contributing 
factors outside the control of the microbiology laboratory, but because laboratories 
frequently try to improve TATs for a specific test, location, or specific type by 
immediately identifying and testing those specimens in question, thereby extending 
the TATs of other tests (Howanitz 2005).  
 
The increased TAT and the majority of the problems directly affecting TAT for 
microbiology tests are associated with preanalytic related test ordering and 
specimen collection. The second cause could be analytic related and technical 
problems, including delays in expecting reporting times and verification of final 
results. It is often not known whether the clinicians have received test result reports 
or not.  
 
The timelines with which test results are delivered is one of the most prominent 
parameters of laboratory medicine, and a common indicator of performance (Novis 
et al. 2004). Common among these are test TAT and time for notification of critical 
results. The ways to improve TAT include the use of automation of various steps in 
the analytic phase, increased use of electronic results reporting, and development 
of automatic electronic alerting systems for critical values. 
 
World class service healthcare organisations are characterised by their attention to 
reducing waits and delays. In contrast, timeliness of results reporting has not been 
a major focus in clinical laboratories. While laboratory professionals often overlook 
timeliness as an important attribute, clinicians judge the adequacy of laboratory 
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services by the speed with which results are reported.  A few studies have explored 
the wishes, wants, and needs of clinicians for the time frame in which laboratory 
results are reported, and, for the most part, these studies indicate laboratories do 
not meet clinician’s expectations (Howanitz and Howanitz 2001). 
 
However, regardless of method, TAT is viewed as a quality measure that reflects 
the performance of the testing process as a whole. Prompt and predictable 
reporting of test results can increase efficiency of patient care and improve 
clinicians and patient satisfactions, even when it does not affect health outcomes 
(Valenstein 1996). Improved TAT can save time and money for the organisation. 
 
Principles of appropriateness in laboratory medicine are embodied in selecting the 
right test at the right time for the right patient. Test appropriateness is inherent to an 
understanding of the specific clinical condition and the value of particular test to the 
respective patient. The ability to make these determinations varies among 
clinicians. Standard measures of appropriateness do not prevail currently, though 
their development is viewed as important. Instead, clinical guideline performance 
indicators of care quality and measures of test use (including underuse and 
overuse) have been the basis for drawing conclusions about appropriateness from 
the current study. These are the reasons the present study was under taken to 
assess the factors responsible for the inappropriate microbiology test utilisation in 
order to reduce the inappropriate test ordering and encourage optimal use of 
microbiology service.  
 
4.3 Causes of inappropriate use of clinical microbiology tests.  
 
From a patient’s perspective, due to inappropriate or missed diagnosis, there can 
be increased morbidity (and occasionally mortality) inappropriate antibiotics, 
unnecessary testing and longer hospital stays also add to the overall cost of the 
health services. Several studies have shown that between 25% and 40% of all tests 
sent to the laboratory are unnecessary, yet few laboratories in the UK have 
managed to reduce these unnecessary tests (Fraser and Woodford 1987, Winkens 
et al. 1996, van Walraven and Naylor 1998).  Even where such reductions have 
been achieved, it has been difficult to sustain them. So, what is it that makes it 
difficult to manage demand and prevent inappropriate test utilisation? Several 
reasons have been suggested (Axt-Adam, Van der Wouden and Van der Does 
1993).  
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These include uncertainty of likely diagnosis (associated with junior and 
inexperienced doctors), lack of understanding of the basis, sensitivity, and 
specificity of the tests, and the desire for diagnostic completeness. Furthermore, 
recommendations of special interest groups, peer and commercial pressure, patient 
expectation, and more recently, fear of litigation, have led to increased demand for 
laboratory tests. With all these barriers, it is not surprising that although attractive in 
concept, demand management has failed to make appreciable inroads and causes 
of inappropriateness of test utilisation are not addressed accordingly.  
Similarly, this study supports the above stated reasons and has identified from the 
results of the current study, three main factors that may be associated with the 
causes of inappropriate microbiology test utilisation. These factors are: 1. Clinicians 
request of inappropriate test (request that is not the required microbiology test and 
patients’ clinical diagnoses). 2. Clinicians lack of adherence to specimen collections 
principles (Specimen quality, specimen transport and antibiotic use). 3. Non-
compliance of the microbiology laboratory with the laboratory working principles 
(test results value, test results interpretations and test turnaround times).  
 
The first two factors are associated with the responsibility of clinicians to an extent.  
It seems that the clinicians were too little reliance on their clinical skills, and too 
much reliance on laboratory investigations. Even when investigations are 
warranted, too many additional tests (nice to haves) are ordered that are not crucial 
for diagnosis resulting in ordering of inappropriate tests and irrelevant tests. The 
third factor is associated with the responsibility of clinical microbiology laboratory to 
a larger extent. The first problem associated with laboratory staff is processing all 
specimens whether appropriate or not such as a specimens on a swab marked ear, 
sinus or wound and poor quality sputum specimens. The clinical microbiologist 
must use interpretative judgement to lend significance and clinical relevance to the 
information conveyed to the physician whether the specimen is easy or difficult to 
obtain.  
 
One of the major causes of inappropriate clinical laboratory test utilisation is the 
elimination of pathology and laboratory medicine from the curriculum in many 
medical schools and consequent lack of knowledge of basic science among the 
junior doctors which is jeopardising patient safety according to the report published 
in 2008 (Khromova and Gray 2008). This study raised one very important question: 
‘with no standardisation of the medical curriculum for teaching of basic science, 
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how will junior doctors become competent in requesting and interpreting 
investigations in laboratory medicine?’ Although patients safety became a 
fundamental priority for the NHS in 2000, “most acutely ill patients are cared for by 
the most junior medical staff with the least knowledge and experience”.  
 
Due to the reduction in the amount of teaching of pathology and laboratory 
medicine, these doctors have little understanding of what tests to order and how 
they should be interpreted. It has been reported also that the junior doctors have 
little concept of how tests should be used, and their role in diagnosis. Moreover, 
many seem unaware that laboratories have staff able to help them, not only with 
interpretation, but also with advice on appropriate testing.  
 
The findings of a survey by Khromova and Gray (2008) demonstrated the need for 
additional teaching in clinical biochemistry. It seems likely or reasonable that the 
teaching of clinical microbiology is the same as the teaching of clinical biochemistry 
and other laboratory medicine areas, and in the medical curriculum in the UK the 
practical application of microbiology is often lacking. Proper collection of 
specimens, optimal use of the clinical laboratory and interpretation of microbiology 
reports are not adequately covered or emphasised in medical and nursing 
education in UK, leading to sub-standard management of infections. The 
knowledge and skills required to manage an infectious disease efficiently are 
knowledge of infectious diseases, suspect and diagnosis an infection, optimal use 
of clinical microbiology laboratory to confirm the diagnosis and treat with 
appropriate antibiotics as per microbiology laboratory results. 
  
There is some evidence that the use of laboratory services can be improved by 
educating clinicians. Bareford and Hayling (1990) showed that there was a definite 
and sustained reduction in inappropriate requests when certain measures, such as 
issuing guidelines, fact sheets and holding seminars, for example in clinical 
biochemistry were implemented. In a study under taken in 2000, (Mishra et al. 
2000) 98% of doctors and medical students agreed that clinicians should be invited 
to seminars to improve their skills in interpreting laboratory investigations. When 
asked about the best method of delivering teaching on the subject, 93% preferred 
seminars with active participation to lectures or symposia. 
 
Of course it has been known that, in general, fear is a very strong driver. In the 
case of laboratory test ordering, the fear of not having ordered what the consultant 
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wanted is part of what drives junior doctors to over-order and fear of the lawyers 
(and possibly the media) is part of what drives consultants to do the same.  
 
Since about half of the overall increase in healthcare spending is the direct result of 
increased utilisation of medical services by physicians, a decrease in utilisation 
practices will directly reduce laboratory costs. There may be a variety of reasons for 
the increase in clinical microbiology laboratory utilisation by physicians (Bartlett 
1974, Robinson 1994). For example, physicians may request unnecessary tests 
because of their insecurity in establishing a diagnosis, or because of poor turn-
around time of the laboratory. Another cause for increased utilisation may be the 
practice of standing orders for routine laboratory testing on patients. This practice is 
for the convenience of the physician and nursing staff, but has been shown to 
greatly increase laboratory utilisation without improvement in patient care. Another 
cause for increased utilisation is the use of check-off boxes on laboratory 
requisition forms which, again, is for convenience of physicians and nurses, but 
requires little conscious thought about what test is actually needed. Another cause 
for increased utilisation may be the automatic ordering of fungal, TB, or anaerobic 
cultures on certain specimen types, even though the physician may not have 
originally ordered nor needed this extra test. Reviewing utilisation practices for 
appropriateness is essential for cutting costs in the laboratory. 
 
One problem with testing which is not justified, is that it wastes money and time 
and, since the money available to the health service is finite, inappropriate testing 
takes resources away from more useful endeavours (such as new tests or other 
clinical services). Clinical laboratory staffs in the laboratories of NHS hospitals have 
no real control over demand for laboratory services, and no real capacity to charge 
for same. Therefore, laboratory service providers depend on their service users 
(“customers”) to think of the greater good of patients as a whole, as opposed to the 
narrow view of just your patients, when you devise test-ordering strategies.  
 
During this study, it has been found one of the greatest wastes of microbiology 
laboratory resources is spending money pursuing tests ordered by the physician 
that have very little effect on patient care. As reported in the study results where the 
microbiology laboratory processed specimens without a test request, sputum 
specimens of poor quality, respiratory tract specimen of too old to process (> 1 or 2 
days old), follow up and further work of microbiology culture without microbiological 
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values. Similarly results shows also reporting of test results with increased TAT and 
microbiology report without interpretation of test results.   
A major obstacle to successful implementation of appropriate laboratory test 
utilisation from the user’s perspective is "consumer resistance". In the UK, neither 
the clinician nor the patient directly pays for the laboratory tests. Thus, there is little 
incentive for clinicians to alter their current patterns for requesting laboratory tests. 
Marketing strategies have to be developed to "sell" the concept of demand 
management to clinicians (consumers). This will require paying attention to the 
product (identifying areas for clinical laboratory demand management in 
consultation with clinicians), placement (bidirectional ward test ordering systems), 
price (clear cost/benefit analysis), and promotion (use of advertising material that 
appeals to both senior and junior medical colleagues) (Gopal Rao et al. 2002). 
Changes in the configuration of clinical laboratory test ordering system are 
inevitable. 
In addition to the stated causes, there are a number of more strategic issues that 
constrain the optimal use of laboratory medicine services. For example, it is rare 
that laboratory medicine is directly involved in strategic planning of health services, 
despite the role that the laboratory is acknowledged to play in delivering healthcare 
services. There is little importance given to the management role of audit, through 
commitment to continuous quality improvement and performance management in 
the context of the care pathway (Price 2012). 
 
4.4  Implications of the study outcome at local NHS service 
 
The present study highlighted inappropriate test utilisation in clinical microbiology 
laboratories. However, during this study period, substantial improvements were 
seen in several areas of microbiology laboratory activities, including the 
development and implementation of restrictive specimen workup, and a process 
policy for screening sputum specimens for acceptability, limiting the duplicate 
specimens, reducing the microbiology test turnaround times across the department, 
increasing the value of microbiology test results, reducing specimen transport 
delay, introducing microbiology comments for certain microbiology results and 
improvement of communications with the microbiology service users. 
   
 -   150 
Similarly, the study recommendations have been very well accepted by all levels of 
staff after the presentation of the study results. Since then it has led to a greater 
ownership of work, staff have been gratified to see improvements in the quality of 
the microbiology service after the introduction of the microbiological rational policies 
through out the laboratory process. More recently, a multidisciplinary to a lean 
system approach has been introduced in order to eliminate the waste of the clinical 
pathology laboratory process including the microbiology laboratory using some of 
the data obtained from the current study as example and reference data. Hence, 
during the past few years, the Barts and The London NHS Trust department of 
microbiology has developed and implemented strategies to eliminate inappropriate 
tests and useless activities.  
 
The microbiology laboratory has introduced and adopted a restrictive policy of 
screening and evaluating the quality of sputum specimens for acceptance by 
macroscopic examination prior their process and to acceptance. Sputum 
specimens with the appearance of watery/saliva and muoid has been rejected with 
the exceptions of certain patients groups such as the neonatal, ITU and 
neutropaenic patients. Poor specimens could potentially have important effect on 
the welfare of the patients with pneumonia and other lower respiratory tract 
infections. 
 
The Barts and The London NHS Trust hospitals had total beds of 1172, 766,844 
patients attended for treatment and admissions and had more than 19,000 routine 
respiratory tact cultures in 2004-2005. In the UK, there are many other hospitals 
with similar number of beds and admission for the period of 2004-2005. If other 
hospitals had routine respiratory tract culture rates similar to our institution (on the 
basis of number of beds, treatment or admission), between 2 and 3 million 
respiratory tract cultures would have been performed in 2000-2005. If 60% (Table 
3.25) of the sputum samples from these cultures were poor specimens, 1 to 2 
million poor specimens would have been sent for culture in 2004-2005. For the 
processing of these poor specimens, a total amount of between £10 and £12 
million could have been used and wasted. Improving the adequacy of sputum 
specimens could therefore have a large impact on personnel time, expenditure, and 
timely diagnosis and treatment of patients with pneumonia.  
 
For the impact on microbiology workload activities, the three day rule strategies 
have been introduced by the Barts and The London NHS Trust microbiology 
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laboratory to reduce the number of daily sputum specimens received for culture 
from each patient. This restrictive policy has been introduced and discussed with 
the clinicians and used routinely since 2006.  This three day rule needed in order to 
reduce the number of duplicate specimens processed every day. When ever the 
microbiology laboratory received similar specimens collected within three days the 
microbiology computer will generate an information comments for the clinician 
requested the culture. The following comment will be sent immediately, the routine 
sputum culture on patients proceeded their sputum sample within last three days 
have not warranted, are not cost effective, and rejected by issuing notification 
comments to clinicians.  
 
The effect of this three day rule and restrictive policy of sputum workup has been 
seen by the reduction of workload activities of respiratory tract specimens 
processed during the last benchmarking audit. The number reduced from 19,618 in 
2005-2006 to 18,166 in 2006-2007. This certainly reduced the processing of 
inappropriate and duplicate sputum specimens by 7%. Similarly, the three day rule 
has been extended and applied to the other areas of routine microbiology 
specimens, such as faeces bacteriology culture. 
 
For the clinical implications for the patients care, although timeliness of results 
reporting has not been a major focus in clinical laboratories, there is now increasing 
pressure from clinicians and government targets to report results rapidly and meet 
the reported TAT targets. Reducing turnaround time’s strategies has been 
introduced for all microbiology tests against the department’s published TAT. As a 
result of this strategy, the microbiology laboratory now routinely monitor monthly 
TAT and consider this to be an indicator of performance published widely to large 
users of the service. Barts and The London NHS Trust microbiology department 
has set the length of time that ideally it should take to issue a report depending on 
the specimen type. For example a positive sputum culture result should be 
available within three days but a positive TB result will take up to 44 days.  
 
The Trust expects that 96% of microbiology samples will be available within 
microbiology laboratory stated TAT and therefore microbiology to monitor these on 
a monthly basis. It has looked at each bench/section or test type and used the 
traffic light system as shown in tables 1 and 2 in the appendix section. Currently 
whole departmental tests have an average TAT of 95% including respiratory tract 
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specimens. The service user’s survey has reported 79% satisfactory with the TAT 
within the Trust pathology service in 2007. 
 
The improving TAT that has been seen since 2006 where 60% of respiratory tract 
specimen culture results have now improved as compared to data obtained 2004-
2005. One of the reasons for this improvement is due to the introduction of LIMS IT 
system known as the Winpath system in 2005 that has greatly improved the 
laboratory TAT. The Trust also implemented, in April 2008, a new CRS. This 
system will provide a full audit trail from specimen request, through collection, 
arrival in clinical pathology laboratories to the final result. It is hoped that by 2011 all 
pathology test requests will be paperless. Therefore, the use of technological 
advances has been embraced of at each step in the laboratory cycle. 
 
In addition to these changes, Barts and The London NHS Trust microbiology 
laboratory has introduced MALDI-TOF technology in 2010 to reduce costs, TAT 
and increase the efficiency of the service (Eydmann et al. 2011). This technology 
has changed the way we think about microbial identifications and strain 
differentiation by providing results from plate to name in approximately five minutes 
for one isolate and around 90 minutes for 60 isolates at minimum costs. This has 
resulted in fast TAT and rapid identification of pathogens of public health 
significance such as multidrug-resistant bacteria (Van Veen et al. 2010, Eydmann 
et al. 2011, Wolk and Dunne Jr 2011).  
 
Similarly, efforts by staff to reduce laboratory TAT, plus monthly monitoring of the 
TAT across the microbiology laboratory sections, has also resulted in reduced TAT.  
To further improve TAT the Barts and The London NHS Trust is in discussion on 
the implementation of a shift system in the near future. However, a short term 
solution is now operating for a late team to work extended time to process the late 
deliveries from BLT and from Newham Healthcare Trust which arrive after 5.30 PM.  
 
As described earlier in Section 4.1, slow and increased test turnaround times can 
lead to duplicate test requests, increased hospital cost and patient’s length of 
hospital stay and result in more unnecessary antimicrobial treatments and more 
microbiological test requests. Thus, improvements of laboratory test TAT is the key 
issue of current microbiology laboratory practice in order to provide appropriate 
laboratory service to service users. 
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Another strategy that has been introduced as a result of this study, was to improve 
the way microbiology test results are reported, and the value of microbiology 
results. It has been described previously that the results of this study highlighted 
the importance of value added reporting in clinical microbiology results, when 
compared to the traditional way of reporting in microbiology test results, which is 
report what you see and forget what is not appropriate.  
 
BLT microbiology laboratory has now started to introduce an interpretative way of 
commenting on certain microbiology results. This will to lead an appropriate 
microbiology test reporting and interpretation. Currently there are selective 
reporting areas with normal bacterial flora and no significant results. There is a 
control of information based on patient’s conditions and laboratory policy of 
appropriateness. There is now a limitation of reporting organisms, with no 
microbiological value and doubtful pathogens, which has grown from respiratory 
tract specimens. For instance there is no follow up and set up of susceptibility tests 
for organisms grown in sputum cultures such as coliform group, Pseudomonas 
species and coagulase–negative Staphylococcus species unless there is a clinical 
justification from the doctors.  
 
Cultures with a clear predominance of a single potential pathogen relative to the 
oropharyngeal flora present would get complete identification and susceptibilities as 
appropriate. For the cultures with three or more potential pathogens, none 
predominating, mixed flora would be reported. In both cases this comment is issued 
with the report. “Further workup; contact the laboratory within 24 hours. Cultures 
having only organisms that are considered normal flora would be reported as 
normal respiratory flora”. 
 
Prior to this study the microbiology laboratory, like other NHS laboratories, used to 
report all the organisms that grow from sputum specimens. Few of the organisms 
that have been reported have a bacteriological significance, and the majority of 
these reported organisms could have been reported as throat flora or mouth flora. 
 
In addition to this limitation of reporting, the microbiology laboratory has started 
using interpretation comments with respect to value of the culture results. It is used 
many areas of the laboratory including sputum culture, urine culture and blood 
culture. This will have an impact on the value of test results and help the clinicians 
to use the test results appropriately. It is important to ensure that the clinicians 
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appreciate they are receiving more clinically useful information than would be 
provided by raw microbiology laboratory data without interpretation comments. 
 
This study has reported that there are many respiratory tract specimens that should 
not be processed due to delays of transport and processing of  more than 48 hours.  
Since this study highlighted these problems, the department has introduced 
appropriate measures to minimise them. These measures include extending the 
microbiology laboratory opening hours in order to receive late collections from the 
health centres and the main hospitals as described earlier. The specimen collection 
times have been monitored and acted the reported delays as soon as possible and 
informed the concerned bodies.  
 
Reducing specimen transport and processing delays has improved the quality of 
the specimen and the laboratory TAT. Currently the majority of all general 
specimens are now received in a scheduled time and transported into the 
microbiology laboratory in a good time compared to previous times. There are also 
another two new developments which contributed to the reduction of specimen 
transport; the lean system is now in operation at BLT pathology services, and all 
clinical pathology laboratories are housed under one roof with only one common 
specimen reception. 
 
Currently, there is a good communication between the microbiology laboratory and 
its service users. The microbiology department of the BLT has taken all necessary 
measures to increase the awareness of the importance of clinical microbiology 
laboratory ordering process and forms between the healthcare workers have been 
applied, these measures included institutional user surveys, active enhanced 
communications, laboratory manuals, education and audits. 
  
As a result of this study it was proposed that within the microbiology department at 
our institution, unacceptable sputum culture specimens would be rejected for 
inpatients, except those patients stated laboratory SOP, and ask that they be 
recalled. The initial specimen would be held refrigerated for up to 24 hours until a 
satisfactory specimen is resubmitted. Rejected specimens would only be processed 
by specific clinician or doctor’s request when clinically justified. If a specimen is 
rejected and not cultured, the sputum culture report will be issued with an 
appropriate comment to ordered clinicians.  
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The study results approaches were set up around the specimen management 
towards the clinical relevant and cost-effective microbiology service at the Barts 
and The London NHS Trust. However, these approaches could be easily amended 
and used to suit local practices in any NHS laboratory. 
 
4.5  Cost implications to microbiology laboratory service 
 
This study has found that the total inappropriate respiratory tract specimens 
processed locally was 9,575 and 2,153,977 nationally as derived figures from local 
NHS hospitals in 2004/2005. The associated total cost of inappropriate respiratory 
tract microbiology test use was £152,111 in local NHS hospitals and £23,903,652 in 
national NHS hospitals as derived data from local hospital. However, the follow up 
study in 2006, the cost of inappropriate sputum specimens were decreased from 
£56,936 to £29,443. As a result of this reduction, the local NHS microbiology 
laboratory has saved sum of £27,493 in 2006 after intervention strategies and staff 
educational initiates. Overall, the NHS laboratories can achieve more cost saving  
using the demand management rules and strategies that can be put in place to 
process appropriate clinical specimens and reject inappropriate specimens as 
present study suggested and advocated by many other researchers.  
 
This study was initially designed to investigate and establish the cost of routine 
microbiological investigations in order to calculate the potential cost-savings when 
used the microbiology test appropriately. The result shows that the total cost of 
microbiology test may be higher than the cost stated the other sources; for 
instance, the cost of routine sputum microbiology investigation may be higher in this 
local NHS laboratory. Due to data confidentiality, the cost of local NHS 
microbiolology laboratory could not be discussed in this discussion. However, the 
author of this study believes that this is needed to inform national policy makers 
about the true cost of pathology tests and to inform the local NHS Trusts about 
possible cost reduction measures. 
 
Although the true cost of pathology tests are not known, the other bodies compared 
the local cost data with other cost data sources, notable the Healthcare 
Commission’s Report known as now Care Quality Commission (Healthcare 
Commission 2007), Lord Carter’s Report (Lord Carter of Coles 2008) and the 
University of Keele Benchmarking Service (National Pathology Benchmarking 
Review 2008). These three data cost sources are very similar and their finding 
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shows that in the NHS pathology services there is a variation in cost. For example 
in clinical microbiology the variation cost is from £4.00 to £9.40, with a median cost 
of £6.10 (Lord Carter of Coles 2008).  
 
The cost of pathology test is higher in London teaching hospitals as compared to 
the other teaching hospitals outside London. One of the main reason is they 
provide more specialist services and employ more medical staff as well as being in 
central London.  This study tried to establish the true cost of microbiology tests 
using respiratory tract specimens; however, the study was unable to establish the 
true cost of microbiology tests. The cost of positive tests and the negative tests is 
equally priced/costed. The reason is that there is no official cost structure in the 
NHS clinical laboratories. 
 
It has been well known for some time that the UK spends less per capita on 
healthcare than other European countries. What may be less well known is that the 
UK has had a pathology service where no one knows the cost per test in terms of 
the single test of microbiology, such as sputum culture and sensitivity. Due to this 
perspective, this study did not manage to obtain the true cost of microbiology tests. 
The reasons for these difficulties is thought to be associated with the lack of cost 
structure in the NHS pathology service. The lack of good and accurate cost 
information is the key constraint in obtained the correct cost. The pathology service 
running cost included microbiology service comes from the Local Strategic Health 
Authorities (SHAs) as a general budget for the whole hospital trust. 
 
The Department of Health (DoH) is considering the introduction of a tariff for 
pathology services. The Government, hoping and anticipating that under this 
system a community tariff could set a level that reflects greater efficiency and lower 
cost achieved by larger networks following consolidation. Such a tariff should relate 
to the end to end service, which Lord Carter advocated in his second report. 
However, the providers who did not consolidate their service would become 
increasingly uneconomic according to the response from the service providers. 
 
The use of data from respiratory tract tests appeared to reduce healthcare 
associated costs in our institution. Based on these results, the study estimated that 
potential savings of between 5 to 10% could be achieved. At a national level, this 
would be implying annual savings of between £130 and £210 million in total, based 
on figures for 2005. If savings from rationalisations of the test utilisation adapted 
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nationally these figures would be even larger. The cost reduction would increase 
when more samples are evaluated and cost-effectiveness determined and more 
cost savings will be achieved. 
 
The Carter reviews (Lord Carter of Coles 2006., Lord Carter of Coles 2008)  
emphasise the need to save 10% of the pathology spending budget. The UK 
national budget for pathology amounts to some £2.5 billion per annum (4% of the 
NHS spending) which equates to an annual national saving of £20 million per 
annum in a climate where demand for diagnostic testing is rising 10% per annum 
over the  years (Beastall 2004).  
 
In order to ensure that savings can be made, it will be essential for the DoH,  
Pathology services, PCTs and SHAs to have tools that enable them to monitor and 
manage demand to ensure that uses of diagnostic services are focussed on 
appropriate testing, which is delivered equitably to the population. This is especially 
so given the new NHS commissioning arrangements. Such tools are needed 
because of the variation in requesting patterns and the concern over inappropriate 
testing raised by the current study. 
 
The increased utilisation (test ordering) and workload does not match with the 
increased microbiology laboratory budget for testing increased workloads. This 
contributes financial uncertainty to the clinical laboratory. It has been determined 
that one half of the laboratory cost increase is the result of increased costs to 
perform the test, and half is due to increased utilisation and new services, not due 
to inflation. Further, authorities believe that 20-60% of laboratory tests may be 
unnecessary and inappropriate, and do not contribute to improved patient care 
(Bartlett 1974, Robinson 1994, van Walraven and Naylor 1998, Gopal Rao, Crook 
and Tillyer 2003). Therefore, changing test ordering practices without compromising 
the quality of patient care is an important aspect of cost-effectiveness in clinical 
laboratories. 
 
Clinical laboratories, including microbiology laboratories, must adapt to these 
economic realities. Laboratory managers and supervisors must develop the skills to 
manage the laboratory efficiently and cost-effectively, critically analysing all stages 
of laboratory operations and making appropriate changes as needed. The 
challenge is to do this without jeopardising patient care. Significant reductions in 
pathology spend are possible without compromising patient care. This study 
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believes that there is a lot of wastage across the healthcare delivery chain, from 
clinicians through to the pathology laboratory services that had thus been identified 
and effectively addressed, would result in considerable savings. 
 
The current study suggests there is a need for cost-effective strategies and 
changes to address this issue. Cost-saving strategies represent change, and 
change is typically met with resistance. Conflicts will inevitably develop in our 
changing environment regarding what comprises quality healthcare, as opposed to 
cost-efficient healthcare, and what financial changes are necessary from the 
hospital administration and from the clinical microbiology laboratory. The laboratory 
needs to take an important role in developing strategies that focus on desirable 
patient outcomes, yet limit unnecessary and inappropriate testing; otherwise, 
changes will be imposed that are not in the best interest of the patient. While it is 
true that times have changed and healthcare economics are different from years 
ago, quality patient care is still the goal, and cost savings in the clinical 
microbiology laboratory must address that goal. 
 
This study suggests that cost control in the clinical microbiology laboratory can be 
achieved most efficiently if microbiology departments first sort their laboratory costs 
into discrete categories and then initiate reforms in each category. In addition to 
this, this study suggests to use the three (albeit arbitrary since there is no known 
true microbiology costs per test) cost categories described below (each is 
discussed in the next section, recommendation strategies). 
 
1. Strategies related to the pre-analytical phase and patients testing which are the 
events that happen before the specimen is received in the laboratory. This includes 
utilisation (when/how/why tests are ordered), specimen collection, and specimen 
transport. Microbiology laboratories should particularly question their laboratory’s 
utilisation practices by asking what test or tests should be requested, and how 
often? Are clinicians failing to request tests that actually should be ordered? Are 
clinicians ordering tests that do not contribute to patient care? Controlling utilisation 
(test ordering practices) is a crucial strategy for cost containment. 
 
2. Strategies related to the analytical phase and laboratory technical operations 
which are the steps performed inside the laboratory after the specimen has been 
received. Questions to ask include what processing and reporting methods are 
being used? Does the laboratory assess the quality of the specimen prior to 
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culture? How extensively, how rapidly, and by what methods does the laboratory 
work up a specimen? Does the workup match the needs of the physician? 
 
3. Lastly, strategies related to laboratory management operations, which are the 
methods used to analyse the specimen and compare it with others. Are laboratory 
resources (personnel and equipment) being used properly? Is the skill mix 
adequate for the laboratory? Does the laboratory know and monitor its labour and 
supply costs? Does the laboratory use automation properly and effectively? Is the 
laboratory productivity being monitored, compared with a reasonable standard, and 
other similar medical institutions? Should some laboratory work be transferred to 
another laboratory e.g. Virology or immunology laboratories? Should some tests be 
brought back into the laboratory? Are contracts with suppliers, vendors, and 
reference laboratories being evaluated for cost?  
 
There is a trend to evaluate how laboratory personnel are used. One of the options 
is suggesting that a microbiology laboratory may reduce overall personnel 
expenses by hiring lower-qualified personnel, such as medical laboratory 
assistants, to perform non-biomedical scientist (BMS) duties. The negative side of 
reducing experienced microbiology BMSs is that they are hard to find again when 
you need them. Therefore, reducing the BMS staffing level is always “a no win” 
situation. There is another option, automation in the microbiology laboratory is often 
suggested as a means of reducing staffing, but in the opinion of this researcher, 
automation does not generally reduce staffing to the same extent it may in other 
departments of the clinical pathology laboratories such as clinical chemistry. 
 
However, this study suggests that the use of the three day rule means there are 
additional practices that can reduce labour, materials, and overhead costs, 
including reducing the frequency of testing, reducing off-hour testing, reducing the 
on-call service, redistributing work into fewer workstations, and increasing the batch 
size. It should be kept in mind, however, that some microbiological tests can’t be 
delayed or postponed for technical reasons. 
 
It is well known that microbiology is an expensive laboratory service because it is 
labour intensive. Staff salaries generally account for 60 to 70% of the microbiology 
laboratory’s operating budget. Most microbiology tests cannot be automated easily, 
so there is a direct relationship between workload and the number of Clinical 
Laboratory Scientists or Biomedical Scientists needed. The government’s pathology 
 -   160 
tsar, Dr Ian Barnes, was recently reported in the Health Service Journal as arguing 
that pathology could save 15-25% of its costs by reducing the proportion of highly 
qualified staff that perform junior tasks (Dowler 2011). 
 
Labour is the greatest expense in clinical microbiology laboratory technical 
operations. Most microbiology procedures are performed manually and certainly 
are not as automated as procedures in chemistry or haematology. Therefore 
anything the laboratory can do to reduce labour costs will help. The most 
conventional approach to cost reduction, especially by non-laboratory personnel, 
such as hospital administrators, is simply cutting some laboratory procedures and 
personnel. This approach, however, may affect quality and service. 
 
From a cost effective clinical microbiology perspective, this study showed that using 
respiratory tract specimens, particularly sputum samples, to streamline the initial 
test appropriateness in microbiology would be associated with cost savings in our 
setting. However, cost-effectiveness of different microbiology samples and long-
term effect on cost-effectiveness would show how more cost saving strategies in 
microbiology services could be effective. Moreover, difference in costs of 
microbiology samples and the proportion of evaluable and appropriate tests may 
lead to different amounts of cost reduction. Our estimation is an easy tool to 
calculate such cost-reduction. 
 
4.6 Recommendations to reduce inappropriate test use 
 
This study has found that there is inappropriate microbiology test utilisation 
happening in the clinical microbiology laboratories in similar patterns, as explained 
in the previous sections. Similar findings have been reported previously by other 
investigators, as reported in the review of literature in section one of the thesis. 
When further analysis of the results conducted and reviewed the practice of test 
utilisation in our local institutions and other similar clinical laboratories both 
nationally and internationally, as well as further analysis of current literature. It has 
been found that there is an existence of similar utilisation problems having with 
similar causes of inappropriateness. Therefore, in order to address this issue 
fundamentally, it is also very important to recommend common test utilisation 
strategies that are based on right test, right time and right patient. 
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If there is a mantra for clinical microbiology laboratory testing, it is “order the right 
test at the right time for the right patient.” The wrong or unnecessary test done well 
is no better than the correct and necessary test done poorly. Ineffective and 
inappropriate ordering of tests has a major impact on the operations of a health 
system, affecting the quality of patient care, infection control measures, formulation 
of local antibiotic policy, length of stay, hospital cost, pfa (priorities for action), target 
for reduction of infection (MRSA, MSSA, Cl. difficile etc) and liability of healthcare 
organisations. 
 
This study also pointed out that many investigations are composed of too many 
individual tests as a routine, and that rational, cost saving 
protocols/algorithms/cascades are not always in place. A fundamental requirement, 
in which this study found on to stress, is that tariff structures on the cost of tests 
needed to be radically detailed. Similarly, while test utilisation management plays 
an increasingly critical role in the clinical laboratory, nationwide, implementation has 
been slow. Now pressure from accreditation agencies, local strategic health 
authorities and changing the diagnosis related groups (DRGs) is driving the 
concept with more urgency. 
 
Managing inappropriate microbiology test utilisations needs to promote appropriate 
ways of laboratory testing and provide more responsive and accessible alternative 
services in the community so as to prevent unnecessary laboratory test utilisation. 
 
The support of physicians and other healthcare professionals will be critical to the 
success, and therefore test utilisation management will have added clinical value. 
Microbiology laboratory test utilisation aims to provide useful clinical information in 
the diagnosis, prognosis, treatment or management of patients suffering from 
infections. Hence, this study would recommend the following test utilisation 
management programmes that should provide useful clinical information, and 
appropriate and effective use of laboratory services, not solely focused on cost or 
test reduction without regard to clinical impact, not hinder a clinician’s ability to care 
properly for a patient, and improve the two way communication between the service 
providers and users. To achieve these appropriate test utilisation programmes, the 
following strategies and programmes are required. 
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1. Evidence-based guidelines: The use of evidence-based guidelines and testing 
protocols or algorithms to support, define and standardise the quality of medical 
microbiology laboratory processes. Such guidelines must be monitored, controlled 
and improved continuously. This study is proposing that the clinical microbiology 
laboratories and clinicians must work together, because the laboratories alone 
cannot successfully promote evidence-based guidelines without the co-operation of 
the ordering clinicians. The following are critical: support and endorsement by the 
executive clinician management, physician ownership of the process, physician 
sponsorship of the programme, physician management of the process and IT 
infrastructure and support. Ultimately, it is the responsibility of clinical microbiology 
laboratory staff to help clinicians understand the increasing complexity of tests and 
microbiological test uses. 
 
2. Devise guidelines on protocols: It is important to devise guidelines on 
protocols for specimen procurement for the medical staff, since all cost-generating 
procedures and inappropriate tests originate with a physician’s order. Some 
medical centres have established “best practices” or “clinical pathways” for 
physicians to follow. The teams that develop the clinical pathways are composed of 
physicians, nurses, and laboratorians. They should create a policy for specific 
microbiology laboratory testing protocols depending on diagnosis and/or clinical 
indications. These should be hospital-wide teams to reduce the confrontational 
component when utilisation is changed, as well as ensure that the clinical pathways 
agree with current medical practice. 
 
Clinical pathway policies should include the best test to order, the number of 
specimens accepted per individual site, and how to properly collect and transport 
specimens. These policies set limitations on testing and specimen collection 
frequency, and contain clearly defined rejection criteria for the medical and nursing 
staff. These policies may also indicate tests the physician overlooked that might 
facilitate a rapid diagnosis. The goal of clinical pathways is to obtain the correct 
specimen and request the correct test. Laboratory utilisation in some medical 
centres has been improved by soliciting the support of Infectious Disease 
Physicians, hospital pharmacists, clinical microbiologists, and the chief of medicine. 
In the future, these clinical pathways or utilisation guidelines for each diagnosis will 
become the standard of care. 
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3. Establish an on going education programme: It is important to establish an on 
going education programme in order to keep knowledge of emerging micro-
organisms, new microbiology laboratory techniques, antibiotics and emerging 
resistance up to date. To achieve this, modifying teaching of clinical microbiology is 
required in medical schools and at Universities. More emphasis should be placed 
on the practical aspects discussed above, especially in later clinical years, or during 
internship. Sessions in the diagnostic laboratory would be ideal. This will give the 
medical practitioners an insight into the working of the laboratory, will emphasise 
the importance of good specimen collection and improve their interpretation skills. 
 
This study recommends that, if changing utilisation of the microbiology laboratory is 
to succeed, the impetus for this education programme must be envisioned by all 
participants as a cooperative educational venture. The educational design should 
be informational, not punitive. As stated earlier, in-service education of the medical 
staff may be one of the most important mechanisms of implementing effective 
changes in laboratory testing practices and providing specimen guidelines. It is 
imperative to get physician participation and involvement in the development of 
laboratory testing algorithms (pathways). If these guidelines are totally dictated by 
the microbiology laboratory they will fail. Physicians who do not understand the 
testing rationale may cost laboratory staff time and money in explanations, 
repeated tests, and stressful interactions. Cost containment alone cannot be used 
as the sole rationale for a cost containment programme. Instead, it is important to 
emphasise the improvement in the quality of care that will occur as a result of 
reducing over-utilisation, under-utilisation, and miss-utilisation of microbiology 
laboratory tests. 
 
This study also recommends that good microbiology laboratory orientation 
programmes and frequent in-service sessions are a must for cost effective and 
relevant clinical microbiology. It is necessary to provide appropriate documentation 
for the changes microbiology laboratory propose—citing, for example: in-house 
laboratory data; Q-Probe data from the College of American Pathologists (CAP), 
CPA regulations; or recent research publications. It has been found it is effective to 
discuss laboratory policies at medical staff meetings. In-service presentations to 
small groups of physicians also seems to work well. Teaching tools, such as 
PowerPoint presentations, are beneficial; physicians are accustomed to this format. 
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4. Nursing staff training: In-service training for nursing personnel is crucial. It is 
important that nurses feel they are part of the solution, rather than to feel the 
microbiology laboratory is dictating to them. Nurses are often the ones to order the 
test, obtain the specimen, and submit the specimen to the clinical laboratory. Their 
buy-in is essential. Nurses can often represent the lab “de facto” because they 
interact with the physician more than the microbiology laboratory personnel. 
Clearly, a new role of the microbiologist is to be a resource to physicians and 
nurses, and laboratory managers and supervisors can only do this by getting out of 
the laboratory to interact with other hospital personnel, particularly the nursing staff. 
 
5. Screen specimens for quality: It is essential to screen specimens for quality. 
Physicians often require guidance on the most appropriate specimens: how to 
collect them, the frequency of their submission, and methods of ensuring specimen 
quality. Also, physicians are often unaware of the detrimental effect on specimens 
of contamination with indigenous microflora. Therefore, the microbiologists need to 
provide information to the physicians. The concept that physicians can submit 
specimens and laboratories will run the requested tests without question is no 
longer valid. Specimens that are not collected or transported properly, even when 
handled optimally within the laboratory, are likely to provide misleading results, 
causing the physician to act on incorrect, misleading, or irrelevant data. Assessing 
specimen quality should be thought of as providing an essential service to the 
physician, and to the patient. 
 
Once the specimen has arrived in the laboratory, the staff needs to screen the 
specimen (wounds and sputa for example) by Gram stain or gross appearance, to 
see if the specimen is adequate for culture. Further, the laboratory must ensure the 
proper storage of the specimen. A urine sample with just a few colony-forming units 
(CFUs) of bacteria left out at room temperature could easily yield a colony count 
that may be considered significant. This may necessitate full and expensive 
identification and susceptibility testing, and/or incorrect therapy, adding not only to 
laboratory costs, but also to overall hospital costs. The inappropriate storage of 
sputum specimens can result in the normal respiratory microbiota overgrowing 
potential pathogens and yielding misleading information. 
 
6. Changing physician ordering practices: It is important to address the 
physician’s test ordering practices and behaviors; however, this changing is one of 
the most controversial and difficult tasks for the laboratory, because many aspects 
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of utilisation cannot be controlled directly by the clinical laboratory. Requesting 
unnecessary testing is a deep-rooted problem stemming from the early training of 
physicians; the pressure to test for unforeseen problems, and the fear of criticism 
for failure to consider certain unusual diagnoses. Also, unnecessary tests may be 
ordered because of academic curiosity, defensive medicine, and the fear of 
litigation. Often, attempting to change a physician’s ordering practices leads to 
confrontation and unpleasant situations. It has been suggested that the place to 
actually start changing physician-ordering practices is with the physicians-in-
training, rather than with currently practicing physicians. It may be easier to change 
the behavior of house officers, registrars, and fellows by performing audits and in-
service training when physicians are employed by medical centres than when they 
have their own practices. 
 
However, this study believes that microbiologists and clinicians may have different 
perceptions of what constitutes rational and necessary laboratory testing. In the 
clinician’s view, a good microbiology test might be one that provides useful clinical 
information quickly. The microbiologist may recognise that such a test is labour-
intensive, requires huge outlays of equipment or supplies, and is very costly. 
However, if the clinician believes this is the only way to make a diagnosis, then the 
test is justified to the physician. The differences between a clinician’s and a 
microbiologist’s perceptions and attitudes are important factors to consider when 
attempting changes in microbiology services. 
 
7. IT infrastructure and support: There is a need for good hospital-wide and 
health centre computer system. One of the initial forays into utilisation management 
problems is due to a lack of system-wide computerised physician order entry 
(CPOE) in which clinical microbiology services and other clinical laboratories will 
need to be selected as test utilisation strategies that can be easily implemented and 
used. 
 
A good hospital-wide computer system is essential to help reduce the frequency of 
laboratory testing and to improve utilisation. Physicians may be willing to abandon 
daily test-ordering if they are convinced that updates on the one culture specimen 
they sent in will be provided early each day, and that all clinically significant 
changes will be brought to their attention or flagged. The physician may not realise, 
for example, that multiple samples have been previously submitted, but a good 
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computer system will alert the requestor to them. Further, the initial requesting 
process is the ideal place to let the physician and other medical staff know about 
laboratory policies and guidelines for specimen submission, frequency, and 
transport. The laboratory’s requesting system must provide clear definitions of what 
information, and exactly what specimen, is required. For example, a physician’s 
request for a generic “wound culture” is not satisfactory. It fails to provide the 
microbiologist with adequate information for culturing procedures, resulting in 
inadequate results for the physician to evaluate. What is needed is a notation of the 
exact specimen source and location, for example, “abdominal surgical drainage”, so 
that the specimen may be cultured appropriately. 
 
8. Encourage communication: it is very important to encourage communication 
between the clinical microbiology laboratory, the physicians and with other 
healthcare professional to maximise the use of the microbiology services in 
management of infectious diseases. 
 
Reviews of the literature and the personnel experience of this study author shows 
that it is easy to suggest these stated recommendations and restrictions, but harder 
to implement them. Therefore, it is recommended to implement the restrictions and 
changes slowly. As reported earlier, use of computer information flags that appear 
whenever someone tries to order these tests, hold in-service sessions with 
physicians and nurses to ensure everyone is informed. One of the ways to enhance 
good communications between service providers and service users is the use of 
posters and publishing a clinical microbiology newsletter, which conveys the 
appropriate laboratory utilisation and changes in the practice of laboratory 
medicine. 
 
Some of the clinical relevant and cost-effective suggestions offered in this study 
may not apply to every microbiology laboratory. However, the strategy behind them, 
trying to generate essential laboratory information at a reasonable cost, is 
universal. As laboratorians we must change many of our approaches and thought 
processes. Change is uncomfortable. However, to be clinically relevant and cost-
effective in the new healthcare environment, change we must. The modern medical 
microbiology laboratory should offer a comprehensive diagnostic service, designed 
to optimise specimen collection, to ensure quality of processing and to assist with 
the interpretation of microbiology reports. 
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Since the beginning of this study, the NHS pathology service has been undergoing 
major changes through reforms, the effects of the economic 'squeeze' and re-
organisation of the service. The new Health and Social Care Bill will lead to a 
further intensification of these changes. 
 
4.7 Conclusions 
 
Sputum is the most common lower respiratory tract specimen received by the 
microbiology laboratory. It is also often the most problematic to assess due to 
contamination by oropharyngeal flora. In spite of numerous guidelines on 
appropriate samples for microbiological examination, laboratories continue to 
receive a large number of inappropriate sputum samples. 
 
The aim of this study was to determine the appropriateness of clinical microbiology 
test utilisation, evaluate the clinical relevance, cost-effectiveness, specimen 
management and recommend better utilisation strategies. Respiratory tract 
specimens were used as an example and quality indicator for the examination of 
the total testing process. 
 
In conclusion, this investigation has accentuated the real need for clear appropriate 
information, especially for test requisition, adherence to specimen collection 
principles, laboratory compliance with the standard operative procedures (SOP) 
and the use of interpretative comments to assist clinicians in interpreting 
microbiology test results. 
 
From the results of the present study, it has been learned that clinicians and other 
healthcare professionals utilise the clinical microbiology services inconsistently, 
often by sending to the laboratory inappropriate specimens and test requests, as 
summarised below. 
 
 Analysis of the findings showed that the usefulness of culture results was 
limited by the collection of inappropriate specimens and lack of clinical 
information on the microbiology request form. 
 
 The crucial importance of the role of clinical and nursing staff is stressed if 
the clinical relevance of sputum culture is to be maximised. 
 -   168 
 
 The increasing introduction of electronic pathology test requesting, gives 
new opportunities to restrict the collection of inappropriate specimens and 
make substantial savings in resources, both in the wards and the laboratory. 
 
 In order to address this issue of inappropriate microbiology test utilisation, it 
is very important to recommend common test utilisation strategies that are 
based on right test, right time and right patient. 
 
During the course of this study project the pathology service has undergone several 
changes and challenges, both locally and nationally, which has impacted and 
influenced the services of clinical microbiology laboratory. Challenges in healthcare 
that affect clinical microbiology are taking place on multiple levels. These 
challenges include changing infectious diseases, patient demographics, medical 
environments, technological revolution, economic environments and work force. 
 
Changes in infectious diseases are directly affecting the practice of clinical 
microbiology. Newly emergent pathogens are playing an increasingly important role 
in the healthcare management of individuals and populations. The changes in 
patient demographics that most affect clinical microbiology are the increases in the 
populations of patients with greater susceptibility to infections. The aging of the 
population in the UK, Europe, USA and worldwide has increased the proportion of 
elderly patients who present with a broad range of new infectious problems caused 
by their declining resistance to infection. The change in the medical environment is 
particularly apparent in the increasing emphasis on evidence-based medicine and 
the use of guidelines. The emphasis on evidence-based diagnostics and the proven 
impact of diagnostic interventions on patient outcome will also put further pressure 
on clinical microbiology to prove its cost-effectiveness and clinical relevances. 
 
The financial constraints imposed upon the healthcare providers are also 
influencing the practice of clinical microbiology. Driven to implement post-Carter 
recommendations, there is an expectation that significant savings, in the region of 
20%, can be made by consolidating pathology services and so benefiting from 
economies of scale. The NHS, as a purchaser of healthcare, wants more value 
from pathology testing to optimise the cost-efficient use of the available resources. 
However, it is a challenge to understand and control the microbiology test costs 
because of there is no cost structure in the NHS, both nationally and locally, as 
 -   169 
current study has revealed. Pathology modernisation also has an impact on the 
organisation of clinical microbiology laboratories. Two kinds of response are 
already clearly visible. The first is the consolidation of separate laboratories into 
bigger entities via mergers, acquisition of smaller laboratories by regional large 
laboratories, or the formation of networks. A second possible response is to 
streamline different sub-speciality laboratories into unified and integrated large-
scale laboratories. 
 
For the changing technological revolution, microbiology laboratory automation is 
emerging and processes are done faster than ever with more standardised and 
comparable tests. The introduction of MALDI TOF into the diagnostic microbiology 
laboratory has greatly reduced the time for identification of bacterial and fungi, and 
allowed the rapid identification of bacteria directly from blood cultures. There is a 
possibility that the trend toward increasing automation will reduce the need for 
highly trained microbiological staff. Thus, a technical workforce with less training 
could comprise a larger part of the clinical microbiology workforce. It is a matter of 
debate whether this will have an impact on the quality of the service. The 
introduction of, for example, molecular techniques, with their potential for 
miniaturisation and automation, will only strengthen this trend. However, 
Modernising Scientific Careers (MSC) will provide new education, training 
programmes and opportunities for scientists at a higher level. 
 
The introduction of the National Laboratory Medicine Catalogue (NLMC), which the 
NHS will be testing in July 2012, will revolutionise pathology services in the way 
pathology tests are requested and reported in the UK. The activity of the clinical 
microbiologist would be towards the evaluation and interpretation of tests, including 
the determination of their sensitivity, specificity and predictive values; 
communication of results to clinicians, in particular, infectious-disease specialists; 
advising on antibiotic therapy and sampling strategy in conjunction with infectious-
disease specialists; following trends in diseases epidemiology and reporting these 
trends to infection control teams. 
 
The vision for the new NHS pathology service is modernising pathology which will 
create an efficient, lean and cost effective pathology service, managed and run by 
highly skilled healthcare scientists, who have knowledge and expertise in 
healthcare science and an understanding of the business of healthcare. From April 
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2013 clinicians will lead to the commissioning of clinical services, including 
community pathology. 
 
The final conclusion from this study is that the microbiology specimen’s 
management is the greatest challenge facing current and future microbiologists due 
to the nature of microbiology specimens and the process ranging from the 
collection to the reporting of results. This type of study and audit can give 
invaluable information about the rationale behind testing, and the appropriateness 
of sampling and transport time. Appropriate measures for corrective actions can be 
identified and implemented. 
 
4.8 Future work 
 
The data collection of this study was not designed to capture the entire process, 
from test ordering, specimen collection, storage, transport, processing to test 
reporting. To assess the impact on the total test process and generate new 
evidence, there is a need to investigate the entire current practice of clinical 
microbiology laboratory test utilisation from test order to test report. An academic 
analysis of current test-ordering practices might suggest that further research is 
needed into why doctors order tests the way they do, whether there really is such a 
high rate of unnecessary testing, and what value current ordering patterns add to 
our highly complex healthcare system. A pragmatic view, however, would suggest 
that there is enough published evidence that over-testing is a characteristic of 
healthcare systems in the developed world, and enough information in existing 
research to guide what should be done to reduce waste and harm resulting from 
inappropriate testing. 
 
A multidisciplinary audit needs to be developed by a team of healthcare 
professionals (microbiologists, nursing, infection control, physicians, hospital 
managers etc) to assess the impact of sputum culture results on patient’s outcome 
to improve quality of care and to reduce overuse of antibiotics. 
 
Few studies have examined the relationship between macroscopic appearance and 
sputum specimen quality. Therefore, there is a need for further research work on 
the reliability of sputum macroscopic examination prior to sample processing in the 
microbiology laboratory, and its value in terms of cost or outcomes. 
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It is time that the focus of work in this area shifted to the development of practical, 
sustainable means of improving the appropriateness of testing. Future research 
may be best directed to understanding the place of sophisticated decision-analysis 
models, the role of point-of-care guidance and feedback systems, and effective 
clinical change-management strategies. As the UK grapples with the problem of 
funding healthcare due to the financial crises taking place around the globe, further 
research on cost effective microbiology laboratory practice in all areas of the 
microbiology laboratory should receive high priority. 
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Chapter 5   Professional and personal reflection  
  
5.1 Introduction and reflective learning 
 
5.1.1  Introduction 
 
 
This part of the thesis describes the benefits of learning through reflection as part of 
a work-based professional doctorate study programme. The section is presented in 
two parts: The first describes the framework for reflective learning in higher 
education with reference to professional doctorate pathways and reflective practice. 
The second is an account of my own reflective learning, based within my academic 
context as a work-based doctorate student, and in my professional context as a 
Senior Biomedical Scientist and Microbiologist working in the hospital microbiology 
laboratory of one of the UK’s largest teaching hospitals, Barts and The London 
NHS Trust. The journey of moving through a doctoral programme can be tedious 
and tiring. The personal journey of this particular doctoral student was weighted by 
the time and energy it has simultaneously taken to maintain a full time job, be an 
active participant in a 20 year marriage, and be a loyal, devoted and involved 
parent of five active teenage children, as well as keeping my present job through 
relocation and three recent restructuring processes that have taken place in our 
NHS Trust during this doctoral course. 
 
5.1.2.  Work-based learning and higher education 
 
Traditionally, universities are viewed to conduct research to build up a body of 
knowledge that is then taught as a ‘truth’. In this model, the subject matter 
knowledge is the defining characteristic. Students follow an existing curriculum. The 
content is fixed and determined. The methodologies used are disciplinary. The 
learning is individual. Problem solving is academic and timeless. The workload is 
uniform and fixed by the university. Learners attend an educational institution on a 
regular basis, or study from home. They sit examinations or complete set 
assignments. Reflection on learning occurs unintentionally and is non systematic. 
According to Costley (Costley 2000), this model has been questioned for some 
time. 
 
When I started the professional doctorate programme, I had discovered that work-
based learning represents a relatively new way of organising and learning in the 
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academy. It does not arise directly from the disciplinary frameworks in which 
knowledge has been traditionally ordered within the university, and in many 
instances it exemplifies more local knowledge, flowing from the particular spatial 
and temporal circumstances of work contexts and situations (Boud 2001). The 
content is flexible and individually determined. Knowledge is derived through a 
multidimensional, inter-professional, work-based frame of reference. It is 
constructing not absorbing knowledge (Costley 2000). Work-based learning is 
concerned with the knowledge gained by doing work and aims to be developmental 
for the practitioner, purposeful for the community of practice and useful in its 
contribution to academic learning and the knowledge stored in higher education. 
Work-based pedagogies focus on the creativity and reflexivity of individuals within a 
work-based context rather than the learning of a set syllabus (Costley 2000). 
 
The methodologies used are transdisciplinary, applied and exploratory research 
methodologies (Boud 2001). They are influenced by contextual factors, the 
individual or community of practitioners who undertake practitioner research and 
development in organisation learning (Costley 2000). 
 
5.1.3. Learning a new language, reflective learning 
 
At the start of the doctoral programme, I had never heard of reflective learning. I 
soon discovered that reflection is an integral part of higher education work-based 
learning programmes. Since then, I have internalised this language to the extent 
that today, I can explain what I was unable to explain before I started the doctoral 
programme. 
 
I have discovered that students in higher education are responsible for their own 
progress as independent learners. They take notice of and act upon formal 
feedback from their lecturers of course, but it is also important that they themselves 
think about (or reflect on) their learning. Numerous learning theories emphasise 
reflection as a key element of the learning process (Kolb 1984, Honey 1986). 
Increasingly, programmes of study explicitly require students to do this. Reflective 
learning is an integral part of work-based learning. In simple terms, reflection can 
be seen as ‘consciously thinking about and analysing what one has done (or is 
doing)’. It is a structured way to reflect upon one’s learning, to understand one’s 
learning processes, and thus allow becoming more autonomous. It is exploring 
one’s experiences of learning to better understand how they learn, ultimately with a 
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view to improving their further learning. During reflection-on-action (after you have 
done it) the learner looks back over an experience and reviews what was learnt. 
Reflection-in-action (while doing something) involves understanding new concepts 
through improvisation and experimentation during an exercise or experience 
(Schön 1983, Schön 1987). 
 
 Learners can develop into reflective learners by using methods such as creating a 
learning diary or portfolio, keeping reflective notes, making constructive use of 
feedback from advisors, consultants, examiners, etc., thinking positively about 
moving themselves and their skills forward (Cottrell 2003a, Cottrell 2003b). 
Engaging in reflective learning allows analysis of one’s experiences and facilitates 
learning from this experience. It encourages critical thinking, and a questioning 
attitude and it promotes professional competences by encouraging recognition of 
mistakes and weaknesses. 
 
5.2   Personal learning and reflection 
 
5.2.1 Developing professionally 
 
My motivation and interest in this doctorate has two dimensions. First, as a 
healthcare professional and healthcare scientist, I need to update and develop my 
knowledge to be able to perform to “best possible practice” for the benefit of the 
patients and their clinicians. Today there is an increasing demand that the clinical 
laboratory scientists have to take responsibilities and lead the service of clinical 
pathology. Second, to engage in lifelong learning and to gain additional skills, 
especially research and advanced qualifications. I started this programme of Doctor 
of Biomedical Science to develop my knowledge on the subject and to develop my 
professional practice. 
 
The professional doctorate programme requires that candidates engage in 
reflective and planning activities explicitly during the early stages of their 
programmes through a review of their previous learning and the development of a 
detailed programme plan. These provide a foundation for the professional projects 
that candidates go on to undertake and engender a critically reflective stance from 
the outset. 
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When I was first asked to systematically undergo a reflective review of my previous  
learning as a biomedical scientist and doctoral student, I felt uncomfortable in doing 
so, I even felt it was irrelevant to what I intended to do in my studies, and I started, 
reluctantly, to describe and record my previous learning. I gradually started to 
identify the knowledge I have acquired during the years, skills, abilities and 
competencies. I learned to analyse, synthesise and evaluate it. The results were 
amazing and truly surprising to me. Although I knew I had worked and studied 
consistently all my life, I had never really realised what and how much I had done, 
had learned, and had developed in being able to do. I found it hard at the beginning 
to present all these in a comprehensive and cogently argued way, but by doing so, I 
gained this skill too. When I went through my previous learning and I recorded what 
I had previously done, what I had gained in terms of knowledge, skills, experiences, 
and capabilities, what I have accomplished, it was only then that I realised how that 
formed a solid background for my doctoral research studies and project, and it was 
only then that I realised the benefit of this activity. 
 
I also undertook taught components of the course, such as professional review and 
development, advanced research techniques, publication and dissemination, the 
proposal for professional research and development. This also involved reflective 
learning and a presentation of course activities.  During this module, I had to keep a 
learning diary as an ongoing record of the insights I gained in research, and write 
an overall reflection and evaluation of my learning at the end of the notes.  
 
The module involved understanding the philosophical and theoretical issues in the 
professional doctorate, practitioner-led research, knowledge of appropriate 
methods, and their limitations and uses. It also included sessions aiming to enable 
all candidates to design and undertake research at doctoral level, devise and use 
appropriate research instruments, critically understand ethical issues in a range of 
contexts and be able to appropriately use approaches and tools in these contexts.  
I reviewed, evaluated and critiqued research approaches and methods in various 
contexts and selected and justified the selection of research methods chosen for 
my project work using research and development experience gained from the 
taught components.  
 
The knowledge and skills acquired during the taught component were invaluable 
whilst writing up my doctoral thesis. For instance, critical evaluation of papers used 
as reference was enhanced through the advanced research techniques unit; this 
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facilitated more informed choices of which bibliographical sources to use for my 
reference and the review of the literature. My research project resulted in the 
presentation in academic meetings such as a short paper presentation at the IBMS 
congress in 2007 (Appendix 5.1). The presentation skills and experience gained 
from the Publication and Dissemination unit have helped me to present research 
findings to a wider audience. 
 
At the end of part one of the course, I had achieved most of the knowledge and key 
skills that are required for the doctoral research project. The research project was 
work-based and professionally relevant. I have further learned more important 
skills. These skills included research methodology, data collection, data analysis, 
record keeping, critically thinking, project management and computer skills and 
other key transferable skills. I have also acquired a basic understanding of the 
fundamentals of financial management in healthcare facilities and the principles of 
medico-economic evaluation of laboratory tests. These tools, skills and theories, 
and the type of language to use were useful in the review of literature, discussion, 
evaluation of research findings and evaluation of the impact of the research on 
professional issues and implications on clinical pathology service. My supervisors 
provided me with valuable guidance throughout the course, on research project, the 
thesis preparation and final writing up. 
 
5.2.2 Acquiring proficiency as a researcher  
 
The second aspect I want to reflect on is my personal growth as a researcher. The 
research programme gave me invaluable experience in a work-based research 
project. I identified the overall direction of the research programme and the topic for 
my work-based project. I justified the relevance of both my own interests and those 
of my organisation, and professional field. I evaluated the ethical implications of my 
proposed project. I described and justified my choice of approach and methods for 
data collection and analysis using MS Excel. 
 
I justified the feasibility of the project, indicated how the project was to be led and 
managed, and provided a realistic action plan for it. I produced a project proposal 
which took account of relevant professional and organisation issues (financial, 
human, etc.) necessary to complete the work-based project. I identified, and gained 
authority to use the resources necessary to complete the work-based project. I 
wrote a coherent learning agreement, which contained a summary of all 
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components of the intended programme, and a detailed project proposal, and I had 
a successful face to face discussion with the university faculty members about the 
importance of the topic of the project and research question. I explained the 
leadership role I intended to fulfil in the proposed project.   
 
Reflection on and in action became a continuous valuable tool in this process, as 
previously explained in section 5.1.3. It made things clearer and pulled things 
together in a logical manner. It also drew my attention to the possible difficulties I 
would face during my research project, and made me start thinking about possible 
ways to address them. The intention here was to understand the project idea 
myself by working with meaning, which is deep approach (Entwistle 1996).  
 
My research project involved the appropriateness of clinical microbiology laboratory 
investigations, and I had conducted a retrospective study of the cost and clinical 
relevance of microbiology specimen management and processing. The aim of this 
investigation was to determine the appropriateness of clinical microbiology test 
utilisation and evaluate the clinical relevance, cost-effectiveness and hence 
recommend better utilisation strategies. The key areas that my project was involved 
in have been stated and described in the previous sections of the thesis. However, 
the concept of the project was to provide valuable research information to   
establish an optimal clinical microbiology service based on the following concepts: 
 
1.  Good microbiology is clinically relevant microbiology (appropriate 
utilisation). 
2. Exhaustively good microbiology may produce irrelevant or even misleading 
information (medical value of a laboratory test). 
3. Good microbiology results only from a well collected, high quality clinical 
specimen, transported appropriately and received in a time frame that 
ensures proper testing (“garbage in, garbage out”). 
4. Microbiology must be practised in a way that ensures adequacy of 
resources so that what needs to be done can be done without 
compromising quality (cost-effective microbiology). 
 
During my research project I continued to keep a record of my reflective learning. I 
used the following methods: I kept notes during the project and I included reflective 
comments in my notes regarding the project investigation and writing up, taking into 
consideration the project expected outcomes and the formal programme criteria. 
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These reflective comments helped me to learn from experience and make sense of 
that experience. I made constructive use of feedback from my supervisors, 
microbiology consultant, staff and other stakeholders. 
 
5.2.3 My personal reflections 
 
Thinking back, I realised that following the University of Portsmouth work-based 
doctoral programme provided me with the opportunity to learn, as a lifelong learner, 
through equal and open access to high quality learning opportunities. Through the 
work-based learning, required by the nature of the doctorate programme, as a way 
of university level learning in the workplace, I was given the opportunity to (a) 
pursue academic research project study grounded within a work context and (b) to 
enhance the effectiveness of the clinical microbiology optimal test utilisation. I had 
the opportunity to be researcher in both my practice and profession. As an insider 
researcher, I learned to manage work and doctoral research projects together. I 
combined the work-based research project philosophy with that of demand 
management and appropriate test utilisation in clinical microbiology disciplines in 
the area of standardisation of laboratory rationalising. I also had the opportunity to 
introduce the concept for introducing a more interactive laboratory service. I 
established the needs of appropriate clinical microbiology test utilisation strategies, 
which were greatly needed by my workplace, and constituted as evidence of my 
work-based project. As a result, I gained knowledge, skills, abilities and experience 
in reviewing the existing microbiology laboratory test practices and establishing 
needs. 
 
At the same time, I also learned how to lead a work-based research project in a 
busy NHS hospital staffed with more than 100 staff members (biomedical scientists, 
clinical scientists, specialist Microbiology registrars, consultants, faculty members, 
medical laboratory assistants, student, office personnel, and administrators) with 
constant work pressure issues. I have learned how to deal with unexpected 
complications of the project, find solutions to problems, make decisions, take 
responsibilities, negotiate, present and discuss the project progress and results. 
 
I also learned to accept that some people are not prepared to accept something 
that does not suit them at the time, and as a result they can be difficult to work with. 
It can be very disheartening to continue working on a research project with such 
people. I learned to accept ignorance and tried to ‘educate’ stakeholders gradually 
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and as much as possible. I learned to accept that work-based research is a hard 
environment to work in because researchers have to prove themselves to many 
different people (colleagues, managers, fellow researchers, various microbiology 
consultants, ethical committees, and other stakeholders). Despite all that, I learned 
that at the same time, work based research is meaningful, motivating, challenging 
and worthwhile. This critical reflection on my practice, and that of team practice and 
development, enabled me to clearly identify achievements and strengths, recognise 
areas of weakness and make improvements. It helped me develop a more 
systematic awareness of all these. I learned to be responsible for my own learning, 
be autonomous, and practice continuous reflection on my learning experiences. 
 
The professional doctorate programme has improved my knowledge of all aspects 
of clinical microbiology laboratory service, and I also feel that my exposure to work-
based research projects will help to keep my options open as to possible career 
paths. It was great to meet other people from varying backgrounds working in the 
NHS or other organisations. Most of my intakes were other healthcare 
professionals with varying backgrounds and experience, including Chiropractics, 
Medical Imaging, Nursing and Pharmacy. 
 
As for my work experience and professional developments, I feel so blessed for the 
opportunities that I have been given during the course. I have learned so many 
valuable skills that I will be able to use in future endeavours. I feel that I have not 
only gained knowledge, skills, experiences and capabilities during my studies, but I 
have also continued to do so in recent years. Through continuous work, 
improvement and implementation of the project outcome, through the feedback I 
keep receiving from colleagues and supervisors, and through continued 
presentations of various aspects of my research results, including journal club, 
academic meetings, etc. This experience has taught me leadership skills, project 
management skills, the importance of teamwork, and effective communication 
skills. 
 
The most significant part of my experience truly was working with my supervisors, 
mentors, colleagues and students of Portsmouth University. The professional 
doctorate programme has granted and rewarded me with better professional skills, 
greater confidence and a large step toward my education growth. Part of my 
research project has involved cost effectiveness of the microbiology tests. Thus, a 
thorough understanding of how UK healthcare services is organised and funded 
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made me aware of the competitive changes that pathology services have 
undergone, as well as the current trends and developments taking place in the 
microbiology profession. I can better understand the priority and importance of 
healthcare economics in the current financial situation. 
 
5.2.4  Reflective conclusions  
 
Becoming more reflective has helped me to achieve a better understanding of my 
own practice and an improved level of performance. Undertaking the DBMS has 
radically altered my professional practice and has enhanced my professional 
confidence and analytical abilities. The undertaking in research project and writing 
up the thesis became a fundamental and transforming process in my life, both 
professional and personal. Undertaking the DBMS enhanced my confidence and 
also my credibility, which gave me the time to think and forced me to articulate my 
ideas and to think analytically. The DBMS fundamentally changed my whole 
professional life; it was transformative and I would never have done a PhD, which 
seemed too academic. But the professional doctorate programme has really 
taught me to do research and to be interested in a much deeper approach to my 
practice and to carry out a research project based on professional practice to gain 
additional qualifications. Completing the programme allows me a sense of 
personal satisfaction as well as the knowledge that allows me to be a better 
microbiologist.  
 
I can note two major contributions of this research project: to research in general 
and to my work organisation in particular. In theory, it offered new knowledge for 
highlighting the fact that there is a need to enhance the key concepts of 
microbiology specimen management, clinical relevance, cost effectiveness of 
diagnostic tests and optimal utilisation of the clinical microbiology laboratory 
service. The study gave invaluable information about the area of uncertainty 
between the clinician and the laboratory, and can identify appropriate measures for 
corrective action. 
 
In  practice,  it  provided  change  and  improvement  in  the  existing  microbiology 
laboratory practice by  developing  and  implementing improvement opportunities to 
ensure accuracy of test results, to improve quality of care and reduce unnecessary 
testing. Improvement opportunities that were identified to meet this goal focussed 
on reducing specimen delays, processing of poor quality sputum, reducing 
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microbiology test TAT, reducing unnecessary workload and cost, introducing test 
result interpretation comments and establishing new concepts which reduced costs 
and TAT.  
 
On reflection, I was very pleased that such a positive outcome resulted from my 
contributions and research. It is my hope that the material that has been presented 
in this thesis demonstrates an ability to move forward with that goal, an ability to 
“stick to it” and see the project through from beginning to end. It is my hope that all 
who view this project and the accompanying materials will feel the same. 
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Appendices   
  
Appendix 1.1: Guidelines of respiratory specimens handling and collection  
  
Type of 
Specimen Method of collection Volume  
Transport and  
storage  Comments 
Lower respiratory: 
Expectorated 
sputum 
Induced sputum 
Sterile container/cup  > 1ml ≤ 2 h, RTa 
delay: 
≤ 24 h, 4Co 
Rinse mouth first, use Gram stain to screen for 
suitability 
Bronchoscopy 
fluid (bronchial 
washing, lavage, 
brush & endotrach 
aspirate) 
Sterile container/cup or tube > 1ml ≤ 2 h, RT 
delay: 
≤ 24 h, 4Co 
 
Upper respiratory: 
Nasal Insert  premoistened swab into 
nares place into transport 
media 
Swab 
transport 
≤ 2 h, RT 
delay: 
≤ 24 h, RT 
For detection of nasal carriage of S. aurous or 
Group A streptococci only 
Nasopharynx Insert calcium alginate Swab 
into posterior nasopharynx via 
nose, inoculate medium at 
bedside or transport swab 
 
Direct 
media 
inoculation 
Plates ≤ 15 min. 
Swab:≤ 2 h, RT 
delay: 
≤ 24 h, RT 
Routine swabs may not support growth of some 
organisms (e.g., B. pertussis). Use calcium 
alginate or dacron/rayon swabs 
Throat Swab posterior pharynx and 
tonsils 
Swab 
transport 
≤ 2h, RT 
delay: 
≤ 24 h, RT 
Inform laboratory if identification of organisms other 
than group A beta haemolytic streptococci is 
indicated (e.g., N. gonorrhoea) 
 
a 
RT: Room
 
temperature
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Appendix 1.2: Useful guide for sputum macroscopic examination 
 
1. Sputum definition:  
 
Sputum is material coughed up from the lungs and expectorated (spit out) though 
the mouth. Sputum is a substance comprised of mucus, foreign matter, and saliva 
that is found in the lungs or bronchial tree. 
 
2. Purpose of sputum culture:  
 
A sputum culture is done to find and identify the microorganism causing an 
infection of the lower respiratory tract such as pneumonia (an infection of the lung). 
Infections of the lungs and bronchial tubes are caused by several types of 
microorganisms, including bacteria, fungi (molds and yeast), and viruses.  
 
3. Common reasons of sputum culture: 
 
 The purpose of a sputum analysis is to help identifying microorganisms that are 
causing respiratory infection. The most common reason for obtaining a sputum 
specimen is to test for infectious tuberculosis, pneumonia, bronchitis, lung abscess, 
or other respiratory infections. 
 
4. Sputum Description:  
 
Based on the clinical condition of the patients, a patient with infections produces 
pus-like material and/or blood may have an infection of the lower respiratory tract, 
see the table for details.  
 
5. Sputum processing:  
 
A portion of the sputum is spread over the surface of several different types of 
culture plates, and placed in an incubator at body temperature for one or two days. 
During incubation, bacteria present in the sputum sample multiply and will appear 
on the plates as visible colonies. The bacteria are identified by the appearance of 
their colonies, by the results of biochemical tests, and through a Gram stain of part 
of a colony. The bacteria are tested against different antibiotics to determine which 
will treat the infection by killing the bacteria. 
 
6. Sputum culture results: 
 
a. Normal results: sputum from a healthy person would have no growth on culture. 
A mixture of micro-organisms, however, normally found in a person’s mouth and 
saliva often contaminates the culture. If these micro- organisms grow in the culture, 
they may be reported as normal flora contamination. 
 
 b. Abnormal results: the presence of bacteria and white blood cells on the Gram 
stain and the isolation of a microorganism from culture, other than normal flora 
contamination, is evidence of a lower respiratory tract infection. Micro-organisms 
commonly isolated from sputum include Streptococcus pneumoniae, Haemophilus 
influenzae, and Moraxella catarrhalis.  
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Sputum Description:  
 
Term Description  Gram staining  Associated with 
Salivary sample 
 
Samples are watery with heavy froth 
and bubbles. 
On microscopic examination it shows predominance of 
epithelial cells and on Gram staining a variety of micro-
organisms typical of the normal oropharyngeal bacterial flora  
Normal patients 
Mucosalivary 
sample 
 
Samples contain mucus with a small 
amount of saliva 
Like salivary samples on microscopic examination contain 
large number of squamous epithelial cells and oropharyngeal 
bacterial flora. 
Normal patients 
Mucoid sample 
 
Samples appeared as transparent or 
translucent with or without debris and 
contain with white flecks and moderate 
froth and bubbles. Mostly mucus. 
Like salivary samples on microscopic examination contain 
large number of squamous epithelial cells and oropharyngeal 
bacterial flora. Epithelial cells in large numbers within sputum 
smears mean that the specimen is predominately oral saliva, 
rather than true sputum fron the lungs. 
Not generally associated 
with broncho-pulmonary 
infection. 
Mucopurulent 
sample 
The mucopurulent samples are 
normally opaque and usually yellow 
color with no froth. Green-looking with 
pus and mucus. 
On microscopic examination, the Gram stain shows a large 
number of pus cells or polymorphonuclear leucocytes 
representing sputum specimen 
Acute and chronic infection 
Purulent sample 
 
A sample appears like pus, yellow or 
greenish sputum, rusty descriptive, 
often copious and thick. Green-
looking, mostly pus. 
On microscopic examination, the Gram stain shows a large 
number of pus cells or polymorphonuclear leucocytes 
representing sputum specimen. White blood cells indicate 
inflammation and possible infection. 
Acute and chronic infection 
Blood stained 
sample 
 
Expectoration of blood or bloody 
sputum, amount may range from blood 
streaked to massive haemorrhage 
(haemoptysis) 
Red blood cells in a direct smear are not usually significant? A variety of pathologies 
Fetid  
 
Foul-smelling, typical of anaerobic 
infection 
 Bronchiectasis, lung 
abscess or cystic fibrosis 
Rusty  Descriptive of the colour of sputum 
(also called prune juice) 
Gram stain of sputum shows abundant inflammatory cells and 
Gram positive diplococci; Streptococcus pneumoniae.  
 
Pneumococcal pneumonia 
 
Sputum colour, consistency, quantity, time of day produced, odour, and presence of blood or other distinguishing matter are important for sputum 
description and quality. Character of sputum description may be indicative of a particular disorder/infection. 
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Appendix 2.1: Ethical approval letter 
  
From: Burke Sandra [mailto:Sandra.Burke@nelondon.nhs.uk]  
Sent: 18 August 2004 09:37 
To: Abdi Yasin 
Subject: Ethical approval for student project 
Dear Mr Abdi 
Further to your letter dated 26th July 2004 the Chairman of Committee 1 Dr A T 
Tucker has read through your draft copy and details of your proposed project and 
consider it to be audit, therefore it does not require ethical approval. 
Yours sincerely 
Sandra Burke 
Acting Research Ethics Committee Manager 
East London and the City Research Ethics Committees 
********************************************************************* 
The North East London Strategic Health Authority does not accept any 
responsibility for the content of this e-mail nor for any consequence of its use and 
storage. 
 
This email and any files transmitted with it are confidential and intended solely for 
the use of the individual or entity to whom they are addressed. If you have received 
this email in error please notify the system manager. 
 
The North East London Strategic Health Authority is subject to The Freedom of 
Information Act 2000. 
 
Our web site address is: www.nelondon.nhs.uk 
********************************************************************* 
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Appendix 2.2: data collection forms  
 
To assess the degree of completeness and appropriateness of clinical microbiology 
laboratory test utilisation and test ordering practice, the Yes/No were used to 
measure the response for the determination of test appropriateness and 
inappropriateness of test and test request. 
 
 
Work Category/Bench……………………  Study Serial NO………….…… 
Specimen type……………………………  Sample Number…………….. 
Hospital site…………………………….  Ward/GP/Source………… 
Hospital Number………………………………       Date……………………..   
Clinical diagnosis………………… 
 
Section 1:  Evaluation of microbiology request form designing  
 
Q.1: Type of request form and designing format Y
  
N  
a. Does the laboratory use standardised request forms to order 
microbiology tests? If yes, specify the type of the request form used in BLT 
as follow: 
  
One page hard copy form/complete page dedicated to microbiology. 
 
  
One page hard copy dedicated one type of microbiology specimen.   
One page hard copy form for all pathology service.   
Multiple copy form for all pathology service.   
Or any other form, please state:   
b. What type of request form used in this Trust?   
Paper format request form   
Electronic format request form   
c. Does the request form provide enough spaces for the completion of test 
requisition? 
  
d. Does the request form contain appropriate instructions to assist in 
specimen collection, transport and test ordering criteria? 
  
Comments: 
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Section 2. Review of microbiology tests requisitions  
Q.2: The requisitions/test request order of entry Y
  
N  
a. Does the requisition include patient’s first and last name?   
b. Does the requisition include date of birth and sex?   
c. Does the requisition include location of the patient ward/clinic/GP?   
d. Does the requisition include Name and address of requesting 
doctor/healthcare provider? 
  
e. Does the requisition include name of tests requested?   
f. Does the requisition include specific anatomic culture site and source of 
the specimen? 
  
g. Does the requisition include date and hour of specimen collection?   
h. Does the requisition include clinical diagnosis and relevant patient’s 
history? 
  
i. Does the requisition include antimicrobial agents, if any, that patient is 
receiving? 
  
j. Does the requisition include the specimen collector’s name if other then 
the ordering doctor/physician? 
  
Comments: 
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Section 3. Evaluation of the sputum quality   
 
 
Sputum quality is measured by macroscopic examination, as recorded on patient’s 
request form during the specimen acceptance and processing. 
 
Q.3: Gross macroscopic examination of sputum evaluation and assessment. Y
  
N
  
a. What type sputum received?   
Expectorated sputum   
Induced sputum   
Any other as:   
Or just sputum stated.   
b. Is the sputum samples quality assessment of macroscopic examination 
appearance described? If yes, check one of the following or as appropriate 
  
Purulent   
Mucopurulent   
Mucosalivary   
Saliva   
Blood stained    
Other descriptions as:   
Not described   
c. Is the reporting of macroscopic examination described as:   
Interpretatively?   
Purely descriptive?   
d. Is the specimen was cultured/processed regardless of macroscopic 
evaluation findings? 
  
e. If macroscopic observation indicated unsuitable or unsatisfactory 
specimen such as saliva or mucoid culture was done due to type of patient 
as: 
  
ITU patient   
Paediatric patient   
Immunocompromise patient   
Or not stated but processed.   
Comments: 
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Section 4. Processing practices and results 
 
Q. 4: Specimen processing and test results Y
  
N
  
a. Is the date specimen received stated on the request form? If yes, specify 
the date specimen received in the laboratory and processed as: 
  
b. Is the specimen received appropriate and match the requested test? If no, 
specify the reason if appropriate:   
  
c. Is the multiple test requests received from the same specimen? If yes, 
specify the type of investigations requested. 
  
d. Are other cultural and special investigations performed that did not stated 
on the requisition? If yes, specify the type of investigations. 
  
e. Is pathogen/s isolated from the specimen? If yes, specify the pathogen/s 
and how is it reported. 
  
f. Is significant organism/s isolated from the specimen? If yes, specify the 
organism/s and how is it reported. 
  
g. If there is no growth on the plates, how is it reported?   
h. If there is growth of commensals/normal flora on the plates, how is it 
reported? 
  
i. If there is a positive or pathogen/s isolated from the culture is any further 
work performed?  If yes, specify the further work. If no, specify the reason if 
appropriate. 
  
Comments: 
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Section 5. Final test report and results interpretation  
 
Q.5: Microbiology report and interpretation of the final results/reports Y
  
N
  
a. Do the reports include:   
Patient’s first name and last name?   
Date of birth and gender?   
Name and location of the patient?   
Name of requesting doctor/healthcare provider?   
Date/time of collection, where necessary?   
Specimen type and source?   
Test name/name of test requested?   
The test performed?   
Date/time specimen received and date processed?    
The test results, if applicable, the reference values, comments and 
recommendation for the clinical importance of the findings? 
  
Accession number and patient’s hospital number?   
b. Are the report/result interpreted in a clinical meaningful manner and 
provide the clinicians with clinically relevant information’s? 
  
c. Are the results being properly interpreted their significance or instead 
reported to clinicians all of microbiologic findings (i.e. no interpretation)? 
  
d. Does the report evaluate normal flora with report as per laboratory 
protocol? 
  
e. Are the data overload leads to confusing or misleading clinicians and 
service users? 
  
f. Does the final result contain reflective reporting where laboratory clinician 
might add on further tests using their microbiological judgement? 
  
g. Is reflective testing used to inform the user when ordering or cancelling 
one test based on the result of another test or specimen? 
  
Comments: 
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Appendix 2.3: BLT Guidelines for respiratory microbiology specimen 
 
A rational approach to the microbiological investigation of respiratory specimens  
 
Guidelines from the Respiratory and Medical Microbiology Departments BLT 2003 
-------------------------------------------------------------------------------- 
The aim of these guidelines is to rationalise the work of the Microbiology 
Department by placing greater emphasis on well-taken and clinically relevant 
specimens.  The Microbiology laboratory can then give more time to service 
development such as a liquid culture system for tuberculosis. 
  
Routine Gram stains will no longer be carried out on sputum specimens at the 
Royal London Hospital.  Gram stains have not been carried out on sputum 
specimens at St Bartholomew’s Hospital for some time.  
  
Where it is felt that a Gram stain would be clinically useful, the medical team should 
telephone the laboratory respiratory bench (ext 2610 / 2009) to request it.  A routine 
Gram stain is not necessary for every patient (Ref: BTS Guidelines). 
N.B.    Specimen Quality    
 For routine culture and sensitivity, no salivary or mucoid specimens are accepted 
from adult patients at either hospital (other than paediatric patients, neutropenic 
patients, ventilated patients or BAL specimens).  This does not apply to specimens 
for AFB investigations.  See point 7. 
  
FURTHER ACTION FOR SPECIFIC CLINICAL CONDITIONS  
 
1.  Chronic Obstructive Pulmonary Disease  
  
In stable COPD, or during exacerbations, there is little evidence that sputum culture 
or sensitivity is of any value and these should not be sent.  If the clinical diagnosis 
only states COPD the specimen will not be processed.  Appropriate reasons for 
sputum examination in patients with COPD are:  if there is pneumonia, a suspicion 
of bronchiectasis or failure to respond to antibiotics.  COPD specimens will only be 
processed if these particular reasons are stated. 
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2.  Pneumonia   
The importance of sputum examination is stated in the B.T.S. guidelines but these 
should be well-collected, expectorated (i.e. coughed up) sputum specimens or 
bronchoscopy specimens.   As mentioned above, if it is considered that a Gram 
stain would be clinically useful for an individual patient, contact the laboratory 
respiratory bench (ext 2610/2009) to request it. 
  
3.   Bronchiectasis  
 Anaerobes are often the main causative organisms of infection in these patients.  
Greater emphasis regarding obtaining specimens representative of lower 
respiratory flora is necessary.  Ideally these specimens should be obtained by a 
physiotherapist.  Rapid transport of sputum specimens is necessary as anaerobes 
can die extremely quickly.  Specimens will be incubated for 5 days. 
  
4.    Nasopharyngeal Aspirate Specimens from Children  
 These are normally collected for virological investigation and will only be accepted 
for bacterial culture if a telephone call is made to the respiratory bench (ext 2610 / 
2009) to request it.  
  
 N.B. For the Neonatal Unit (Elizabeth and Constance Green Wards) routine 
bacterial culture is also carried out on ‘deep’ nasopharyngeal aspirate specimens 
and this will continue.  Where Gram stains are also required for individual patients 
on these specimens, the ward should telephone the request to the respiratory 
bench (ext 2610 / 2009). 
 
5.   Other Sputum Specimens  
 Greater emphasis should be made on efficient transport of these samples to the 
laboratory. (Specimens which take a long time to arrive are unlikely to yield relevant 
pathogens.) 
  
6.   Ventilated Patients  
 It would be preferable for non-directed broncheoalveolar lavage specimens to be 
obtained from ventilated patients when clinically indicated (not routinely at 
weekends).  Quantitative estimates of the organisms present could be undertaken 
and will give more relevant clinical information. 
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7.  AFB Investigation (Direct line to TB laboratory ext 2652)  
 
 a) Sputum  
Non-purulent as well as purulent specimens of sputum will be processed for AFB. 
 
 b)  Lymph nodes or specimens from superficial sites  
  Biopsy specimens or specimens of pus are always preferable and will give the 
best results.  As a last resort, where there is insufficient pus to be put into a 
container, normal swabs can be taken and placed in charcoal medium.  This should 
be pre-arranged with the TB Lab Senior (ext 2652).  Direct staining for acid fast 
bacilli is unreliable and should not be undertaken.  The swabs will be 
decontaminated and subsequently placed in liquid media for rapid mycobacterial 
culture. 
  
 c) EMU specimens should only be taken in cases of suspected renal or miliary TB.  
The whole of three consecutive early morning urine samples should be collected 
(large containers are available from Clin Labs) and not just an aliquot.  
  
 d)  Special blood cultures for AFB should be considered from immune suppressed 
patients and patients with miliary/disseminated disease.   
  For molecular investigations, discuss with Microbiology ext 7251 or 7249 
  
8.  General Comment  
 
 In the future molecular techniques may augment the clinical service and help 
elucidate the clinical relevance of organisms grown from respiratory samples.  We 
also wish to encourage further research into this area.  Results obtained using 
molecular techniques could be compared with those obtained from standard 
microbiological techniques (including near-patient testing).  
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Appendix 3.1: Results of throat swab TAT in days (in all phases) 
__________________________________________________________________ 
TAT   Throat swab  Throat  swab  Throat swab 
(Days)   specimens specimens   specimens 
   Phase 1   Phase  2                        Phase 3 
   (n = 3549)  (n = 100)                     (n = 11) 
   No.  (%)              No.  (%)              No. (%)              
_________________________________________________________________ 
0    0  0   0   
 
1   45 (1)    1 (1)   4 (36)  
 
2   679 (19)  12 (12)   3 (27)  
 
3   873 (25)  22 (22)   1 (9)  
       
4   767(22)  23 (23)   0  
       
≥ 5   1185 (33)   42 (42)     3 (27)  
__________________________________________________________________ 
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Appendix 3.2: Results of ear swab TAT in days (in all phases) 
_______________________________________________________________ 
TAT   Ear swab specimens   Ear swab specimens   
(Days)                Phase 1    Phase  2                                      
    (n = 1393)   (n = 63)                      
    No.  (%)               No.  (%)                
______________________________________________________________ 
0    0    0    
   
1   14 (1)      0    
 
2   264 (19)   9 (14)    
 
3   301 (22)   18 (28)   
       
4   252 (18)    5 (8)     
       
≥ 5   562 (40)    31 (49)      
__________________________________________________________________ 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -   194 
Appendix 3.3: Summary of culture results from other RT specimens in phase 1 study 
__________________________________________________________________________________________________________________ 
Culture results  Nose  (n =410)     ETT  (n =431)     BAL (n =107)     MS (n =163)     TS (n =60)    T/S  (n =51)    NPA (n =211)      
   No. (%)      No. (%)          No. (%)  No. (%)   No. (%)        No. (%)  No. (%) 
__________________________________________________________________________________________________________________ 
Positive  183 (45)  249 (56) 44 (41)  41(25)  22 (37)  38 (76)  128 (61) 
 
Negative  227 (55)  182 (42) 63 (59)  122 (75) 38 (63)  13 (25)  83 (39)  
________________________________________________________________________________________________________________ 
Nose  swab      ETT: endotracheal tube       BAL: Bronchoalveolar lavage      MS: mouth swab      TS: tongue swab   T/S: Tracheal secretion  
NPA: nasopharyngeal aspirate   
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Appendix 3.4: Culture findings from other respiratory tract specimens in phase 1 reported as culture positive 
_______________________________________________________________________________________________________________________________________________________ 
Microorganism/s  Nose  (n =183)     ETT  (n = 249)     BAL (n = 107)    MS (n = 163)  TS (n = 22)    T/S  (n = 38)    NPA (n = 128)      
    No. (%)      No. (%)          No. (%)  No. (%) No. (%)   No. (%)  No. (%) 
_______________________________________________________________________________________________________________________________________________________ 
Beta-haem.streptococcus A 6 (3.3)           1 (2.3)  1 (2.4)  
Staphylococcus aureus 78 (42.6) 8 (3.2)   7 (15.9)  8 (19.5)  2 (9)   5 (13.2)  22 (17.2) 
MRSA    11 (6.0) 5 (2)    2 (4.6)  2 (4.9)     7 (18.4)  
Beta-haem.streptococcus B 4 (2.2)  2(0.8)   1 (2.3)        1 (0.8)  
Beta-haem.streptococcus C 1 (0.6)    
Candida tropicalis  1 (0.6)  
Candida albicans    4 (1.6)    2 (4.6)   26 (63.4)  15 (68.2)  2 (5.3)   3 (2.3) 
Haemophilus influenzae   2 (0.8)   3 (6.8)        4 (3.1)  
Streptococcus pneumoniae 14 (7.7)    5 (11.4)        8 (6.3)  
Moraxella catarrhalis  3 (1.1)  1 (0.4)         2 (5.3)   3 (2.3) 
Pseudomonas species  7 (3.8)  5 (2)   8 (18.2)  1(2.4)   1 (4.6)  7 (18.4)  7 (5.5) 
Coag. neg. staphylococcus 18 (9.8) 135 (54.2)        3 (7.9)  31(24.2)  
Organism of coliform group 28 (15.3) 77 (30.9)  12 (27.3)  2 (2.9)  4 (18.2)  6 (15.8)  43 (33.6) 
Enterococcus species  1 (0.6)  3 (1.2)  
Escherichia coli  1 (0.6)  2(0.8)         1 (2.6)  
Enterobacter cloacae  1 (0.6)  1 (0.4)         1 (2.6)   
Acinetobacter species  1 (0.6)           2 (5.3)  1 (0.8)   
Klebsiella species         1 (2.4)    1 (2.6)  1 (0.8) 
Serratia marcescens        1 (2.3)  
Proteus species  8 (4.4)  1 (0.4)          1 (2.6)  4 (3.1)  
Stenotrophomonas maltophilia  3 (1.2) 
Aspergillus species       2 (4.6) 
_________________________________________________________________________________________________________________________________________________________________ 
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Appendix 3.5 :Culture findings from other RT specimens in phase 1 reported as culture negative 
_______________________________________________________________________________________________________________________________________________________ 
Microorganism/s  Nose  (n = 227)     ETT  (n = 182)    BAL (n = 63)     MS (n = 122)  TS (n = 38)    T/S  (n = 13)    NPA (n = 83)      
    No. (%)      No. (%)          No. (%)  No. (%) No. (%)   No. (%)  No. (%) 
______________________________________________________________________________________________________________________________________________________ 
No growth   72 (31.7) 137 (75.3)  6 (9.5)  6 (4.9)    7 (53.9) 49 (59) 
No significant growth  2 (0.9) 
No staur/BHSA  6 (2.6) 
Coag. neg. staphylococcus 2 (0.9)  5 (2.85)       
Enterococcus species    1 (0.55)  
Organism of the coliform 5 (2.2)  4 (2.2)     4 (3.3)  2 (5.3)    7 (8.4) 
Pseudomonas species  2 (0.9)              
Yeast species     2 (1.1)      9 (7.4)  3 (7.9)    1 (1.2)   
Skin flora             138 (60.8) 
Mouth flora/Throat flora   33 (18.1)   57 (90.5)  103(84.4)  33 (86.8)  6 (46.2)  26 (31.3) 
___________________________________________________________________________________________________________________________________________________ 
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Appendix 5.1: Abdi, Y. (2008). Investigation of factors affecting quality of sputum 
specimen and culture results. The Biomedical Scientist, January: 27-33 
 
 
Investigation of factors affecting quality of sputum specimen and culture results 
 
 
Y ABDI 
Department of Medical Microbiology, Barts and The London NHS Trust,  
Royal London Hospital, 80 Newark Street, London E1 2ES, UK 
 
 
Sputum is the most common lower respiratory tract specimen received by the 
microbiology laboratory. It is also often the most problematic to assess due to 
contamination by oropharyngeal flora. In spite of numerous guidelines on 
appropriate samples for microbiological examination, laboratories continue to 
receive large number of inappropriate sputum samples.  
 
The aim of this study was to investigate the quality of sputum specimens, 
appropriateness of test requisition and adherence to specimen collection principles. 
 
 In this study 511 microbiology laboratory request forms from patients in whom 
sputum culture was requested in 3 months period were examined.  
 
The factors studied included (a) sputum description based on macroscopic 
inspection (b) microbiological test requisition of sputum for microscopy, culture, and 
sensitivity (MC  & S) (c) age of the specimen when received in the microbiology 
laboratory (d) whether patients were on antibiotic treatment (e) patients clinical 
diagnosis.  
 
Analysis of the findings showed that the usefulness of culture results was limited by 
the collection of inappropriate specimens and lack of clinical information on the 
microbiology request form.  
 
The crucial importance of the role of clinical and nursing staff is stressed if the 
clinical relevance of sputum culture is to be maximised.  
 
The increasing introduction of electronic pathology test request gives new 
opportunities to restrict the collection of inappropriate specimens and make 
substantial savings in resources both in the ward and the laboratory. 
 
 
